CA2954802C - Antibodies specific for epidermal growth factor receptor variant iii - Google Patents

Antibodies specific for epidermal growth factor receptor variant iii

Info

Publication number
CA2954802C
CA2954802C CA2954802A CA2954802A CA2954802C CA 2954802 C CA2954802 C CA 2954802C CA 2954802 A CA2954802 A CA 2954802A CA 2954802 A CA2954802 A CA 2954802A CA 2954802 C CA2954802 C CA 2954802C
Authority
CA
Canada
Prior art keywords
seq
sequence shown
region
cdr3
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2954802A
Other languages
French (fr)
Other versions
CA2954802A1 (en
Inventor
Oi Kwan WONG
Joyce Ching CHOU
Barbra Johnson Sasu
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CA2954802A1 publication Critical patent/CA2954802A1/en
Application granted granted Critical
Publication of CA2954802C publication Critical patent/CA2954802C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention provides antibodies that specifically bind to EGFRvlll (Epidermal Growth Factor Receptor Variant III). The invention further provides bispecific antibodies that bind to EGFRvlll and another antigen (e.g., CD3) as well as antibody conjugates (e.g., antibody-drug-conjugates). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific) and antibody conjugates.

Description

 CA 02954802 2017-01-12 50054-294 - 1 - ANTIBODIES SPECIFIC FOR EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III Field 5 The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to Epidermal Growth Factor Receptor Variant III (EGFRvlll). The invention further relates to heteromultimeric antibodies (e.g., bispecific antibodies) and antibody conjugates (e.g., antibody-drug- conjugates). Compositions comprising the EGFRvlll antibodies, and methods for 10 producing and purifying such antibodies. Background EGFR variant III (EGFRvlll), a tumor specific mutant of EGFR, is a product of genomic rearrangement which is often associated with wild-type EGFR gene 15 amplification. EGFRvlll is formed by an in-frame deletion of exons 2-7, leading to deletion of 267 amino acids with a glycine substitution at the junction. The truncated receptor loses its ability to bind ligands but acquires constitutive kinase activity. Interestingly, EGFRvlll frequently co-expresses with full length wild-type EGFR in the same tumor cells. Moreover, EGFRvlll expressing cells exhibit increased 20 proliferation, invasion, angiogenesis and resistance to apoptosis. EGFRvlll is most often found in glioblastoma multiforme (GBM). It is estimated that 25-35% of GBM carries this truncated receptor. Moreover, its expression often reflects a more aggressive phenotype and poor prognosis. Besides GBM, expression of EGFRvlll has also been reported in other solid tumors such as non-small cell lung 25 cancer, head and neck cancer, breast cancer, ovarian cancer and prostate cancer. In contrast, EGFRvlll is not expressed in healthy tissues. The lack of expression in normal tissues makes EGFRvlll an ideal target for developing tumor specific targeted therapy. To date, there has not been any FDA approved monoclonal antibody (e.g., monospecific or bispecific) against EGFRvlll identified with high affinity, high 30 specificity, and high potency in treating cancers such as GBM. Accordingly, there  CA 02954802 2017-01-12 50054-294 - 2 - remains a need for antibodies (e.g., monospecific or bispecific) which can provide potential development candidates for treating cancers such as GBM with improved efficacy and safety profile, and suitable for use with human patients. Summary 5 The invention disclosed herein is directed to antibodies (e.g., monospecific or bispecific antibodies) and antibody conjugates that specifically bind to Epidermal Growth Factor Receptor Variant III (EGFRvlll). In one aspect, the invention provides an isolated antibody which specifically binds to EGFRvlll, wherein the antibody comprises (a) a heavy chain variable (VH) region comprising (i) a VH 10 complementarity determining region one (CDR1) comprising the sequence shown in SEQ ID NO: 62, 63, 64, 74, 75, 76, 80, 81, 82, 88, 89, 90, 93, 94, 95, 99, 100, 101, 109, 110, 111, 115, 116, 117, 121, 122, 123, 132, 133, 134, 137, 138, 139, 143, 144, or 145; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 65, 66, 68, 69, 70, 71, 77, 78, 83, 84, 86, 87, 91, 92, 96, 97, 98, 102, 103, 105, 106, 112, 113, 15 118, 119, 124, 125, 127, 128, 130, 131, 135, 136, 140, 141, 146, 147, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, or 237; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 67, 72, 73, 79, 85, 104, 107, 108, 114, 120, 126, 129, 142, 148, 219, 220, 221, 222, 223, or 236; and/or a light chain variable (VL) region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID 20 NO: 149, 154, 156, 159, 162, 165, 166, 168, 169, 170, 171, 173, 174, 176, 178, 181, 182, 185, 187, 190, 192, 195, 198, 238, or 239; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 150, 152, 155, 157, 160, 163, 172, 175, 179, 183, 186, 188, 191, 193, 196, or 199; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 151, 153, 158, 161, 164, 167, 177, 180, 184, 189, 194, 197, or 200. 25 In another aspect, provided is an isolated antibody which specifically binds to EGFRvlll, wherein the antibody comprises: a VH region comprising a VH CDR1, VH CDR2, and VH CDR3 of the VH sequence shown in SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 30, 32, 34, 35, 37, 39, 41, 43, 44, 46, 48, 50, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 202, 203, 204, 205, 206, 207, 208, 209, 210, 214, 216, 30 217, or 218; and/or a VL region comprising VL CDR1, VL CDR2, and VL CDR3 of the  CA 02954802 2017-01-12 50054-294 -3- VL sequence shown in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 29, 31, 33, 36, 38, 40, 42, 45, 47, 49, 51, 211, 212, 213, or 215. In some embodiments, the VH region as described herein comprises a variant with one or several conservative amino acid substitutions in residues that are not within a CDR 5 and/or the VL region as described herein comprises a variant with one or several amino acid substitutions in amino acids that are not within a CDR. For example, in some embodiments, the VH or VL region can comprise an amino acid sequence described above or a variant thereof with no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 conservative substitutions in residues that are not within a CDR. 10 In some embodiments, provided is an isolated antibody which specifically binds to EGFRvlll, wherein the antibody comprises: a VH region comprising the sequence shown in SEQ ID NO: 5, 9, 11, 15, 30, 37, or 41; and/or a VL region comprising the sequence shown in SEQ ID NO: 6, 10, 12, 16, 31, 38, or 42. In some embodiments, the VH region comprises the sequence shown in SEQ ID NO: 5 and 15 the VL region comprises the sequence shown in SEQ ID NO: 6. In some embodiments, the VH region comprises the sequence shown in SEQ ID NO: 9 and the VL region comprises the sequence shown in SEQ ID NO: 10. In some embodiments, the VH region comprises the sequence shown in SEQ ID NO: 11 and the VL region comprises the sequence shown in SEQ ID NO: 12. In some 20 embodiments, the VH region comprises the sequence shown in SEQ ID NO: 15 and the VL region comprises the sequence shown in SEQ ID NO: 16. In some embodiments, the VH region comprises the sequence shown in SEQ ID NO: 30 and the VL region comprises the sequence shown in SEQ ID NO: 31. In some embodiments, the VH region comprises the sequence shown in SEQ ID NO: 37 and 25 the VL region comprises the sequence shown in SEQ ID NO: 38. In some embodiments, the VH region comprises the sequence shown in SEQ ID NO: 41 and the VL region comprises the sequence shown in SEQ ID NO: 42. In another aspect, provided is a bispecific antibody wherein the bispecific antibody is a full-length human antibody, comprising a first antibody variable domain 30 of the bispecific antibody specifically binding to a target antigen (e.g., EGFRvlll), and  CA 02954802 2017-01-12 50054-294 -4- comprising a second antibody variable domain of the bispecific antibody capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen (e.g., Cluster of differentiation 3 (CD3)) located on the human immune effector cell. In some embodiments, the first antibody variable domain 5 comprises a heavy chain variable (VH) region comprising a VH CDR1, VH CDR2, and VH CDR3 of the VH sequence shown in SEQ ID NO: 1,3,5,7,9,11,13,15,17, 19, 21, 23, 25, 27, 30, 32, 34, 35, 37, 39, 41, 43, 44, 46, 48, 50, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 202, 203, 204, 205, 206, 207, 208, 209, 210, 214, 216, 217, or 218; and/or a light chain variable (VL) region comprising VL CDR1, VL CDR2, and VL 10 CDR3 of the VL sequence shown in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 29, 31, 33, 36, 38, 40, 42, 45, 47, 49, 51, 211, 212, 213, or 215. In some embodiments, the first antibody variable domain comprises (a) a heavy chain variable (VH) region comprising (i) a VH complementarity determining region one (CDR1) comprising the sequence shown in SEQ ID NO: 62, 63, 64, 74, 75, 76, 80, 81, 82, 88, 15 89, 90, 93, 94, 95, 99, 100, 101, 109, 110, 111, 115, 116, 117, 121, 122, 123, 132, 133, 134, 137, 138, 139, 143, 144, or 145; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 65, 66, 68, 69, 70, 71, 77, 78, 83, 84, 86, 87, 91, 92, 96, 97, 98, 102, 103, 105, 106, 112, 113, 118, 119, 124, 125, 127, 128, 130, 131, 135, 136, 140, 141, 146, 147, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, or 20 237; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 67, 72, 73, 79, 85, 104, 107, 108, 114, 120, 126, 129, 142, 148, 219, 220, 221, 222, 223, or 236; and/or (b) a light chain variable (VL) region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 149, 154, 156, 159, 162, 165, 166, 168, 169, 170, 171, 173, 174, 176, 178, 181, 182, 185, 187, 190, 192, 195, 198, 238, or 239; (ii) a 25 VL CDR2 comprising the sequence shown in SEQ ID NO: 150, 152, 155, 157, 160, 163, 172, 175, 179, 183, 186, 188, 191, 193, 196, or 199; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 151, 153, 158, 161, 164, 167, 177, 180, 184, 189, 194, 197, or 200. In some embodiments, the second antibody variable domain comprises the VH 30 and/or VL region specific against CD3. For example, the second antibody variable  CA 02954802 2017-01-12 50054-294 - 5 - domain comprises a heavy chain variable (VH) region comprising a VH CDR1, VH CDR2, and VH CDR3 of the VH sequence shown in SEQ ID NO:240 ; and/or a light chain variable (VL) region comprising a VL CDR1, VL CDR2, and VL CDR3 of the VL sequence shown in SEQ ID NO: 241. In some embodiments, the second antibody 5 variable domain comprises (a) a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 244, 110, or 245; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 246 or 247; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 248; and/or a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 249; (ii) a VL CDR2 comprising the 10 sequence shown in SEQ ID NO: 250; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 251. In some embodiments, the antibodies described herein comprise a constant region. In some embodiments, the antibodies described herein are of the human lgG1, lgG2 or lgG2Aa, lgG3, or lgG4 subclass. In some embodiments, the 15 antibodies described herein comprise a glycosylated constant region. In some embodiments, the antibodies described herein comprise a constant region having decreased binding affinity to one or more human Fc gamma receptor(s). In some embodiments, both the first and the second antibody variable domains of the bispecific antibody comprise amino acid modifications at positions 20 223, 225, and 228 (e.g., (C223E or C223R), (E225R), and (P228E or P228R)) in the hinge region and at position 409 or 368 (e.g., K409R or L368E (EU numbering scheme)) in the CH3 region of human lgG2 (SEQ ID NO: 290). In some embodiments, both the first and the second antibody variable domains of the bispecific antibody comprise amino acid modifications at position 265 25 (e.g., D265A) of the human lgG2. In some embodiments, both the first and the second antibody variable domains of the bispecific antibody comprise amino acid modifications at one or more of positions 265 (e.g., D265A), 330 (e.g., A330S), and 331 (e.g., P331S) of the human lgG2. In some embodiments, both the first and the second antibody variable 30 domains of the bispecific antibody comprise amino acid modifications at each of  CA 02954802 2017-01-12 50054-294 - 6 - positions 265 (e.g., D265A), 330 (e.g., A330S), and 331 (e.g., P331S) of the human lgG2. In another aspect, the invention provides an isolated antibody comprising an acyl donor glutamine-containing tag engineered at a specific site of the EGFRvlll 5 antibody of the present invention. In one variation, the invention provides an isolated antibody comprising an acyl donor glutamine-containing tag and an amino acid modification at position 222, 340, or 370 of the EGFRvlll antibody of the present invention. In some embodiments, the amino acid modification is a substitution from lysine to arginine. 10 In some embodiments, the EGFRvlll antibody of the present invention further comprises a linker. In another aspect, the invention provides a conjugate of the EGFRvlll antibody as described herein, wherein the antibody is conjugated to an agent, wherein the agent is selected from the group consisting of a cytotoxic agent, an 15 immunomodulating agent, an imaging agent, a therapeutic protein, a biopolymer, and an oligonucleotide. In some embodiments, the agent is a cytotoxic agent including, but not limited to, an anthracycline, an auristatin, a camptothecin, a combretastatin, a dolastatin, a duocarmycin, an enediyne, a geldanamycin, an indolino-benzodiazepine dimer, a maytansine, a puromycin, a pyrrolobenzodiazepine dimer, a taxane, a vinca 20 alkaloid, a tubulysin, a hemiasterlin, a spliceostatin, a pladienolide, and stereoisomers, isosteres, analogs, or derivatives thereof. For example, the cytotoxic agent is MMAD (Monomethyl Auristatin D), 0101 (2-methylalanyl-/V-[(3R,4S,5S)-3- methoxy-1-{(2S)-2-[(1R,2R)-1 -methoxy-2-methyl-3-oxo-3-{[(1S)-2-phenyl-1-(1,3- thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-A/-methyl-L- 25 valinamide), 3377 (N,2-dimethylalanyl-N-{(1S,2R)-4-{(2S)-2-[(1R,2R)-3-{[(1S)-1- carboxyl-2-phenylethyl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-2- methoxy-1-[( 1S)-1-methylpropyl]-4-oxobutyl}-N-methyl-L-valinamide), 0131 (2-methyl- L-proly-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S)-1-carboxy-2-phenylethyl]amino}-1- methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]- 30 N-methyl-L-valinamide), or 0121(2-methyl-L-proly-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-  81802864 -7- 3-{[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3- oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide). In some embodiments, the present invention provides a conjugate comprising the formula: antibody-(acyl donor glutamine-containing tag)-(linker)-(cytotoxic agent). 5 In other embodiments, the invention provides pharmaceutical compositions comprising any of the antibodies or antibody conjugates described herein. The invention also provides cell lines that recombinantly produce any of the antibodies described herein. The invention also provides nucleic acids encoding any of the antibodies 10 described herein. The invention also provides nucleic acids encoding a heavy chain variable region and/or a light chain variable region of any of the antibodies described herein. In an embodiment, there is provided an isolated antibody, which specifically binds to Epidermal Growth Factor Receptor Variant III (EGFRvlll), wherein the antibody 15 comprises: (a) a heavy chain variable (VH) region comprising (i) a VH complementarity determining region one (CDR1) comprising the sequence shown in SEQ ID NO: 74, 75, or 76; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 77 or 78; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 79; and a light chain variable (VL) region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 156; (ii) a 20 VL CDR2 comprising the sequence shown in SEQ ID NO: 157; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 158; or (b) a VH region comprising (i) a CDR1 comprising the sequence shown in SEQ ID NO: 80, 81 or, 82; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 83 or 84; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 85; and a VL region comprising (i) a VL CDR1 25 comprising the sequence shown in SEQ ID NO: 159; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 160; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 161 or; (c) a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 80, 81 or, 82; (ii) a VH CDR2 comprising the sequence shown in Date ReQue/Date Received 2023-06-14  81802864 -7a- SEQ ID NO: 86 or 87; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 79; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 162; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 163; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 164; or (d) a VH region comprising 5 (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 88, 89, or 90; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 91 or 92; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 85; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 165; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 163; and (iii) a VL CDR3 comprising the sequence shown 10 in SEQ ID NO: 161 or; (e) a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 93, 94, or 95; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 96 or 97; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 79; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 166; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 163; and (iii) a VL 15 CDR3 comprising the sequence shown in SEQ ID NO: 167; or (f) a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 93, 94, or 95; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 96 or 97; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 85 and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 168; (ii) a VL CDR2 comprising the 20 sequence shown in SEQ ID NO: 163; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 167; or (g) a VH region comprising (i) a CDR1 comprising the sequence shown in SEQ ID NO: 80, 81, or 82; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 83 or 84; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 85; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID 25 NO: 169; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 163; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 161; or (h) a VH region comprising (i) a CDR1 comprising the sequence shown in SEQ ID NO: 80, 81 or, 82; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 83 or 84; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 85; and a VL region comprising (i) a VL CDR1 30 comprising the sequence shown in SEQ ID NO: 170; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 163; and (iii) a VL CDR3 comprising the sequence shown Date ReQue/Date Received 2023-06-14  81802864 -7b¬ in SEQ ID NO: 161 or; (i) a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 80, 81 or, 82; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 98 or 78; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 85; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID 5 NO: 171; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 172; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 167; or (j) a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 80, 81 or, 82; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 98 or 78; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 85; and a VL region comprising (i) a VL 10 CDR1 comprising the sequence shown in SEQ ID NO: 174; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 175; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 167; or (k) a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 99, 100, or 101; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 83 or 84; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 15 85; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 173; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 163; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 161; or (I) a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 74, 75, or 76; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 102 or 103; and iii) a VH CDR3 20 comprising the sequence shown in SEQ ID NO: 104; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 176; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 172; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 177; or (m) a VH region comprising (i) a CDR1 comprising the sequence shown in SEQ ID NO: 74, 75, or 76; (ii) a VH CDR2 comprising the sequence shown in 25 SEQ ID NO: 105 or 103; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 178; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 179; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 180; or (n) a VH region comprising (i) a CDR1 comprising the sequence shown in SEQ ID NO: 74, 75, or 76; (ii) a 30 VH CDR2 comprising the sequence shown in SEQ ID NO: 102 or 103; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 108; and a VL region comprising (i) a VL Date ReQue/Date Received 2023-06-14  81802864 -7c- CDR1 comprising the sequence shown in SEQ ID NO: 176; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 172; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 177; or (o) a VH region comprising (i) a CDR1 comprising the sequence shown in SEQ ID NO: 74, 75, or 76; (ii) a VH CDR2 comprising the sequence shown in 5 SEQ ID NO: 106 or 87; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 85; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 181; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 172; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 167; or (p) a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 109, 110, or 111; (ii) a VH 10 CDR2 comprising the sequence shown in SEQ ID NO: 112 or 113; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 114; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 182; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 183; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 184; or (q) a VH region comprising (i) a VH CDR1 comprising the sequence 15 shown in SEQ ID NO: 115, 116, or 177; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 118 or 119; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 120; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 185; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 186; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 184; or (r) a VH region 20 comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 121, 122, or 123; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 124 or 125; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 126; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 187; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 188; and (iii) a VL CDR3 comprising 25 the sequence shown in SEQ ID NO: 189; or (s) a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 115, 116, or 117; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 127 or 128; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 129; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 185; (ii) a VL CDR2 comprising the 30 sequence shown in SEQ ID NO: 186; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 184; or (t) a VH region comprising (i) a VH CDR1 comprising the sequence Date ReQue/Date Received 2023-06-14  81802864 -7d- shown in SEQ ID NO: 115, 116, or 117; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 130 or 131; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 120; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 190; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 191 and; 5 (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 184; or (u) a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 132, 133, or 134; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 135 or 136; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 126; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 192; (ii) a VL 10 CDR2 comprising the sequence shown in SEQ ID NO: 193; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 194. Brief Description of the Fiqures/Drawinqs FIGs. 1A, 1B, and 1C show examples of FACS binding histograms of three 15 EGFRvlll antibodies: mAb 42G9 (FIG. 1A), 32A10 (FIG. 1B) and 32G8 (FIG. 1C), to the three F98 cell lines: F98 (EGFR negative), F98-EGFRwt, and F98-EGFRvllL The X-axis is fluorescence intensity; the Y-axis is percentage of maximum / normalized to mode. FIGs. 2A, 2B and 2C depict histograms showing the expression of wild-type EGFR and EGFRvlll in GBM cell lines as measured by flow cytometry: LN229-EGFRvlll 20 (FIG. 2A), LN18-EGFRvlll (FIG. 2B) and DKMG (FIG. 2C). EGFRvlll was detected with mAb 42G9 and EGFRwt was detected with an EGFR wild-type specific mAb. The X-axis is fluorescence intensity; the Y-axis is percentage of maximum / normalized to mode. FIGs. 3A and 3B show graphs demonstrating the cytotoxicity of three EGFRvlll-CD3 bispecific antibodies in EGFRvlll transduced LN18-EGFRvlll (FIG. 3A) and 25 parental LN18 (FIG. 3B) cells. FIGs. 4A and 4B show graphs demonstrating the cytotoxicity of three Date ReQue/Date Received 2023-06-14  CA 02954802 2017-01-12 50054-294 -8- EGFRvlll-CD3 bispecific antibodies in EGFRvlll transduced LN229-EGFRvlll (FIG. 4A) and parental LN229 (FIG. 4B) cells. FIG. 5 shows a graph demonstrating the cytotoxicity of three EGFRvlll-CD3 bispecific antibodies in DKMG cells, which express endogenous EGFRvlll and EGFR 5 wild-type proteins. FIG. 6 shows a graph illustrating the in vivo anti-tumor activity of EGFRvlll- CD3 bispecific antibodies in a subcutaneous model of LN229-EGFRvlll GBM cell line. Detailed Description The invention disclosed herein provides antibodies (e.g., monospecific or 10 bispecific) and antibody conjugates that specifically bind to EGFRvlll (e.g., human EGFRvlll). The invention also provides polynucleotides encoding these antibodies, compositions comprising these antibodies and antibody conjugates, and methods of making these antibodies and antibody conjugates. 15 General Techniques The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, immunology, virology, monoclonal antibody generation and engineering, which are within the skill of the art. Such techniques are 20 explained fully in the literature, such as, Molecular Cloning: A Laboratory Manual, second edition (Sambrook et al., 1989) Cold Spring Harbor Press; Oligonucleotide Synthesis (M.J. Gait, ed., 1984); Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Notebook (J.E. Cellis, ed., 1998) Academic Press; Animal Cell Culture (R.L Freshney, ed., 1987); Introduction to Cell and Tissue Culture (J.P. 25 Mather and P.E. Roberts, 1998) Plenum Press; Cell and Tissue Culture: Laboratory Procedures (A. Doyle, J.B. Griffiths, and D.G. Newell, eds., 1993-1998) J. Wiley and Sons; Methods in Enzymology (Academic Press, Inc.); Handbook of Experimental Immunology (D.M. Weir and C.C. Blackwell, eds.); Gene Transfer Vectors for Mammalian Cells (J.M. Miller and M.P. Calos, eds., 1987); Current Protocols in  CA 02954802 2017-01-12 50054-294 - 9 - Molecular Biology (F.M. Ausubel et al., eds., 1987); PGR: The Polymerase Chain Reaction, (Mullis et al., eds., 1994); Current Protocols in Immunology (J.E. Coligan et al., eds., 1991); Short Protocols in Molecular Biology (Wiley and Sons, 1999); Immunobiology (C.A. Janeway and P. Travers, 1997); Antibodies (P. Finch, 1997); 5 Antibodies: a practical approach (D. Catty., ed., IRL Press, 1988-1989); Monoclonal antibodies: a practical approach (P. Shepherd and C. Dean, eds., Oxford University Press, 2000); Using antibodies: a laboratory manual (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999); The Antibodies (M. Zanetti and J.D. Capra, eds., Harwood Academic Publishers, 1995). 10 Definitions An “antibody” is an immunoglobulin molecule capable of specific binding to a target, such as a carbohydrate, polynucleotide, lipid, polypeptide, etc., through at least one antigen recognition site, located in the variable region of the 15 immunoglobulin molecule. As used herein, the term encompasses not only intact polyclonal or monoclonal antibodies, but also antigen binding fragments thereof (such as Fab, Fab’, F(ab’)2, Fv), single chain (ScFv) and domain antibodies (including, for example, shark and camelid antibodies), and fusion proteins comprising an antibody, and any other modified configuration of the immunoglobulin molecule that comprises 20 an antigen recognition site. An antibody includes an antibody of any class, such as IgG, IgA, or IgM (or sub-class thereof), and the antibody need not be of any particular class. Depending on the antibody amino acid sequence of the constant region of its heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these 25 may be further divided into subclasses (isotypes), e.g., lgG1, lgG2, lgG3, lgG4, lgA1 and lgA2. The heavy-chain constant regions that correspond to the different classes of immunoglobulins are called alpha, delta, epsilon, gamma, and mu, respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.  CA 02954802 2017-01-12 50054-294 - 10 - The term "antigen binding fragment" or “antigen binding portion” of an antibody, as used herein, refers to one or more fragments of an intact antibody that retain the ability to specifically bind to a given antigen (e.g., EGFRvlll). Antigen binding functions of an antibody can be performed by fragments of an intact antibody. 5 Examples of binding fragments encompassed within the term "antigen binding fragment" of an antibody include Fab; Fab’; F(ab’)2; an Fd fragment consisting of the VH and CH1 domains; an Fv fragment consisting of the VL and VH domains of a single arm of an antibody; a single domain antibody (dAb) fragment (Ward et aL, Nature 341:544-546, 1989), and an isolated complementarity determining region 10 (CDR). An antibody, an antibody conjugate, or a polypeptide that “preferentially binds” or “specifically binds” (used interchangeably herein) to a target (e.g., EGFRvlll protein) is a term well understood in the art, and methods to determine such specific or preferential binding are also well known in the art. A molecule is said to exhibit 15 “specific binding” or “preferential binding” if it reacts or associates more frequently, more rapidly, with greater duration and/or with greater affinity with a particular cell or substance than it does with alternative cells or substances. An antibody “specifically binds” or “preferentially binds” to a target if it binds with greater affinity, avidity, more readily, and/or with greater duration than it binds to other substances. For example, 20 an antibody that specifically or preferentially binds to an EGFRvlll epitope is an antibody that binds this epitope with greater affinity, avidity, more readily, and/or with greater duration than it binds to other EGFRvlll epitopes or non-EGFRvlll epitopes. It is also understood that by reading this definition, for example, an antibody (or moiety or epitope) that specifically or preferentially binds to a first target may or may not 25 specifically or preferentially bind to a second target. As such, “specific binding” or “preferential binding” does not necessarily require (although it can include) exclusive binding. Generally, but not necessarily, reference to binding means preferential binding. A “variable region” of an antibody refers to the variable region of the antibody 30 light chain or the variable region of the antibody heavy chain, either alone or in  CA 02954802 2017-01-12 50054-294 - 11 - combination. As known in the art, the variable regions of the heavy and light chain each consist of four framework regions (FR) connected by three complementarity determining regions (CDRs) also known as hypervariable regions. The CDRs in each chain are held together in close proximity by the FRs and, with the CDRs from the 5 other chain, contribute to the formation of the antigen binding site of antibodies. There are at least two techniques for determining CDRs: (1) an approach based on cross-species sequence variability (i.e., Kabat et al. Sequences of Proteins of Immunological Interest, (5th ed., 1991, National Institutes of Health, Bethesda MD)); and (2) an approach based on crystallographic studies of antigen-antibody 10 complexes (Al-lazikani et al., 1997, J. Molec. Biol. 273:927-948). As used herein, a CDR may refer to CDRs defined by either approach or by a combination of both approaches. A “CDR” of a variable domain are amino acid residues within the variable region that are identified in accordance with the definitions of the Kabat, Chothia, the 15 accumulation of both Kabat and Chothia, AbM, contact, and/or conformational definitions or any method of CDR determination well known in the art. Antibody CDRs may be identified as the hypervariable regions originally defined by Kabat et al. See, e.g., Kabat et al., 1992, Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, NIH, Washington D.C. The positions of the CDRs may 20 also be identified as the structural loop structures originally described by Chothia and others. See, e.g., Chothia et aL, Nature 342:877-883, 1989. Other approaches to CDR identification include the “AbM definition,” which is a compromise between Kabat and Chothia and is derived using Oxford Molecular's AbM antibody modeling software (now Accelrys®), or the “contact definition” of CDRs based on observed 25 antigen contacts, set forth in MacCallum et al., J. Mol. Biol., 262:732-745, 1996. In another approach, referred to herein as the “conformational definition” of CDRs, the positions of the CDRs may be identified as the residues that make enthalpic contributions to antigen binding. See, e.g., Makabe et al., Journal of Biological Chemistry, 283:1156-1166, 2008. Still other CDR boundary definitions may not 30 strictly follow one of the above approaches, but will nonetheless overlap with at least  CA 02954802 2017-01-12 50054-294 - 12 - a portion of the Kabat CDRs, although they may be shortened or lengthened in light of prediction or experimental findings that particular residues or groups of residues or even entire CDRs do not significantly impact antigen binding. As used herein, a CDR may refer to CDRs defined by any approach known in the art, including combinations 5 of approaches. The methods used herein may utilize CDRs defined according to any of these approaches. For any given embodiment containing more than one CDR, the CDRs may be defined in accordance with any of Kabat, Chothia, extended, AbM, contact, and/or conformational definitions. As used herein, "monoclonal antibody" refers to an antibody obtained from a 10 population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations, which typically include different antibodies directed 15 against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be 20 used in accordance with the present invention may be made by the hybridoma method first described by Kohler and Milstein, Nature 256:495, 1975, or may be made by recombinant DNA methods such as described in U.S. Pat. No. 4,816,567. The monoclonal antibodies may also be isolated from phage libraries generated using the techniques described in McCafferty et al., Nature 348:552-554, 1990, for 25 example. As used herein, "humanized" antibody refers to forms of non-human (e.g. murine) antibodies that are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (such as Fv, Fab, Fab’, F(ab’)2 or other antigen binding subsequences of antibodies) that contain minimal sequence derived from non-human 30 immunoglobulin. Preferably, humanized antibodies are human immunoglobulins  CA 02954802 2017-01-12 50054-294 - 13 - (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human 5 immunoglobulin are replaced by corresponding non-human residues. Furthermore, the humanized antibody may comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences, but are included to further refine and optimize antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable 10 domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region or domain (Fc), typically that of a human immunoglobulin. Preferred are antibodies having Fc 15 regions modified as described in WO 99/58572. Other forms of humanized antibodies have one or more CDRs (CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, or CDR H3) which are altered with respect to the original antibody, which are also termed one or more CDRs “derived from” one or more CDRs from the original antibody. 20 As used herein, “human antibody” means an antibody having an amino acid sequence corresponding to that of an antibody produced by a human and/or which has been made using any of the techniques for making human antibodies known to those skilled in the art or disclosed herein. This definition of a human antibody includes antibodies comprising at least one human heavy chain polypeptide or at 25 least one human light chain polypeptide. One such example is an antibody comprising murine light chain and human heavy chain polypeptides. Human antibodies can be produced using various techniques known in the art. In one embodiment, the human antibody is selected from a phage library, where that phage library expresses human antibodies (Vaughan et al., Nature Biotechnology, 14:309- 30 314, 1996; Sheets et al., Proc. Natl. Acad. Sci. (USA) 95:6157-6162, 1998;  CA 02954802 2017-01-12 50054-294 - 14- Hoogenboom and Winter, J. Mol. Biol., 227:381, 1991; Marks et al., J. Mol. Biol., 222:581, 1991). Human antibodies can also be made by immunization of animals into which human immunoglobulin loci have been transgenically introduced in place of the endogenous loci, e.g., mice in which the endogenous immunoglobulin genes 5 have been partially or completely inactivated. This approach is described in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; and 5,661,016. Alternatively, the human antibody may be prepared by immortalizing human B lymphocytes that produce an antibody directed against a target antigen (such B lymphocytes may be recovered from an individual or from single cell cloning of the 10 cDNA, or may have been immunized in vitro). See, e.g., Cole et al. Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77, 1985; Boerner et al., J. Immunol., 147 (1):86-95, 1991; and U.S. Pat. No. 5,750,373. The term “chimeric antibody” is intended to refer to antibodies in which the variable region sequences are derived from one species and the constant region 15 sequences are derived from another species, such as an antibody in which the variable region sequences are derived from a mouse antibody and the constant region sequences are derived from a human antibody. The terms “polypeptide”, “oligopeptide”, “peptide” and “protein” are used interchangeably herein to refer to chains of amino acids of any length. For example, 20 the chain may be relatively short (e.g., 10-100 amino acids), or longer. The chain may be linear or branched, it may comprise modified amino acids, and/or may be interrupted by non-amino acids. The terms also encompass an amino acid chain that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or 25 modification, such as conjugation with a labeling component. Also included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art. It is understood that the polypeptides can occur as single chains or associated chains.  CA 02954802 2017-01-12 50054-294 - 15- A “monovalent antibody” comprises one antigen binding site per molecule (e.g., IgG or Fab). In some instances, a monovalent antibody can have more than one antigen binding sites, but the binding sites are from different antigens. A “monospecific antibody” comprises two identical antigen binding sites per 5 molecule (e.g. IgG) such that the two binding sites bind identical epitope on the antigen. Thus, they compete with each other on binding to one antigen molecule. Most antibodies found in nature are monospecific. In some instances, a monospecific antibody can also be a monovalent antibody (e.g. Fab). A “bivalent antibody” comprises two antigen binding sites per molecule (e.g., 10 IgG). In some instances, the two binding sites have the same antigen specificities. However, bivalent antibodies may be bispecific. A “bispecific” or “dual-specific” is a hybrid antibody having two different antigen binding sites. The two antigen binding sites of a bispecific antibody bind to two different epitopes, which may reside on the same or different protein targets. 15 A “bifunctional” is antibody is an antibody having identical antigen binding sites (i.e., identical amino acid sequences) in the two arms but each binding site can recognize two different antigens. A "heteromultimer", "heteromultimeric complex", or "heteromultimeric polypeptide" is a molecule comprising at least a first polypeptide and a second 20 polypeptide, wherein the second polypeptide differs in amino acid sequence from the first polypeptide by at least one amino acid residue. The heteromultimer can comprise a "heterodimer" formed by the first and second polypeptide or can form higher order tertiary structures where polypeptides in addition to the first and second polypeptide are present. 25 A "heterodimer," "heterodimeric protein," “heterodimeric complex,” or "heteromultimeric polypeptide" is a molecule comprising a first polypeptide and a second polypeptide, wherein the second polypeptide differs in amino acid sequence from the first polypeptide by at least one amino acid residue. The "hinge region," "hinge sequence", and variations thereof, as used herein, 30 includes the meaning known in the art, which is illustrated in, for example,  CA 02954802 2017-01-12 50054-294 - 16 - Janeway et al., ImmunoBiology: the immune system in health and disease, (Elsevier Science Ltd., NY) (4th ed., 1999); Bloom et al., Protein Science (1997), 6:407-415; Humphreys et al., J. Immunol. Methods (1997), 209:193-202. The “immunoglobulin-like hinge region,” “immunoglobulin-like hinge 5 sequence,” and variations thereof, as used herein, refer to the hinge region and hinge sequence of an immunoglobulin-like or an antibody-like molecule (e.g., immunoadhesins). In some embodiments, the immunoglobulin-like hinge region can be from or derived from any lgG1, lgG2, lgG3, or lgG4 subtype, or from IgA, IgE, IgD or IgM, including chimeric forms thereof, e.g., a chimeric lgG1/2 hinge region. 10 The term “immune effector cell” or “effector cell as used herein refers to a cell within the natural repertoire of cells in the human immune system which can be activated to affect the viability of a target cell. The viability of a target cell can include cell survival, proliferation, and/or ability to interact with other cells. Antibodies of the invention can be produced using techniques well known in 15 the art, e.g., recombinant technologies, phage display technologies, synthetic technologies or combinations of such technologies or other technologies readily known in the art (see, for example, Jayasena, S.D., Clin. Chern., 45: 1628-50, 1999 and Fellouse, F.A., et al, J. Mol. Biol., 373(4):924-40, 2007). As known in the art, “polynucleotide,” or “nucleic acid,” as used 20 interchangeably herein, refer to chains of nucleotides of any length, and include DNA and RNA. The nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and/or their analogs, or any substrate that can be incorporated into a chain by DNA or RNA polymerase. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and their analogs. If present, 25 modification to the nucleotide structure may be imparted before or after assembly of the chain. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. Other types of modifications include, for example, “caps”, substitution of one or more of the naturally occurring nucleotides 30 with an analog, internucleotide modifications such as, for example, those with  CA 02954802 2017-01-12 50054-294 - 17 - uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoamidates, carbamates, etc.) and with charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), those containing pendant moieties, such as, for example, proteins (e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), 5 those with intercalators (e.g., acridine, psoralen, etc.), those containing chelators (e.g., metals, radioactive metals, boron, oxidative metals, etc.), those containing alkylators, those with modified linkages (e.g., alpha anomeric nucleic acids, etc.), as well as unmodified forms of the polynucleotide(s). Further, any of the hydroxyl groups ordinarily present in the sugars may be replaced, for example, by 10 phosphonate groups, phosphate groups, protected by standard protecting groups, or activated to prepare additional linkages to additional nucleotides, or may be conjugated to solid supports. The 5’ and 3’ terminal OH can be phosphorylated or substituted with amines or organic capping group moieties of from 1 to 20 carbon atoms. Other hydroxyls may also be derivatized to standard protecting groups. 15 Polynucleotides can also contain analogous forms of ribose or deoxyribose sugars that are generally known in the art, including, for example, 2’-O-methyl-, 2’-O-allyl, 2’- fluoro- or 2’-azido-ribose, carbocyclic sugar analogs, alpha- or beta-anomeric sugars, epimeric sugars such as arabinose, xyloses or lyxoses, pyranose sugars, furanose sugars, sedoheptuloses, acyclic analogs and abasic nucleoside analogs such as 20 methyl riboside. One or more phosphodiester linkages may be replaced by alternative linking groups. These alternative linking groups include, but are not limited to, embodiments wherein phosphate is replaced by P(O)S(“thioate”), P(S)S (“dithioate”), (O)NR2 (“amidate”), P(O)R, P(O)OR’, CO or CH2 (“formacetal”), in which each R or R’ is independently H or substituted or unsubstituted alkyl (1-20 C) 25 optionally containing an ether (-O-) linkage, aryl, alkenyl, cycloalkyl, cycloalkenyl or araldyl. Not all linkages in a polynucleotide need be identical. The preceding description applies to all polynucleotides referred to herein, including RNA and DNA. As known in the art, a “constant region” of an antibody refers to the constant region of the antibody light chain or the constant region of the antibody heavy chain, 30 either alone or in combination.  CA 02954802 2017-01-12 50054-294 - 18 - As used herein, “substantially pure” refers to material which is at least 50% pure (i.e., free from contaminants), more preferably, at least 90% pure, more preferably, at least 95% pure, yet more preferably, at least 98% pure, and most preferably, at least 99% pure. 5 A “host cell” includes an individual cell or cell culture that can be or has been a recipient for vector(s) for incorporation of polynucleotide inserts. Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in genomic DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation. A host cell includes cells 10 transfected in vivo with a polynucleotide(s) of this invention. As known in the art, the term "Fc region" is used to define a C-terminal region of an immunoglobulin heavy chain. The "Fc region" may be a native sequence Fc region or a variant Fc region. Although the boundaries of the Fc region of an immunoglobulin heavy chain might vary, the human IgG heavy chain Fc region is 15 usually defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl-terminus thereof. The numbering of the residues in the Fc region is that of the EU index as in Kabat. Kabat et aL, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991. The Fc region of an immunoglobulin generally comprises two 20 constant regions, CH2 and CH3. As used in the art, "Fc receptor" and “FcR” describe a receptor that binds to the Fc region of an antibody. The preferred FcR is a native sequence human FcR. Moreover, a preferred FcR is one which binds an IgG antibody (a gamma receptor) and includes receptors of the FcyRI, FcyRII, and FcyRIII subclasses, including allelic 25 variants and alternatively spliced forms of these receptors. FcyRII receptors include FcyRIIA (an "activating receptor") and FcyRIIB (an "inhibiting receptor"), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof. FcRs are reviewed in Ravetch and Kinet, Ann. Rev. Immunol., 9:457-92, 1991; Capel et al., Immunomethods, 4:25-34, 1994; and de Haas et al., J. Lab. Clin. Med., 30 126:330-41, 1995. “FcR” also includes the neonatal receptor, FcRn, which is  CA 02954802 2017-01-12 50054-294 - 19 - responsible for the transfer of maternal IgGs to the fetus (Guyer et aL, J. Immunol., 117:587, 1976; and Kim et aL, J. Immunol., 24:249, 1994). The term “compete”, as used herein with regard to an antibody, means that a first antibody, or an antigen binding fragment (or portion) thereof, binds to an epitope 5 in a manner sufficiently similar to the binding of a second antibody, or an antigen binding portion thereof, such that the result of binding of the first antibody with its cognate epitope is detectably decreased in the presence of the second antibody compared to the binding of the first antibody in the absence of the second antibody. The alternative, where the binding of the second antibody to its epitope is 10 also detectably decreased in the presence of the first antibody, can, but need not be the case. That is, a first antibody can inhibit the binding of a second antibody to its epitope without that second antibody inhibiting the binding of the first antibody to its respective epitope. However, where each antibody detectably inhibits the binding of the other antibody with its cognate epitope or ligand, whether to the same, greater, or 15 lesser extent, the antibodies are said to “cross-compete” with each other for binding of their respective epitope(s). Both competing and cross-competing antibodies are encompassed by the present invention. Regardless of the mechanism by which such competition or cross-competition occurs (e.g., steric hindrance, conformational change, or binding to a common epitope, or portion thereof), the skilled artisan would 20 appreciate, based upon the teachings provided herein, that such competing and/or cross-competing antibodies are encompassed and can be useful for the methods disclosed herein. A “functional Fc region” possesses at least one effector function of a native sequence Fc region. Exemplary “effector functions” include C1q binding; 25 complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cell- mediated cytotoxicity; phagocytosis; down-regulation of cell surface receptors (e.g. B cell receptor), etc. Such effector functions generally require the Fc region to be combined with a binding domain (e.g. an antibody variable domain) and can be assessed using various assays known in the art for evaluating such antibody effector 30 functions.  CA 02954802 2017-01-12 50054-294 - 20 - A “native sequence Fc region” comprises an amino acid sequence identical to the amino acid sequence of an Fc region found in nature. A “variant Fc region” comprises an amino acid sequence which differs from that of a native sequence Fc region by virtue of at least one amino acid modification, yet retains at least one 5 effector function of the native sequence Fc region. In some embodiments, the variant Fc region has at least one amino acid substitution compared to a native sequence Fc region or to the Fc region of a parent polypeptide, e.g. from about one to about ten amino acid substitutions, and preferably, from about one to about five amino acid substitutions in a native sequence Fc region or in the Fc region of the parent 10 polypeptide. The variant Fc region herein will preferably possess at least about 80% sequence identity with a native sequence Fc region and/or with an Fc region of a parent polypeptide, and most preferably, at least about 90% sequence identity therewith, more preferably, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% sequence identity therewith. 15 The term “effector function” refers to the biological activities attributable to the Fc region of an antibody. Examples of antibody effector functions include, but are not limited to, antibody-dependent cell-mediated cytotoxicity (ADCC), Fc receptor binding, complement dependent cytotoxicity (CDC), phagocytosis, C1q binding, and down regulation of cell surface receptors (e.g., B cell receptor; BCR). See, e.g., U.S. 20 Pat No. 6,737,056. Such effector functions generally require the Fc region to be combined with a binding domain (e.g., an antibody variable domain) and can be assessed using various assays known in the art for evaluating such antibody effector functions. An exemplary measurement of effector function is through Fcy3 and/or C1q binding. 25 As used herein “antibody-dependent cell-mediated cytotoxicity” or “ADCC” refers to a cell-mediated reaction in which nonspecific cytotoxic cells that express Fc receptors (FcRs) (e.g. natural killer (NK) cells, neutrophils, and macrophages) recognize bound antibody on a target cell and subsequently cause lysis of the target cell. ADCC activity of a molecule of interest can be assessed using an in vitro ADCC 30 assay, such as that described in U.S. Patent No. 5,500,362 or 5,821,337. Useful  CA 02954802 2017-01-12 50054-294 - 21 - effector cells for such assays include peripheral blood mononuclear cells (PBMC) and NK cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes et aL, 1998, PNAS (USA), 95:652-656. 5 “Complement dependent cytotoxicity” or “CDC” refers to the lysing of a target in the presence of complement. The complement activation pathway is initiated by the binding of the first component of the complement system (C1q) to a molecule (e.g. an antibody) complexed with a cognate antigen. To assess complement activation, a CDC assay, e.g. as described in Gazzano-Santoro et aL, J. Immunol. 10 Methods, 202: 163 (1996), may be performed. An “individual” or a "subject" is a mammal, more preferably, a human. Mammals also include, but are not limited to primates, horses, dogs, cats, mice and rats. 15 As used herein, "vector" means a construct, which is capable of delivering, and, preferably, expressing, one or more gene(s) or sequence(s) of interest in a host cell. Examples of vectors include, but are not limited to, viral vectors, naked DNA or RNA expression vectors, plasmid, cosmid or phage vectors, DNA or RNA expression vectors associated with cationic condensing agents, DNA or RNA expression vectors 20 encapsulated in liposomes, and certain eukaryotic cells, such as producer cells. As used herein, "expression control sequence" means a nucleic acid sequence that directs transcription of a nucleic acid. An expression control sequence can be a promoter, such as a constitutive or an inducible promoter, or an enhancer. The expression control sequence is operably linked to the nucleic acid sequence to 25 be transcribed. As used herein, "pharmaceutically acceptable carrier" or "pharmaceutical acceptable excipient" includes any material which, when combined with an active ingredient, allows the ingredient to retain biological activity and is non-reactive with the subject's immune system. Examples include, but are not limited to, any of the 30 standard pharmaceutical carriers such as a phosphate buffered saline solution,  CA 02954802 2017-01-12 50054-294 - 22 - water, emulsions such as oil/water emulsion, and various types of wetting agents. Preferred diluents for aerosol or parenteral administration are phosphate buffered saline (PBS) or normal (0.9%) saline. Compositions comprising such carriers are formulated by well known conventional methods (see, for example, Remington's 5 Pharmaceutical Sciences, 18th edition, A. Gennaro, ed., Mack Publishing Co., Easton, PA, 1990; and Remington, The Science and Practice of Pharmacy 21st Ed. Mack Publishing, 2005). The term “acyl donor glutamine-containing tag” or “glutamine tag” as used herein refers to a polypeptide or a protein containing one or more Gin residue(s) that 10 acts as a transglutaminase amine acceptor. See, e.g., WO2012059882 and WO2015015448. The term "kon" or “ka”, as used herein, refers to the rate constant for association of an antibody to an antigen. Specifically, the rate constants (kon/ka and koff/kd) and equilibrium dissociation constants are measured using whole antibody (i.e. 15 bivalent) and monomeric EGFRvlll proteins (e.g., Histidine-tagged EGFRvlll fusion protein). The term "kOff " or “kd”, as used herein, refers to the rate constant for dissociation of an antibody from the antibody/antigen complex. The term "KD", as used herein, refers to the equilibrium dissociation constant 20 of an antibody-antigen interaction. Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. For example, description referring to “about X” includes description of “X.” Numeric ranges are inclusive of the numbers defining the range. Generally speaking, the term “about” 25 refers to the indicated value of the variable and to all values of the variable that are within the experimental error of the indicated value (e.g. within the 95% confidence interval for the mean) or within 10 percent of the indicated value, whichever is greater. Where the term “about” is used within the context of a time period (years, months, weeks, days etc.), the term “about” means that period of time plus or minus 30 one amount of the next subordinate time period (e.g. about 1 year means 11-13  CA 02954802 2017-01-12 50054-294 - 23 - months; about 6 months means 6 months plus or minus 1 week; about 1 week means 6-8 days; etc.), or within 10 per cent of the indicated value, whichever is greater. It is understood that wherever embodiments are described herein with the language “comprising,” otherwise analogous embodiments described in terms of 5 “consisting of’ and/or “consisting essentially of” are also provided. Where aspects or embodiments of the invention are described in terms of a Markush group or other grouping of alternatives, the present invention encompasses not only the entire group listed as a whole, but each member of the group individually and all possible subgroups of the main group, but also the main group absent one or 10 more of the group members. The present invention also envisages the explicit exclusion of one or more of any of the group members in the claimed invention. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In case of conflict, the present specification, including 15 definitions, will control. Throughout this specification and claims, the word "comprise," or variations such as "comprises" or "comprising" will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers. Unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. 20 Exemplary methods and materials are described herein, although methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention. The materials, methods, and examples are illustrative only and not intended to be limiting. EGFRvlll Antibodies and Methods of Making Thereof 25 The present invention provides an antibody that binds to EGFRvlll [e.g., human EGFRvlll (e.g., accession number: P00533 Feature Identifier VAR_066493, or GenBank Acession No. AJN69267; mrpsgtagaallallaalcp asraleekkgnyvvtdhgscvracgadsyemeedgvrkckkcegpcrkvcngigigefkdsls inatnikhfknotsisgdlhilpvafrgdsfthtppldpqeldilktvkeitgflliqawpen 30 rtdlhafenleiirgrtkqhgqfslawsInitslglrslkeisdgdviisgnknlcyantin  CA 02954802 2017-01-12 50054-294 - 24 - wkklfgtsgqktkiisnrgensckatgqvchalcspegcwgpeprdcvscrnvsrgrecvdkc nllegeprefvenseciqchpeclpqamnitctgrgpdnciqcahyidgphcvktcpagvmge nntlvwkyadaghvchlchpnctygctgpglegcptngpkipsiatgmvgalllllwalgig Ifmrrrhivrkrtlrrllqerelvepltpsgeapnqallrilketefkkikvlgsgafgtvyk 5 glwipegekvkipvaikelreatspkankeildeayvmasvdnphvcrllgiclt tvqlits q Impfgclldyvrehkdnigsqyllnwcvqiakgmnyledrrlvhrdlaarnvlvktpqhvkit dfglakllgaeekeyhaeggkvpikwmalesilhriythqsdvwsygvtvwelmtfgskpydg ipaseissilekgerlpqppictidvymimvkcwmidadsrpkfreliiefskmardpqrylv iqgdermhlpsptdsnfyralmdeedmddvvdadeylipqqgffsspstsrtpllsslsatsn 10 nstvacidrnglqscpikedsfIqryssdptgaltedsiddtfIpvpeyinqsvpkrpagsvq npvyhnqplnpapsrdphyqdphstavgnpeylntvqptcvnstfdspahwaqkgshqisldn pdyqqdffpkeakpngifkgstaenaeylrvapqssefiga(SEQ ID NO: 201))]. In some embodiments, such antibodies are characterized by any one or more of the following characteristics: (a) decrease or downregulate the protein expression of EGFRvlll; (b) 15 treat, prevent, ameliorate one or more symptoms of a condition associated with malignant cells expressing EGFRvlll in a subject (e.g., cancer such as glioblastoma multiform); (c) inhibit tumor growth or progression in a subject (who has a malignant tumor expressing EGFRvlll); (d) inhibit metastasis of cancer (malignant) cells expressing EGFRvlll in a subject (who has one or more malignant cells expressing 20 EGFRvlll); (e) induce regression (e.g., long-term regression) of a tumor expressing EGFRvlll; (f) exert cytotoxic activity in malignant cells expressing EGFRvlll; (g) block EGFRvlll interaction with other yet to be identified factors; and/or (h) induce bystander effect that kill or inhibit growth of non-EGFRvlll expressing malignant cells in the vicinity. 25 In one aspect, provided is an isolated antibody which specifically binds to EGFRvlll, wherein the antibody comprises (a) a heavy chain variable (VH) region comprising (i) a VH complementarity determining region one (CDR1) comprising the sequence shown in SEQ ID NO: 62, 63, 64, 74, 75, 76, 80, 81, 82, 88, 89, 90, 93, 94, 95, 99, 100, 101, 109, 110, 111, 115, 116, 117, 121, 122, 123, 132, 133, 134, 137, 30 138, 139, 143, 144, or 145; (ii) a VH CDR2 comprising the sequence shown in SEQ  CA 02954802 2017-01-12 50054-294 - 25 - ID NO: 65, 66, 68, 69, 70, 71, 77, 78, 83, 84, 86, 87, 91, 92, 96, 97, 98, 102, 103, 105, 106, 112, 113, 118, 119, 124, 125, 127, 128, 130, 131, 135, 136, 140, 141, 146, 147, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, or 237; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 67, 72, 73, 79, 85, 104, 107, 5 108, 114, 120, 126, 129, 142, 148, 219, 220, 221, 222, 223, or 236; and/or (b) a light chain variable (VL) region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 149, 154, 156, 159, 162, 165, 166, 168, 169, 170, 171, 173, 174, 176, 178, 181, 182, 185, 187, 190, 192, 195, 198, 238, or 239; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 150, 152, 155, 157, 160, 163, 172, 175, 179, 10 183, 186, 188, 191, 193, 196, or 199; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 151, 153, 158, 161, 164, 167, 177, 180, 184, 189, 194, 197, or 200. In another aspect, provided is an isolated antibody which specifically binds to EGFRvlll, wherein the antibody comprises: a VH region comprising a VH CDR1, VH 15 CDR2, and VH CDR3 of the VH sequence shown in SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 30, 32, 34, 35, 37, 39, 41, 43, 44, 46, 48, 50, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 202, 203, 204, 205, 206, 207, 208, 209, 210, 214, 216, 217, or 218; and/or a VL region comprising VL CDR1, VL CDR2, and VL CDR3 of the VL sequence shown in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 20 29, 31, 33, 36, 38, 40, 42, 45, 47, 49, 51, 211, 212, 213, or 215. In some embodiments, provided is an antibody having any one of partial light chain sequence as listed in Table 1 and/or any one of partial heavy chain sequence as listed in Table 1. In Table 1, the underlined sequences are CDR sequences according to Kabat and in bold according to Chothia. 25  CA 02954802 2017-01-12 50054-294 - 26 - Table 1 mAb Light Chain Heavy Chain m62G7 DWMTQTPLTLSVTIGQPASISCK EVQLQQSGPELVKPGASVKISCKT SSQSLLYSNGKTYLNWLLQRPG SGYTFTDYTLHWVKQSHVKSLEWI QSPKRLIYLVSKLDSGVPDRFTG GGIDPINGGTTYNQKFKGKATLTV SGSGTDFTLKISRVEAEDLGFYY DKSSSTAYMELRSLTSEDSAVYYC CVQDTHFPLTFGAGTKLELK ARGEAMDSWGQGTSVTVSS (SEQ ID NO: 2) (SEQ ID NO: 1) h62G7 DWMTQSPLSLPVTLGQPASISC QVQLVQSGAEVKKPGASVKVSCK KSSQSLLYSNGKTYLNWFQQRP ASGYTFTDYTLHWVRQAPGQGLE GQSPRRLIYLVSKLDSGVPDRFS WMGGINPINGGTTYNQKFKGRVT GSGSGTDFTLKISRVEAEDVGVY MTRDTSTSTVYMELSSLRSEDTAV YCVQDTHFPLTFGGGTKVEIK YYCARGEAM DSWGQGTLVTVSS (SEQ ID NO: 4) (SEQ ID NO: 3) h62G7- DWMTQSPLSLPVTLGQPASISC QVQLVQSGAEVKKPGASVKVSCK EQ/L6 KSSQSLLYSNGKTYLNWFQQRP ASGYTFTDYTLHWVRQAPGQGLE GQSPRRLIYQVSKLDSGVPDRFS WMGGIWPITGGTTYNQKFKGRVT GSGSGTDFTLKISRVEAEDVGVY MTRDTSTSTVYMELSSLRSEDTAV YCGQDTHFPLTFGGGTKVEIK YYCARGEAQGSWGQGTLVTVSS (SEQ ID NO: 6) (SEQ ID NO: 5) h62G7 DWMTQSPLSLPVTLGQPASISC QVQLVQSGAEVKKPGASVKVSCK H14/L1- KSSQSLLYSNDKTYTNWFQQRP ASGYTFTDYTLHWVRQAPGQGLE DV GQSPRRLIYEVSKLDVGVPDRFS WMGGIWPITGGTTYNQKFKGRVT GSGSGTDFTLKISRVEAEDVGVY MTRDTSTSTVYMELSSLRSEDTAV YCGQDTHFPLTFGGGTKVEIK YYCARGEAEGSWGQGTLVTVSS (SEQ ID NO: 8) (SEQ ID NO: 7) 42G9 EWLTQSPATLSVSPGERATLSC QVTLKESGPVLLKPTETLTLTCTVS RASQSVRSNLAWYQQKSGQAP GFSLSNPRMGVSWIRQPPGKALE RLLIYGSTIRATGVPARFSGSGS WFAHIFSTDEKSLKLSLRSRLTLSK  CA 02954802 2017-01-12 50054-294 - 27 - mAb Light Chain Heavy Chain GTEFTLTISSLQSEDFAVYYCQQ DTSKSQVVLTMTNMAPVDSATYY YSDWPFTFGPGTKVDIK (SEQ ID CARDSSNYEGYFDFWGQGTLVTV NO: 10) SS (SEQ ID NO: 9) 32A10 EVVMTQSPATLSVSPGERVTLSC QVTLKESGPVLVKPTETLTLTCTV RASQSVSSNFAWYQQRPGQAP SGFSLSNARMGVSWIRQPPGKAL RLLLYGATTRATGLPGRFSGSGS EWLAHIFSTDEKSIRRSLRSRLTLS GTENILTISSLQSEDFAIYFCQQY KDTSKSQVVLTMTNMDPVDTATY KDWPFTFGPGSKVDIK (SEQ ID FCARDSSNYEGYFDYWGQGTLVT NO: 12) VSS (SEQ ID NO: 11) 20B9 EIVMTQSPATLSVSPGERATLSC QVTLKESGPVLVKPTETLTLTCTV RVSQSIGANLAWYQQKFGQAPR SGFSLSNARMGVSWIRQPPGKAL LLIYGASTRATGIPVRFSGGGSG EWLGHIFSTDEKSYSTSLRGRITIS TEFTLTISSLQSEDFAIYSCQQYIY KDTSRGLVVLTLTNMDPVDTATYY WPFTFGPGTTVDIK CARDSSNYEGYFDFWGPGFLVTV (SEQ ID NO: 14) SS (SEQ ID NO: 13) 14C11 EIVMTQSPATLSVSPGERATLSC QVTLKESGPVLVKPTETLTLTCTV RASQSVSNNLAWYQQKPGQAP SGFSLNNARMGVSWIRQPPGKAL RLLIYGASTRATGVPARFSGSDS EWFAHIFSTDEKSFRTSLRSRLTL GTEFSLTISSLQSEDFAVYFCQQ SKDTSKSQVVLTMTNMDPVDTAT YKDWPFTFGPGTKVEIK (SEQ ID YYCARDSSNYEGYFDYWGQGILV NO: 16) TVSS (SEQ ID NO: 15) 21E11 DMWTQSPATLSVSPGERATLSC QVTLKESGPVLVKPTETLTLTCTV RASQSVGSDLAWYQQPPGQSP SGFSLSNVRMGVSWIRQPPGKAL RLLIYGASTRATGVPARFSGSGS EWFAHIFSSDEKSIRRSLRSRLTLS GTDFTLTITSLESEDFAVYYCQQY KDTSKSQVVLTMTNMDPVDTATY NDWPFTFGPGTKVDIK (SEQ ID YCARDSSNYEGYFDFWGQGTLVT NO: 18) VSSN (SEQ ID NO: 17) 49B11 EMEVTQSPATLSVSPGERATLSC QVTLKESGPVLVKPTETLTLTCTV  CA 02954802 2017-01-12 50054-294 -28 - mAb Light Chain Heavy Chain RASQNIGSDLAWYQQQSGQAP SGFSLSNVRMGVSWIRQPPGKAL RLLISGASTRATGVPTRFSGSGS EWFAHIFSSDEKSIRRSLRSRLTLS GTDFTLTITSLQSEDFAVYYCQQ KDTSKSQVVLTMTNMDPVDTATY YNDWPFTFGPGTKVDIK (SEQ ID YCARDSSNYEGYFDYWGQGTLVT NO: 20) VSS (SEQ ID NO: 19) 46E10 EVVMTQSPPNLSVSPGERATLSC QVTLKESGPVLVKPTETLTLTCTV RASQSVTSNFAWYQQRPGQSP SGFSLSNARMGVSWIRQPPGKAL RLLLYGASTRATGVPGRFSGSG EWLAHIFSTDEKSIRRSLRSRLTLS SGTENILTISSLQSEDFAVYFCQQ KDTSKSQWLIMTNMDPVDTATYY YKDWPFTFGPGSKVDIK (SEQ ID CARDSSNYEGYFDYWGQGTLVTV NO: 22) SS (SEQ ID NO: 21) 12H6 EWMTQSPATLSVSPGERATLSC QVTLKESGPVLVKPTETLTLTCTV RASQGVSSNFAWYQQRPGQSP SGFSLSNARMGVSWIRQPPGKAL RLLLYGASTRATGVPGRFSGSG EWLAHIFSTDEKSIRRSLRSRLTLS SGTENILTISSLQSEDFAIYFCQQ KDTSKSQWLTMTNMDPVDTATY YKDWPFTFGPGSKVDIK (SEQ ID YCARDSSNYEGYFDYWGQGTLVT NO: 24) VSS (SEQ ID NO: 23) 19A9 EWMTQSPATLSVSPGERATLSC QVTLEESGPVLVKPTETLTLTCTV RASQSVNRNLAWYQQKPGQAP SGFSLSNARMGVSWIRQPPGKAP RLLIFGTSTRATGIPARFSGSGSG EWFAHIFSTDEKSLRLSLRSRLTL TEFTLTIDSLQSEHSGLYYCQQY SKDTSKSQWLTMTNMDPVDTAT NDWPFTFGPGTKVDIK (SEQ ID YYCARDSSNYEGYFDYWGQGTLV NO: 26) TVSS (SEQ ID NO: 25) 11B11 EVLMTQS PATLSVSPGERATLSC QVTLKESGPVLVKPTETLTLTCTV RASQSVSTNFAWYQQRPGQAP SGFSLSNAKMGVSWIRQPPGKAL RLLLFGASTRATG PG1 RFSGSGS EWLAHIFSTDEKSIRRSLRSRLTM GTENILTISSLQSEDFAIYFCQQY SKDTSKSQWLTMTNMDPVDTAT KDWPFTFGPGSKVEIK (SEQ ID YYCVRDSSNYEGYFDYWGQGTLV  CA 02954802 2017-01-12 50054-294 - 29 - mAb Light Chain Heavy Chain NO: 28) TVSS (SEQ ID NO: 27) 21E7 DVVLTQSPATLSVSPGERATLSC QVTLEESGPVLVKPTETLTLTCTV RASQSVNSNLAWYQQNPGQAP SGFSLSNARMGVSWIRQPPGKAP RLLIFGSSTRATGIPASFSGSGSG EWFAHIFSTDEKSLRLSLRSRLTL TEFTLTINSLQSEHSAVYYCQQY SKDTSKSQVVLTMTNMDPVDTAT NDWPFTFGPGTKVDIK (SEQ ID YYCARDSSNYEGYFDYWGQGTLV NO: 29) TVSS (SEQ ID NO: 25) 12B2 EWMTQSPATLSVSPGERATLSC QVTLKESGPVLVKPTETLTLTCTV RASQSVINNLAWYQQKPGQAPR SGFSLSNPRMGVSWIRQPPGKAL LLIYGTSTRATDIPARFSGSGSGT EWLGHIFSSDEKSYRLSLRSRLSIS EFTLTISSLQSEDFAVYYCQDYN KDTSKSQVVLTMTNMDPVDTATY NWPFTFGPGTKVDIK (SEQ ID YCVRDSSNYGGYFDYWGQGTLV NO: 31) TVSS (SEQ ID NO: 30) 11F10 EIVMTQSPATLSVSPGERTTLSC QVTLKESGPVLVKPIETLTLTCTVC RASQSVGSNLAWYQQKPGQAP GFSLSNPRMGVSWIRQPPGKALE RLLIYGASTRASGVPARFSGSGS WLGHIFSSDEKSYRLFLRSRLSISK GTEFTLTISSLQSEDFAVYSCQEY DTSKSQVVLTMTNMDPVDTATYY NNWPFTFGQGTKVEIK (SEQ ID CARDSSDYEGYFDYWGQGTLVTV NO: 33) SS (SEQ ID NO: 32) 17G11 EVVMTQSPATLSVSPGERATLSC QVTLKESGPVLVKPTETLTLTCTVF RASQSVINNLAWYQQKPGQAPR GFSLSNPRMGVSWIRQPPGKAPE LLIYGTSTRATDIPARFSGSGSGT WLGHIFSSDEKSYRLSLRSRLSISK EFTLTISSLQSEDFAVYYCQDYN DTSKSQVVFXMTNMDPGDPATYY NWPFTFGPGTKVDIK (SEQ ID CVRDSSNYEEYFDYWGQGTLVTV NO: 31) SS (SEQ ID NO: 34) 29D5 KIVMTQSPATLSVSPGERATLSC QVTLKESGPVLVKPTETLTLTCTV RANQIVSSNLAWYQQKPGQAPR SGFSLSNPRMGVSWLRQPPGKAL LLVFGTSTRATGIPIRFSGSGSGT EWFAHIFSTDEKSYSPSLRGRLTV  CA 02954802 2017-01-12 50054-294 - 30 - mAb Light Chain Heavy Chain EFTLTVSSLQSEDFAVYVCQQYN SKDTSKSQVVLTLTNMDPVDTATY DWPFTFGPGTKVDIK (SEQ ID YCARDSSNYEGYFDYWGQGTLVT NO: 36) VSS (SEQ ID NO: 35) 30D8 DIVMTQSPLSLPVTPGEPASISCR EVQLVESGGGLVKPGGSLRLSCE SSQSLLHNKRNNYLDWFLQKPG ASGFTFSDAWMSWVRQAPGKGL QSPQLLIYLASNRASGVPDRFSG EWVGRIKSKTDGGTTDYVVPLNG GGSGTDFTLKISRVEAEDVGVYY RFIISRDDSRNTLYLQLNNLKTEDT CMQAQQTPITFGQGTRLEIK AVYYCTTVPGSYGYWGQGTLVTV (SEQ ID NO: 38) SS (SEQ ID NO: 37) 20E12 DIVLTQSPLSLSVTPGEPASISCR EVNLVESGGGLVKPGGSLRLSCE SSQSLLYSNGKNYLDWFLHKPG ASGFTFSYAWMSWVRQAPGKGL QSPQLLIYLGSNRASGVPDRFSG EWVGRIKSIADGGATDYAAPVRN SGSGIDFILKISRVEAEDVGVYYC RFTISRDDSRNTLYLEMHSLKTED MQAQQTPITFGQGTRLEIK (SEQ TAVYYCTTIPGNDAFDMWGQGTM ID NO: 40) VTVSS (SEQ ID NO: 39) 26B9 DIVLTQSPLSLPVTPGEPASISCR EVQLVESWGVLVKPGGSLRLSCA SSQSLLHRDGFNYLDWFLQKPG ASGFIFNNAWMSWVRQAPGKGLE QSPQLLIYLASSRASGVPDRFSG WIGRIKSKSDGGTTDYAAPVKDRF SDSGTDFTLKISRVEAEDVGVYY TISRDDSKDTLYLQMNGLKTEDTA CMQALQTPITFGQGTRLEIK VYFCTTAPGGPFDYWGQGTLVTV (SEQ ID NO: 42) SS (SEQ ID NO: 41) 32G8 DIVLTQSPLSLSVTPGEPASISCR EVNLVESGGGLVKPGGSLRLSCE SSQSLLYSNGKNYLDWFLHKPG ASGFTFSYAWMSWVRQAPGKGL QSPQLLIYLGSNRASGVPDRFSG EWVGRIKSITDGGVIDYAAPVRNR SGSGIDFILKISRVEAEDVGVYYC CTISRDDSRNTLYLEMHSLKTEDT MQAQQTPITFGQGTRLEIK (SEQ AVYYCTTIPGNDDFDMWGQGRM ID NO: 40) VTVSS (SEQ ID NO: 43) 34E7 DIVLTQSPLSLSVTPGEPASISCR EVNLVESGGGLVKPGGSLRLSCE  CA 02954802 2017-01-12 50054-294 - 31 - mAb Light Chain Heavy Chain STQSLLYSNGKNYLDWFLHKPG ASGFTFSYAWMSWVRQAPGKGL QSPQLLIFLGSIRASGVPDRFSG EWVGRIKSINDGGATDYASPVRN SGSGIDFILKISRVEAEDVGVYYC RFTISRDDSRNMLYLEMHSLKTED MQAQQTPITFGQGTRLEIK (SEQ TAVYYCTTIPGNDAFDMWGQGTL ID NO: 45) VTVSS (SEQ ID NO: 44) 20G5 DIVLTQSPLSLPVTPGEPASISCR EVQLVESGGDLVKPGGSLRLSCA SSQSLLYSDRRNYLDWFLQKPG ASGFTFTNAWMSWVRQAPGKGL QSPHLLIYLGSYRASGVPDRFSG EWVGRIKSKIDGGTTDYAAPVKG SGSGTDFTLKISRVEAEDVGVYY RFIISRDDSKNTLSLQMNSLKTEDT CMQALQIPITFGQGTRLEIK (SEQ AMYYCTTAPGGPFDYWGQGSLV ID NO: 47) TVSS (SEQ ID NO: 46) C6 ELQSVLTQPPSASGTPGQRVTIS QVQLVQSGAEVKKPGSSVKVSCK CSGSSSNIGSNYVYWYQQLPGT ASGDTFSSNAISWVRQAPGQGLE APKILIYRNNQRPSGVPDRFSGS WMGVIIPIFGTADYAQKFQGRVTIT KSGTSASLAISGLRSEDEADYYC ADESTSTAYMELSSLRSEDTAVYY AAWDDNLSGWVFGTGTKLTVL CARHTYHEYAGGYYGGAMDPWG (SEQ ID NO: 49) QGTLVTVSS (SEQ ID NO: 48) B5 DIQMTQSPSSLSASVGDRVTITC EVQLLESGGGLVQPGGSLRLSCA RASQSISSYLNWYQQKPGKAPK ASGFTFSNYAMSWVRQAPGKGLE LLIYAASSLQSGVPSRFSGSGSG WVSDISGGGGRTYYADSVKGRFTI TDFTLTISSLQPEDFATYYCQQSY SRDNSKNTLYLQMNSLRAEDTAV STPLTFGQGTKVEIK (SEQ ID YYCARAGLLYGGGVYPMDIWGQ NO: 51) GTLVTVSS (SEQ ID NO: 50) 42G9-1 EWLTQSPATLSVSPGERATLSC QVTLKESGPVLLKPTETLTLTCTVS RASQSVRSNLAWYQQKSGQAP GFSLSNPRMGVSWIRQPPGKALE RLLIYGSTIRATGVPARFSGSGS WFAHIFSTDEKSLKLSLRSRLTLSK GTEFTLTISSLQSEDFAVYYCQQ DTSKSQVVLTMTNMAPVDSATYY YSDWPFTFGPGTKVDIK (SEQ ID CARX1X2SNYEGYFDFWGQGTLVT  CA 02954802 2017-01-12 50054-294 - 32 - mAb Light Chain Heavy Chain NO: 10) VSS, wherein Xi is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, I, L, M, F, Y, or W, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, I, L, M, F, Y, or W (SEQ ID NO: 52) 32A10- EVVMTQSPATLSVSPGERVTLSC QVTLKESGPVLVKPTETLTLTCTV 1 RASQSVSSNFAWYQQRPGQAP SGFSLSNARMGVSWIRQPPGKAL RLLLYGATTRATGLPGRFSGSGS EWLAHIFSTDEKSIRRSLRSRLTLS GTENILTISSLQSEDFAIYFCQQY KDTSKSQWLTMTNMDPVDTATY KDWPFTFGPGSKVDIK (SEQ ID FCARX1X2SNYEGYFDYWGQGTLV NO: 12) TVSS, wherein Xi is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, orW, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 53) 20B9-1 EIVMTQSPATLSVSPGERATLSC QVTLKESGPVLVKPTETLTLTCTV RVSQSIGANLAWYQQKFGQAPR SGFSLSNARMGVSWIRQPPGKAL LLIYGASTRATGIPVRFSGGGSG EWLGHIFSTDEKSYSTSLRGRITIS TEFTLTISSLQSEDFAIYSCQQYIY KDTSRGLVVLTLTNMDPVDTATYY WPFTFGPGTTVDIK CARX1X2SNYEGYFDFWGPGFLVT (SEQ ID NO: 14) VSS, wherein Xi is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 54) 14C11- EIVMTQSPATLSVSPGERATLSC QVTLKESGPVLVKPTETLTLTCTV 1 RASQSVSNNLAWYQQKPGQAP SGFSLNNARMGVSWIRQPPGKAL RLLIYGASTRATGVPARFSGSDS EWFAHIFSTDEKSFRTSLRSRLTL  CA 02954802 2017-01-12 50054-294 - 33 - mAb Light Chain Heavy Chain GTEFSLTISSLQSEDFAVYFCQQ SKDTSKSQVVLTMTNMDPVDTAT YKDWPFTFGPGTKVEIK (SEQ ID YYCARXiXgSNYEGYFDYWGQG 1L NO: 16) VTVSS, wherein X! is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 55) 21E11- DMWTQSPATLSVSPGERATLSC QVTLKESGPVLVKPTETLTLTCTV 1 RASQSVGSDLAWYQQPPGQSP SGFSLSNVRMGVSWIRQPPGKAL RLLIYGASTRATGVPARFSGSGS EWFAHIFSSDEKSIRRSLRSRLTLS GTDFTLTITSLESEDFAVYYCQQY KDTSKSQWLTMTNMDPVDTATY NDWPFTFGPGTKVDIK (SEQ ID YCARXiXgSNYEGYFDFWGQGTLV NO: 18) TVSSN, wherein X! is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 56) 49B11- EMEVTQSPATLSVSPGERATLSC QVTLKESGPVLVKPTETLTLTCTV 1 RASQNIGSDLAWYQQQSGQAP SGFSLSNVRMGVSWIRQPPGKAL RLLISGASTRATGVPTRFSGSGS EWFAHIFSSDEKSIRRSLRSRLTLS GTDFTLTITSLQSEDFAVYYCQQ KDTSKSQWLTMTNMDPVDTATY YNDWPFTFGPGTKVDIK (SEQ ID YCARXiXgSNYEGYFDYWGQGTLV NO: 20) TVSS, wherein X1 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 57) 46E10- EWMTQSPPNLSVSPGERATLSC QVTLKESGPVLVKPTETLTLTCTV  CA 02954802 2017-01-12 50054-294 -34- mAb Light Chain Heavy Chain 1 RASQSVTSNFAWYQQRPGQSP SGFSLSNARMGVSWIRQPPGKAL RLLLYGASTRATGVPGRFSGSG EWLAHIFSTDEKSIRRSLRSRLTLS SGTENILTISSLQSEDFAVYFCQQ KDTSKSQVVLIMTNMDPVDTATYY YKDWPFTFGPGSKVDIK (SEQ ID CARX1X2SNYEGYFDYWGQGTLVT NO: 22) VSS, wherein Xi is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 58) 12H6-1 EWMTQSPATLSVSPGERATLSC QVTLKESGPVLVKPTETLTLTCTV RASQGVSSNFAWYQQRPGQSP SGFSLSNARMGVSWIRQPPGKAL RLLLYGASTRATGVPGRFSGSG EWLAHIFSTDEKSIRRSLRSRLTLS SGTENILTISSLQSEDFAIYFCQQ KDTSKSQVVLTMTNMDPVDTATY YKDWPFTFGPGSKVDIK (SEQ ID YCARX1X2SNYEGYFDYWGQGTLV NO: 24) TVSS, wherein Xi is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 59) 19A9-1 EWMTQSPATLSVSPGERATLSC QVTLEESGPVLVKPTETLTLTCTV RASQSVNRNLAWYQQKPGQAP SGFSLSNARMGVSWIRQPPGKAP RLLIFGTSTRATGIPARFSGSGSG EW FAH1FSTDEKSLRLSLRSRLTL TEFTLTIDSLQSEHSGLYYCQQY SKDTSKSQVVLTMTNMDPVDTAT NDWPFTFGPGTKVDIK (SEQ ID YYCARX1X2SNYEGYFDYWGQGTL NO: 26) VTVSS, wherein Xi is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, I, L, M, F, Y, or W, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, I, L, M, F, Y, or W (SEQ ID NO: 60)  CA 02954802 2017-01-12 50054-294 - 35 - mAb Light Chain Heavy Chain 11B11- EVLMTQSPATLSVSPGERATLSC QVTLKESGPVLVKPTETLTLTCTV 1 RASQSVSTNFAWYQQRPGQAP SGFSLSNAKMGVSWIRQPPGKAL RLLLFGASTRATGIPGRFSGSGS EWLAHIFSTDEKSIRRSLRSRLTM GTENILTISSLQSEDFAIYFCQQY SKDTSKSQVVLTMTNMDPVDTAT KDWPFTFGPGSKVEIK (SEQ ID YYCVRX^SNYEGYFDYWGQGTL NO: 28) VTVSS, wherein Xi is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, I, L, M, F, Y, or W, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, I, L, M, F, Y, or W (SEQ ID NO: 61) 21E7-1 DVVLTQSPATLSVSPGERATLSC QVTLEESGPVLVKPTETLTLTCTV RASQSVNSNLAWYQQNPGQAP SGFSLSNARMGVSWIRQPPGKAP RLLIFGSSTRATGIPASFSGSGSG EWFAHIFSTDEKSLRLSLRSRLTL TEFTLTINSLQSEHSAVYYCQQY SKDTSKSQVVLTMTNMDPVDTAT NDWPFTFGPGTKVDIK (SEQ ID YYCARX1X2SNYEGYFDYWGQGTL NO: 29) VTVSS, wherein is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 202) 12B2-1 EVVMTQSPATLSVSPGERATLSC QVTLKESGPVLVKPTETLTLTCTV RASQSVINNLAWYQQKPGQAPR SGFSLSNPRMGVSWIRQPPGKAL LLIYGTSTRATDIPARFSGSGSGT EWLGHIFSSDEKSYRLSLRSRLSIS EFTLTISSLQSEDFAVYYCQDYN KDTSKSQVVLTMTNMDPVDTATY NWPFTFGPGTKVDIK (SEQ ID YCVRX1X2SNYGGYFDYWGQGTL NO: 31) VTVSS, wherein is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y,  CA 02954802 2017-01-12 50054-294 - 36 - inAb Light Chain Heavy Chain or W (SEQ ID NO: 203) 11F10-1 EIVMTQSPATLSVSPGERTTLSC QVTLKESGPVLVKPIETLTLTCTVC RASQSVGSNLAWYQQKPGQAP GFSLSNPRMGVSWIRQPPGKALE RLLIYGASTRASGVPARFSGSGS WLGHIFSSDEKSYRLFLRSRLSISK GTEFTLTISSLQSEDFAVYSCQEY DTSKSQVVLTMTNMDPVDTATYY NNWPFTFGQGTKVEIK (SEQ ID CARX1X2SDYEGYFDYWGQGTLVT NO: 33) VSS, wherein Xi is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, I, L, M, F, Y, or W, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, I, L, M, F, Y, or W (SEQ ID NO: 204) 17G11- EVVMTQSPATLSVSPGERATLSC QVTLKESGPVLVKPTETLTLTCTVF 1 RASQSVINNLAWYQQKPGQAPR GFSLSNPRMGVSWIRQPPGKAPE LLIYGTSTRATDIPARFSGSGSGT WLGHIFSSDEKSYRLSLRSRLSISK EFTLTISSLQSEDFAVYYCQDYN DTSKSQVVFXMTNMDPGDPATYY NWPFTFGPGTKVDIK (SEQ ID CVRX1X2SNYEEYFDYWGQGTLVT NO: 31) VSS, wherein Xt is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 205) 29D5-1 KIVMTQSPATLSVSPGERATLSC QVTLKESGPVLVKPTETLTLTCTV RANQIVSSNLAWYQQKPGQAPR SGFSLSNPRMGVSWLRQPPGKAL LLVFGTSTRATGIPIRFSGSGSGT EWFAHIFSTDEKSYSPSLRGRLTV EFTLTVSSLQSEDFAVYVCQQYN SKDTSKSQVVLTLTNMDPVDTATY DWPFTFGPGTKVDIK (SEQ ID YCARX1X2SNYEGYFDYWGQGTLV NO: 36) TVSS, wherein X1 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, I, L, M, F,  CA 02954802 2017-01-12 50054-294 - 37 - mAb Light Chain Heavy Chain Y, or W, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 206) 30D8-1 DIVMTQSPLSLPVTPGEPASISCR EVQLVESGGGLVKPGGSLRLSCE SSQSLLHNKRNNYLDWFLQKPG ASGFTFSDAWMSWVRQAPGKGL QSPQLLIYLASNRASGVPDRFSG EWVGRIKSKTX1X2GTTDYWPLN GGSGTDFTLKISRVEAEDVGVYY GRFIISRDDSRNTLYLQLNNLKTED CMQAQQTPITFGQGTRLE1 K TAVYYCTTVPGSYGYWGQGTLVT (SEQ ID NO: 38) VSS, wherein X-i is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 207) 20E12- DIVLTQSPLSLSVTPGEPASISCR EVNLVESGGGLVKPGGSLRLSCE 1 SSQSLLYSX^KNYLDWFLHKP ASGFTFSYAWMSWVRQAPGKGL GQSPQLLIYLGSNRASGVPDRFS EWVGRIKSIAX1X2GATDYAAPVRN GSGSGIDFILKISRVEAEDVGVYY RFTISRDDSRNTLYLEMHSLKTED CMQAQQTPITFGQGTRLEIK. TAVYYCTTIPGNDAFDMWGQGTM wherein Xi is R, H, K, D, E, S, T, VTVSS, wherein X! is R, H, K, D, E, N, Q, C, G, P, A, V, I, L, M, F, Y, or S, T, N, Q, C, G, P, A, V, 1, L, M, F, W, and X2 is R, H, K, D, E, S, T, N, Y, or W, and X2 is R, H, K, D, E, S, Q, C, G, P, A, V, I, L, M, F, Y, or W T, N, Q, C, G, P, A, V, 1, L, M, F, Y, (SEQ ID NO; 211) or W (SEQ ID NO: 208) 26B9-1 DIVLTQSPLSLPVTPGEPASISCR EVQLVESWGVLVKPGGSLRLSCA SSQSLLHRXiXgFNYLDWFLQKP ASGFIFNNAWMSWVRQAPGKGLE GQSPQLLIYLASSRASGVPDRFS WlGRIKSKSX1X2GTTDYAAPVKDR GSDSGTDFTLKISRVEAEDVGVY FTISRDDSKDTLYLQMNGLKTEDT YCMQALQTPITFGQGTRLEIK. AVYFCTTAPGGPFDYWGQGTLVT  CA 02954802 2017-01-12 50054-294 - 38 - mAb Light Chain Heavy Chain wherein Xi is R, H, K, D, E, S, T, VSS, wherein Xi is R, H, K, D, E, S, N, Q, C, G, P, A, V, 1, L, M, F, Y, or T, N, Q, C, G, P, A, V, I, L, M, F, Y, W, and X2 is R, H, K, D, E, S, T, N, or W, and X2 is R, H, K, D, E, S, T, Q, C, G, P, A, V, 1, L, M, F, Y, orW N, Q, C, G, P, A, V, I, L, M, F, Y, or (SEQ ID NO: 212) W (SEQ ID NO: 209) 32G8-1 DIVLTQSPLSLSVTPGEPASISCR EVNLVESGGGLVKPGGSLRLSCE SSQSLLYSXiX2KNYLDWFLHKP ASGFTFSYAWMSWVRQAPGKGL GQSPQLLIYLGSNRASGVPDRFS EWVGRIKSITX1X2GVIDYAAPVRN GSGSGIDFILKISRVEAEDVGVYY RCTISRDDSRNTLYLEMHSLKTED CMQAQQTPITFGQGTRLEIK. TAVYYCTTIPGNDDFDMWGQGRM wherein Xi is R, H, K, D, E, S, T, VTVSS, wherein Xi is R, H, K, D, E, N, Q, C, G, P, A, V, I, L, M, F, Y, or S, T, N, Q, C, G, P, A, V, I, L, M, F, W, and X2 is R, H, K, D, E, S, T, N, Y, or W, and X2 is R, H, K, D, E, S, Q, C, G, P, A, V, I, L, M, F, Y, or W T, N, Q, C, G, P, A, V, I, L, M, F, Y, (SEQ ID NO: 213) or W (SEQ ID NO: 210) 34E7-1 DIVLTQSPLSLSVTPGEPASISCR EVNLVESGGGLVKPGGSLRLSCE STQSLLYSX1X2KNYLDWFLHKP ASGFTFSYAWMSWVRQAPGKGL GQSPQLLIFLGSIRASGVPDRFS EWVGRIKSINXiX2GATPYASPVRN GSGSGIDFILKISRVEAEDVGVYY RFTISRDDSRNMLYLEMHSLKTED CMQAQQTPITFGQGTRLEIK. TAVYYCTTIPGNDAFDMWGQGTL wherein Xi is R, H, K, D, E, S, T, VTVSS, wherein Xi is R, H, K, D, E, N, Q, C, G, P, A, V, I, L, M, F, Y, or S, T, N, Q, C, G, P, A, V, I, L, M, F, W, and X2 is R, H, K, D, E, S, T, N, Y, or W, and X2 is R, H, K, D, E, S, Q, C, G, P, A, V, I, L, M, F, Y, or W T, N, Q, C, G, P, A, V, I, L, M, F, Y, (SEQ ID NO: 215) or W (SEQ ID NO: 214) 20G5-1 DIVLTQSPLSLPVTPGEPASISCR EVQLVESGGDLVKPGGSLRLSCA SSQSLLYSDRRNYLDWFLQKPG ASGFTFTNAWMSWVRQAPGKGL QSPHLLIYLGSYRASGVPDRFSG EWVGRIKSKIXiXgGTTDYAAPVKG  CA 02954802 2017-01-12 50054-294 - 39 - mAb Light Chain Heavy Chain SGSGTDFTLKISRVEAEDVGVYY RFIISRDDSKNTLSLQMNSLKTEDT CMQALQIPITFGQGTRLEIK (SEQ AMYYCTTAPGGPFDYWGQGSLV ID NO: 47) TVSS, wherein X! is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, I, L, M, F, Y, or W, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, I, L, M, F, Y, or W (SEQ ID NO: 216) C6-1 ELQSVLTQPPSASGTPGQRVTIS QVQLVQSGAEVKKPGSSVKVSCK CSGSSSNIGSNYVYWYQQLPGT ASGDTFSSNAISWVRQAPGQGLE APKILIYRNNQRPSGVPDRFSGS WMGVIIPIFGTADYAQKFQGRVTIT KSGTSASLAISGLRSEDEADYYC ADESTSTAYMELSSLRSEDTAVYY AAWDDNLSGWVFGTGTKLTVL CARHTYHEYAGGYYGGAMX1X2W (SEQ ID NO: 49) GQGTLVTVSS, wherein is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, I, L, M, F, Y, or W, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, I, L, M, F, Y, or W (SEQ ID NO: 217) B5-1 DIQMTQSPSSLSASVGDRVTITC EVQLLESGGGLVQPGGSLRLSCA RASQSISSYLNWYQQKPGKAPK ASGFTFSNYAMSWVRQAPGKGLE LLIYAASSLQSGVPSRFSGSGSG WVSDISGGGGRTYYAXiXgVKGRF TDFTLTISSLQPEDFATYYCQQSY TISRDNSKNTLYLQMNSLRAEDTA STPLTFGQGTKVEIK (SEQ ID VYYCARAGLLYGGGVYPMDIWG NO: 51) QGTLVTVS, wherein X-i is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 218)  CA 02954802 2017-01-12 50054-294 - 40 - Also provided herein are CDR portions of antigen binding domains of antibodies to EGFRvlll (including Chothia, Kabat CDRs, and CDR contact regions). Determination of CDR regions is well within the skill of the art. It is understood that in 5 some embodiments, CDRs can be a combination of the Kabat and Chothia CDR (also termed "combined CRs" or "extended CDRs"). In some embodiments, the CDRs are the Kabat CDRs. In other embodiments, the CDRs are the Chothia CDRs. In other words, in embodiments with more than one CDR, the CDRs may be any of Kabat, Chothia, combination CDRs, or combinations thereof. Table 2 provides 10 examples of CDR sequences provided herein. Table 2 Heavy Chain mAb CDRH1 CDRH2 CDRH3 m62G7 TDYTLH (SEQ ID NO: 62) GIDPINGGTTYNQKFK GEAMDS (SEQ ID (Kabat); G (SEQ ID NO: 65) NO: 67) GYTFTD (SEQ ID NO: 63) (Kabat) (Chothia); GIDPINGGTTY (SEQ GYTFTDYTLH (SEQ ID NO: 64) ID NO: 66) (Chothia) (extended) h62G7 TDYTLH (SEQ ID NO: 62) GINPINGGTTYNQKFK GEAMDS (SEQ ID (Kabat); G (SEQ ID NO: 68) NO: 67) GYTFTD (SEQ ID NO: 63) (Kabat) (Chothia); GINPINGGTTY (SEQ GYTFTDYTLH (SEQ ID NO: 64) ID NO: 69) (Chothia) (extended) h62G7-H14 TDYTLH (SEQ ID NO: 62) GIWPITGGTTYNQKFK GEAEGS (SEQ ID (Kabat); G (SEQ ID NO: 70) NO: 72) GYTFTD (SEQ ID NO: 63) (Kabat)  CA 02954802 2017-01-12 50054-294 - 41 - (Chothia); GIWPITGGTTY (SEQ GYTFTDYTLH (SEQ ID NO: 64) ID NO: 71) (Chothia) (extended) h62G7-EQ TDYTLH (SEQ ID NO: 62) GIWPITGGTTYNQKFK GEAQGS (SEQ ID (Kabat); G (SEQ ID NO: 70) NO: 73) GYTFTD (SEQ ID NO: 63) (Kabat) (Chothia); GIWPITGGTTY (SEQ GYTFTDYTLH (SEQ ID NO: 64) ID NO: 71) (Chothia) (extended) 42G9 SNPRMGVS (SEQ ID NO: 74) HIFSTDEKSLKLSLRS(S DSSNYEGYFDF (Kabat); EQ ID NO: 77) (Kabat) (SEQ ID NO: 79) GFSLSNPR (SEQ ID NO: 75) HIFSTDEKSL (SEQ ID (Chothia); NO: 78) (Chothia) GFSLSNPRMGVS (SEQ ID NO: 76) (extended) 32A10 SNARMGVS (SEQ ID NO: 80) HIFSTDEKSIRRSLRS DSSNYEGYFDY (Kabat); (SEQ ID NO: 83) (SEQ ID NO: 85) GFSLSNAR (SEQ ID NO: 81) (Kabat) (Chothia); HIFSTDEKSI (SEQ ID GFSLSNARMGVS (SEQ ID NO: NO: 84) (Chothia) 82) (extended) 20B9 SNARMGVS (SEQ ID NO: 80) HIFSTDEKSYSTSLRG(S DSSNYEGYFDF (Kabat); EQ ID NO: 86) (Kabat) (SEQ ID NO: 79) GFSLSNAR (SEQ ID NO: 81) HIFSTDEKSY (SEQ ID (Chothia); NO: 87) (Chothia) GFSLSNARMGVS (SEQ ID NO: 82) (extended) 14C11 NNARMGVS (SEQ ID NO: 88) HIFSTDEKSFRTSLRS(S DSSNYEGYFDY  CA 02954802 2017-01-12 50054-294 - 42 - (Kabat); EQ ID NO: 91) (Kabat) (SEQ ID NO: 85) GFSLNNAR (SEQ ID NO: 89) HIFSTDEKSF (SEQ ID (Chothia); NO: 92) (Chothia) GFSLNNARMGVS (SEQ ID NO: 90) (extended) 21E11 SNVRMGVS (SEQ ID NO: 93) HIFSSDEKSIRRSLRS(SE DSSNYEGYFDF (Kabat); QID NO: 96) (Kabat) (SEQ ID NO: 79) GFSLSNVR (SEQ ID NO: 94) HIFSSDEKSI (SEQ ID (Chothia); NO: 97) (Chothia) GFSLSNVRMGVS (SEQ ID NO: 95) (extended) 49B11 SNVRMGVS (SEQ ID NO: 93) HIFSSDEKSIRRSLRS(SE DSSNYEGYFDY (Kabat); QID NO: 96) (Kabat) (SEQ ID NO: 85) GFSLSNVR (SEQ ID NO: 94) HIFSSDEKSI (SEQ ID (Chothia); NO: 97) (Chothia) GFSLSNVRMGVS (SEQ ID NO: 95) (extended) 46E10 SNARMGVS (SEQ ID NO: 80) HIFSTDEKSIRRSLRS DSSNYEGYFDY 12H6 (Kabat); (SEQ ID NO: 83) (SEQ ID NO: 85) GFSLSNAR (SEQ ID NO: 81) (Kabat) (Chothia); HIFSTDEKSI (SEQ ID GFSLSNARMGVS (SEQ ID NO: NO: 84) (Chothia) 82) (extended) 19A9 SNARMGVS (SEQ ID NO: 80) HIFSTDEKSLRLSLRS DSSNYEGYFDY 21E7 (Kabat); (SEQ ID NO: 98) (SEQ ID NO: 85) GFSLSNAR (SEQ ID NO: 81) (Kabat) (Chothia); HIFSTDEKSL (SEQ ID GFSLSNARMGVS (SEQ ID NO: NO: 78) (Chothia)  CA 02954802 2017-01-12 50054-294 - 43 - 82) (extended) 11B11 SNAKMGVS (SEQ ID NO: 99) HIFSTDEKSIRRSLRS DSSNYEGYFDY (Kabat); (SEQ ID NO: 83) (SEQ ID NO: 85) GFSLSNAK (SEQ ID NO: 100) (Kabat) (Chothia); HIFSTDEKSI (SEQ ID GFSLSNAKMGVS (SEQ ID NO: NO: 84) (Chothia) 101) (extended) 12B2 SNPRMGVS (SEQ ID NO: 74) HIFSSDEKSYRLSLRS DSSNYGGYFDY (Kabat); (SEQ ID NO: 102) (SEQ ID NO: 104) GFSLSNPR (SEQ ID NO: 75) (Kabat) (Chothia); HIFSSDEKSY (SEQ ID GFSLSNPRMGVS (SEQ ID NO: NO: 103) (Chothia) 76) (extended) 11F10 SNPRMGVS (SEQ ID NO: 74) HIFSSDEKSYRLFLRS DSSDYEGYFDY (Kabat); (SEQ ID NO: 105) (SEQ ID NO: 107) GFSLSNPR (SEQ ID NO: 75) (Kabat) (Chothia); HIFSSDEKSY (SEQ ID GFSLSNPRMGVS (SEQ ID NO: NO: 103) (Chothia) 76) (extended) 17G11 SNPRMGVS (SEQ ID NO: 74) HIFSSDEKSYRLSLRS DSSNYEEYFDY (Kabat); (SEQ ID NO: 102) (SEQ ID NO: 108) GFSLSNPR (SEQ ID NO: 75) (Kabat) (Chothia); HIFSSDEKSY (SEQ ID GFSLSNPRMGVS (SEQ ID NO: NO: 103) (Chothia) 76) (extended) 29D5 SNPRMGVS (SEQ ID NO: 74) HIFSTDEKSYSPSLRG DSSNYEGYFDY (Kabat); (SEQ ID NO: 106) (SEQ ID NO: 85) GFSLSNPR (SEQ ID NO: 75) (Kabat)  CA 02954802 2017-01-12 50054-294 - 44 - (Chothia); HIFSTDEKSY (SEQ ID GFSLSNPRMGVS (SEQ ID NO: NO: 87) (Chothia) 76) (extended) 30D8 SDAWMS (SEQ ID NO: 109) RIKSKTDGGTTDYVVPL VPGSYGY (SEQ ID (Kabat); NG NO: 114) GFTFSD (SEQ ID NO: 110) (SEQ ID NO: 112) (Chothia); (Kabat) GFTFSDAWMS (SEQ ID NO: RIKSKTDGGTTDY 111) (extended) (SEQ ID NO: 113) (Chothia) 20E12 SYAWMS (SEQ ID NO: 115) RIKSIADGGATDYAAP IPGNDAFDM (SEQ (Kabat); VRN (SEQ ID NO: ID NO: 120) GFTFSY (SEQ ID NO: 116) 118) (Kabat) (Chothia); RIKSIADGGATDY (SEQ GFTFSYAWMS (SEQ ID NO: ID NO: 119) (Chothia) 117) (extended) 26B9 NNAWMS (SEQ ID NO: 121) RIKSKSDGGTTDYAAP APGGPFDY (SEQ (Kabat); VKD (SEQ ID NO: 124) ID NO: 126) GFIFNN (SEQ ID NO: 122) (Kabat) (Chothia); RIKSKSDGGTTDY GFIFNNAWMS (SEQ ID NO: (SEQ ID NO: 125) 123) (extended) (Chothia) 32G8 SYAWMS (SEQ ID NO: 115) RIKSITDGGVIDYAAPV IPGNDDFDM (Kabat); RN (SEQ ID NO: 127) (SEQ ID NO: 129) GFTFSY (SEQ ID NO: 116) (Kabat) (Chothia); RIKSITDGGVIDY (SEQ GFTFSYAWMS (SEQ ID NO: ID NO: 128) (Chothia) 117) (extended)  CA 02954802 2017-01-12 50054-294 - 45 - 34E7 SYAWMS (SEQ ID NO: 115) RIKSINDGGATDYASPV IPGNDAFDM (SEQ (Kabat); RN (SEQ ID NO: 130) ID NO: 120) GFTFSY (SEQ ID NO: 116) (Kabat) (Chothia); RIKSINDGGATDY GFTFSYAWMS (SEQ ID NO: (SEQ ID NO: 131 117) (extended) (Chothia) 20G5 TNAWMS (SEQ ID NO: 132) RIKSKIDGGTTDYAAPV APGGPFDY (SEQ (Kabat); KG (SEQ ID NO: 135) ID NO: 126) GFTFTN (SEQ ID NO: 133) (Kabat) (Chothia); RIKSKIDGGTTDY (SEQ GFTFTNAWMS (SEQ ID NO: ID NO: 136) (Chothia) 134) (extended) C6 SSNAIS (SEQ ID NO: 137) VIIPIFGTADYAQKFQG HTYHEYAGGYYGG (Kabat); (SEQ ID NO: 140) AMDP (SEQ ID GDTFSS (SEQ ID NO: 138) (Kabat) NO: 142) (Chothia); VIIPIFGTADY (SEQ ID GDTFSSNAIS (SEQ ID NO: NO: 141) (Chothia) 139) (extended) B5 SNYAMS (SEQ ID NO: 143) DISGGGGRTYYADSVK AGLLYGGGVYPM (Kabat); G (SEQ ID NO: 146) DI (SEQ ID NO: GFTFSN (SEQ ID NO: 144) (Kabat) 148) (Chothia); DISGGGGRTYY (SEQ GFTFSNYAMS (SEQ ID NO: ID NO: 147) (Chothia) 145) (extended) 42G9-1 SNPRMGVS (SEQ ID NO: 74) HIFSTDEKSLKLSLRS XjXzSNYEGYFDF, (Kabat); (SEQ ID NO: 77) wherein Xx is R, GFSLSNPR (SEQ ID NO: 75) (Kabat) H, K, D, E, S, T, N, (Chothia); HIFSTDEKSL (SEQ ID Q, C, G, P, A, V, 1,  CA 02954802 2017-01-12 50054-294 - 46 - GFSLSNPRMGVS (SEQ ID NO: NO: 78) (Chothia) L, M, F, Y, or W, 76) (extended) and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 219) 32A10-1 SNARMGVS (SEQ ID NO: 80) HIFSTDEKSIRRSLRS X1X2SNYEGYFDY, (Kabat); (SEQ ID NO: 83) wherein Xi is R, GFSLSNAR (SEQ ID NO: 81) (Kabat) H, K, D, E, S, T, N, (Chothia); HIFSTDEKSI (SEQ ID Q, C, G, P, A, V, 1, GFSLSNARMGVS (SEQ ID NO: NO: 84) (Chothia) L, M, F, Y, or W, 82) (extended) and X2 is R, H, K, D, E, S, T, N, Q C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 220) 20B9-1 SNARMGVS (SEQ ID NO: 80) HIFSTDEKSYSTSLRG(S X1X2SNYEGYFDF, (Kabat); EQ ID NO: 86) (Kabat) wherein Xi is R, GFSLSNAR (SEQ ID NO: 81) HIFSTDEKSY (SEQ ID H, K, D, E, S, T, N, (Chothia); NO: 87) (Chothia) Q, C, G, P, A, V, 1, GFSLSNARMGVS (SEQ ID NO: L, M, F, Y, or W, 82) (extended) and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 219) 14C11-1 NNARMGVS (SEQ ID NO: 88) HIFSTDEKSFRTSLRS X^SNYEGYFDY, (Kabat); (SEQ ID NO: 91) wherein Xx is R,  CA 02954802 2017-01-12 50054-294 - 47 _ GFSLNNAR (SEQ ID NO: 89) (Kabat) H, K, D, E, S, T, N, (Chothia); HIFSTDEKSF (SEQ ID Q, C, G, P, A, V, 1, GFSLNNARMGVS (SEQ ID NO: 92) (Chothia) L, M, F, Y, or W, NO: 90) (extended) and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 220) 21E11-1 SNVRMGVS (SEQ ID NO: 93) HIFSSDEKSIRRSLRS XiX2SNYEGYFDF, (Kabat); (SEQ ID NO: 96) wherein Xi is R, GFSLSNVR (SEQ ID NO: 94) (Kabat) H, K, D, E, S, T, N, (Chothia); HIFSSDEKSI (SEQ ID Q, C, G, P, A, V, lz GFSLSNVRMGVS (SEQ ID NO: NO: 97) (Chothia) L, M, F, Y, or W, 95) (extended) and X2 is R, H, K, D, E, S, T, N, Q, Q G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 219) 49B11-1 SNVRMGVS (SEQ ID NO: 93) HIFSSDEKSIRRSLRS(SE X1X2SNYEGYFDY, (Kabat); QID NO: 96) (Kabat) wherein Xi is R, GFSLSNVR (SEQ ID NO: 94) HIFSSDEKSI (SEQ ID H, K, D, E, S, T, N, (Chothia); NO: 97) (Chothia) Q, C, G, P, A, V, 1, GFSLSNVRMGVS (SEQ ID NO: L, M, F, Y, or W, 95) (extended) and X2 is R; H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 220)  CA 02954802 2017-01-12 50054-294 - 48 - 46E10-1 SNARMGVS (SEQ ID NO: 80) HIFSTDEKSIRRSLRS XjX2SNYEGYFDY, 12H6-1 (Kabat); (SEQ ID NO: 83) wherein Xi is R, GFSLSNAR (SEQ ID NO: 81) (Kabat) H, K, D, E, S, T, N, (Chothia); HIFSTDEKSI (SEQ ID Q, C, G, P, A, V, 1, GFSLSNARMGVS (SEQ ID NO: NO: 84) (Chothia) L, M, F, Y, or W, 82) (extended) and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 220) 19A9-1 SNARMGVS (SEQ ID NO: 80) HIFSTDEKSLRLSLRS XiX2SNYEGYFDY, 21E7-1 (Kabat); (SEQ ID NO: 98) wherein Xi is R, GFSLSNAR (SEQ ID NO: 81) (Kabat) H, K, D, E, S, T, N, (Chothia); HIFSTDEKSL (SEQ ID Q, C, G, P, A, V, 1, GFSLSNARMGVS (SEQ ID NO: NO: 78) (Chothia) L, M, F, Y, or W, 82) (extended) and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, L L, M, F, Y, or W (SEQ ID NO: 220) 11B11-1 SNAKMGVS (SEQ ID NO: 99) HIFSTDEKSIRRSLRS XiX2SNYEGYFDY, (Kabat); (SEQ ID NO: 83) wherein Xj is R, GFSLSNAK (SEQ ID NO: 100) (Kabat) H, K, D, E; S, T, N, (Chothia); HIFSTDEKSI (SEQ ID Q, C, G, P, A, V, 1, GFSLSNAKMGVS (SEQ ID NO: NO: 84) (Chothia) L, M, F, Y, or W, 101) (extended) and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M,  CA 02954802 2017-01-12 50054-294 - 49 - F, Y, or W (SEQ ID NO: 220) 12B2-1 SNPRMGVS (SEQ ID NO: 74) HIFSSDEKSYRLSLRS XiX2SNYGGYFDY, (Kabat); (SEQ ID NO: 102) wherein Xi is R, GFSLSNPR (SEQ ID NO: 75) (Kabat) H, K, D, E, S, T, N, (Chothia); HIFSSDEKSY (SEQ ID Q, C, G, P, A, V, 1, GFSLSNPRMGVS (SEQ ID NO: NO: 103) (Chothia) L, M, F, Y, or W, 76) (extended) and X2 is R, H, K, D, E, S, T, N, a C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 221) 11F10-1 SNPRMGVS (SEQ ID NO: 74) HIFSSDEKSYRLFLRS XjX2SDYEGYFDY, (Kabat); (SEQ ID NO: 105) wherein Xi is R, GFSLSNPR (SEQ ID NO: 75) (Kabat) H, K, D, E, S, T, N, (Chothia); HIFSSDEKSY (SEQ ID Q, C, G, P, A, V, 1, GFSLSNPRMGVS (SEQ ID NO: NO: 103) (Chothia) L, M, F, Y, or W, 76) (extended) and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, I, L, M, F, Y, or W (SEQ ID NO: 222) 17G11-1 SNPRMGVS (SEQ ID NO: 74) HIFSSDEKSYRLSLRS XiX2SNYEEYFDY, (Kabat); (SEQ ID NO: 102) wherein Xi is R, GFSLSNPR (SEQ ID NO: 75) (Kabat) H, K, D, E, S, T, N, (Chothia); HIFSSDEKSY (SEQ ID 0, C, G, P, A, V, 1, GFSLSNPRMGVS (SEQ ID NO: NO: 103) (Chothia) L, M, F, Y, or W, 76) (extended) and X2 is R, H, K,  CA 02954802 2017-01-12 50054-294 - 50 - D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 223) 29D5-1 SNPRMGVS (SEQ ID NO: 74) HIFSTDEKSYSPSLRG(S XiX2SNYEGYFDY, (Kabat); EQ ID NO: 106) wherein Xi is R, GFSLSNPR (SEQ ID NO: 75) (Kabat) H, K, D, E, S, T, N, (Chothia); HIFSTDEKSY (SEQ ID Q, C, G, P, A, V, 1, GFSLSNPRMGVS (SEQ ID NO: NO: 87) (Chothia) L, M, F, Y, or W, 76) (extended) and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 220) 30D8-1 SDAWMS (SEQ ID NO: 109) RIKSKTXiX2GTTDYVV VPGSYGY (SEQ ID (Kabat); PLNG, wherein Xx is NO: 114) GFTFSD (SEQ ID NO: 110) R, H, K, D, E, S, T, N, (Chothia); Q, C, G, P, A, V, 1, L, GFTFSDAWMS (SEQ ID NO: M, F, Y, or W, and X2 111) (extended) is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 224) (Kabat) RIKSKTXiX2GTTDY, wherein Xx is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W, and X2 is R, H, K,  CA 02954802 2017-01-12 50054-294 - 51 - D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 225) (Chothia) 20E12-1 SYAWMS (SEQ ID NO: 115) RIKSIAXiX2GATDYAAP IPGNDAFDM (SEQ (Kabat); VRN, wherein Xi is R, ID NO: 120) GFTFSY (SEQ ID NO: 116) H, K, D, E, S, T, N, Q, (Chothia); C, G, P, A, V, 1, L, M, GFTFSYAWMS (SEQ ID NO: F, Y, or W, and X2 is R, 117) (extended) H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 226) (Kabat) RIKSIAXiX2GATDY, wherein Xx is R, H, K, D, E, S, T, N, Q, Q G, P, A, V, 1, L, M, F, Y, or W, and X2 is R, H, K, D, E, S, T, N, a C, G, P, A, V, 1, L, M, F, X, or W (SEQ ID NO: 227) (Chothia) 26B9-1 NNAWMS (SEQ ID NO: 121) RIKSKSX1X2GTTDYAAP APGGPFDY (SEQ (Kabat); VKD, wherein Xi is R, ID NO: 126) GFIFNN (SEQ ID NO: 122) H, K, D, E, S, T, N, Q, (Chothia); C, G, P, A, V, 1, L, M, GFIFNNAWMS (SEQ ID NO: F, Y, or W, and X2 is R, 123) (extended) H, K, D, E, S, T, N, Q,  CA 02954802 2017-01-12 50054-294 - 52 - C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 228) (Kabat) RIKSKSXiX2GTTDY, wherein Xi is R, H, K, D, E, S, T, N, Q C, G, P, A, V, l; L, M, F, Y, or W, and X2 is R, H, K, D, E, S, T, N, Q C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 229) (Chothia) 32G8-1 SYAWMS (SEQ ID NO: 115) RIKSITXiX2GVIDYAAP IPGNDDFDM (Kabat); VRN, wherein Xi is R, (SEQ ID NO: 129) GFTFSY (SEQ ID NO: 116) H, K, D, E, S, T, N, Q, (Chothia); C, G, P, A, V, 1, L, M, GFTFSYAWMS (SEQ ID NO: F, Y, or W, and X2 is R, 117) (extended) H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 230) (Kabat) RIKSITXiX2GVIDY, wherein Xi is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W, and X2 is R, H, K, D, E, S, T, N, Q C, G, P, A, V, 1, L, M, F, Y, or  CA 02954802 2017-01-12 50054-294 - 53 - W (SEQ ID NO: 231) (Chothia) 34E7-1 SYAWMS (SEQ ID NO: 115) RIKSINXiX2GATDYASP IPGNDAFDM (SEQ (Kabat); VRN, wherein Xi is R, ID NO: 120) GFTFSY (SEQ ID NO: 116) H, Kz D, E, Sz Tz N, Qz (Chothia); C, G, P, A, V, 1, L, M, GFTFSYAWMS (SEQ ID NO: F, Y, or W, and X2 is R, 117) (extended) H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 232) (Kabat) RIKSINXjXzGATDY, wherein Xi is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, Az V, 1, L, M, F, Y, or W (SEQ ID NO: 233 (Chothia) 20G5-1 TNAWMS (SEQ ID NO: 132) RIKSKIXiX2GTTDYAAP APGGPFDY (SEQ (Kabat); VKG, wherein Xx is R, ID NO: 126) GFTFTN (SEQ ID NO: 133) H, K, D, Ez S, T, N, Q, (Chothia); C, G, P, A, V, 1, L, M, GFTFTNAWMS (SEQ ID NO: F, Y, or W, and X2 is R, 134) (extended) H, K, D, E, S, T, N, a C, G, P, A, V, lz L, M, F, Yz or W (SEQ ID  CA 02954802 2017-01-12 50054-294 - 54 - NO: 234) (Kabat) RIKSKIXiX2GTTDY, wherein Xx is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 235) (Chothia) C6-1 SSNAIS (SEQ ID NO: 137) VIIPIFGTADYAQKFQG HTYHEYAGGYYGG (Kabat); (SEQ ID NO: 140) AMXiX2; wherein GDTFSS (SEQ ID NO: 138) (Kabat) Xi is R, H, K, D, E, (Chothia); VIIPIFGTADY (SEQ ID S, T, N, Q, C, G, P, GDTFSSNAIS (SEQ ID NO: NO: 141) (Chothia) A, V, 1, L, M, F, Y, 139) (extended) or W, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID NO: 236) B5-1 SNYAMS (SEQ ID NO: 143) DISGGGGRTYYAXiX2V AGLLYGGGVYPM (Kabat); KG, wherein Xi is R, DI (SEQ ID NO: GFTFSN (SEQ ID NO: 144) H, K, D, E, S, T, N, Q, 148) (Chothia); C, G, P, A, V, 1, L, M, GFTFSNYAMS (SEQ ID NO: F, Y, or W, and X2 is R, 145) (extended) H, K, D, E, S, T, N, Q, C, G, P, A, V, 1, L, M, F, Y, or W (SEQ ID  CA 02954802 2017-01-12 50054-294 - 55 - NO: 237) (Kabat) DISGGGGRTYY (SEQ ID NO: 147) (Chothia) Light Chain mAb CDRL1 CDRL2 CDRL3 m62G7 KSSQSLLYSNGKTYLN (SEQID LVSKLDS (SEQ ID NO: VQDTHFPLT (SEQ h62G7 NO: 149) 150) ID NO: 151) h62G7-L6 KSSQSLLYSNGKTYLN (SEQID QVSKLDS (SEQ ID NO: GQDTHFPLT (SEQ NO: 149) 152) ID NO: 153) h62G7-Ll-DV KSSQSLLYSNDKTYTN (SEQ EVSKLDV (SEQ ID NO: GQDTHFPLT (SEQ ID NO: 154) 155) ID NO: 153) 42G9 RASQSVRSNLA (SEQ ID NO: GSTIRAT (SEQ ID NO: QQYSDWPFT 156) 157) (SEQID NO: 158) 32A10 RASQSVSSNFA (SEQ ID NO: GATTRAT (SEQ ID NO: QQYKDWPFT 159) 160) (SEQID NO: 161) 20B9 RVSQSIGANLA (SEQ ID NO: GASTRAT (SEQ ID NO: QQYIYWPFT (SEQ 162) 163) ID NO: 164) 14C11 RASQSVSNNLA (SEQ ID NO: GASTRAT (SEQ ID NO: QQYKDWPFT 165) 163) (SEQID NO: 161) 21E11 RASQSVGSDLA (SEQ ID NO: GASTRAT (SEQ ID NO: QQYNDWPFT 166) 163) (SEQID NO: 167) 49B11 RASQNIGSDLA (SEQ ID NO: GASTRAT (SEQ ID NO: QQYNDWPFT 168) 163) (SEQID NO: 167) 46E10 RASQSVTSNFA (SEQ ID NO: GASTRAT (SEQ ID NO: QQYKDWPFT 169) 163) (SEQID NO: 161) 12H6 RASQGVSSNFA (SEQ ID NO: GASTRAT (SEQ ID NO: QQYKDWPFT 170) 163) (SEQID NO: 161) 19A9 RASQSVNRNLA (SEQ ID NO: GTSTRAT (SEQ ID NO: QQYNDWPFT  CA 02954802 2017-01-12 50054-294 - 56 - 171) 172) (SEQ ID NO: 167) 11B11 RASQSVSTNFA (SEQ ID NO: GASTRAT (SEQ ID NO: QQYKDWPFT 173) 163) (SEQ ID NO: 161) 21E7 RASQSVNSNLA (SEQ ID NO: GSSTRAT (SEQ ID NO: QQYNDWPFT 174) 175) (SEQ ID NO: 167) 12B2 RASQSVINNLA (SEQ ID NO: GTSTRAT (SEQ ID NO: QDYNNWPFT 17G11 176) 172) (SEQ ID NO: 177) 11F10 RASQSVGSNLA (SEQ ID NO: GASTRASG (SEQ ID QEYNNWPFT 178) NO: 179) (SEQ ID NO: 180) 29D5 RANQIVSSNLA (SEQ ID NO: GTSTRAT (SEQ ID NO: QQYNDWPFT 181) 172) (SEQ ID NO: 167) 30D8 RSSQSLLHNKRNNYLD (SEQ LASNRAS (SEQ ID NO: MQAQQTPIT (SEQ ID NO: 182) 183) ID NO: 184 ) 20E12 RSSQSLLYSNGKNYLD (SEQ LGSNRAS (SEQ ID NO: MQAQQTPIT (SEQ 32G8 ID NO: 185) 186) ID NO: 184 ) 26B9 RSSQSLLHRDGFNYLD (SEQ LASSRAS (SEQ ID NO: MQALQTPIT (SEQ ID NO: 187) 188) ID NO: 189 ) 34E7 RSTQSLLYSNGKNYLD (SEQ LGSIRAS (SEQ ID NO: MQAQQTPIT (SEQ ID NO: 190) 191) ID NO: 184) 20G5 RSSQSLLYSDRRNYLD (SEQ LGSYRAS (SEQ ID NO: MQALQIPIT(SEQ ID NO: 192) 193) ID NO: 194 ) C6 SGSSSNIGSNYVY RNNQRPS AAWDDNLSGWV (SEQ ID NO: 195) (SEQ ID NO: 196) (SEQ ID NO: 197) B5 RASQSISSYLN AASSLQS (SEQ ID NO: QQSYSTPLT(SEQ (SEQ ID NO: 198) 199) ID NO: 200) 20E12-1 RSSQSLLYSXiX2KNYLD, LGSNRAS (SEQ ID NO: MQAQQTPIT (SEQ 32G8-1 wherein Xi is R, H, K, D, E, S, 186) ID NO: 184 ) T, N, Q, C, G, P, A, V, 1, L, M,  CA 02954802 2017-01-12 50054-294 - 57 - F, Y, or W, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, I, L, M, F, Y, or W (SEQ ID NO: 238) 26B9-1 rssqsllhrx1x2fnyld, LASSRAS (SEQ ID NO: MQALQTPIT (SEQ wherein Xx is R, H, K, D, E, 5, 188) ID NO: 189 ) T, N, Q, C, G, P, A, V, I, L, M, F, Y, or W, and X2 is R, H, K, D, E, S, T, N, Q, C, G, P, A, V, I, L, M, F, Y, or W (SEQ ID NO: 239) In some embodiments, the present invention provides an antibody that binds to and competes with the antibody as described herein, including m62G7, h62G7, h62G7-H14/L1-DV, h62G7-EQ/L6, 42G9, 32A10, 20B9, 14C11, 21E11, 49B11, 5 46E10, 12H6, 19A9, 21E7, 11B11, 12B2, 11F10, 17G11, 29D5, 30D8, 20E12, 26B9, 32G8, 34E7, 20G5, 06, B5, 42G9-1, 32A10-1, 20B9-1, 14C11-1, 21E11-1, 49B11-1, 46E10-1, 12H6-1, 19A9-1, 21E7-1, 11B11-1, 12B2-1, 11F10-1, 17G11-1, 29D5-1, 30D8-1 20E1 , 2-1, 26B9-1, 32G8-1 34E7-1, , 20G5-1, C6-1, and B5-1. In some embodiments, the invention also provides CDR portions of antibodies 10 to EGFRvlll antibodies based on CDR contact regions. CDR contact regions are regions of an antibody that imbue specificity to the antibody for an antigen. In general, CDR contact regions include the residue positions in the CDRs and Vernier zones which are constrained in order to maintain proper loop structure for the antibody to bind a specific antigen. See, e.g., Makabe et aL, J. Biol. Chern., 15 283:1156-1166, 2007. Determination of CDR contact regions is well within the skill of the art. The binding affinity (KD) of the EGFRvlll antibody as described herein to EGFRvlll (such as human EGFRvlll (e.g., (SEQ ID NO: 201)) can be about 0.001 to  CA 02954802 2017-01-12 50054-294 - 58 - about 5000 nM. In some embodiments, the binding affinity is about any of 5000 nM, 4500 nM, 4000 nM, 3500 nM, 3000 nM, 2500 nM, 2000 nM, 1789 nM, 1583 nM, 1540 nM, 1500 nM, 1490 nM, 1064 nM, 1000 nM, 933 nM, 894 nM, 750 nM, 705 nM, 678 nM, 532 nM, 500 nM, 494 nM, 400 nM, 349 nM, 340 nM, 353 nM, 300 nM, 250 nM, 5 244 nM, 231 nM, 225 nM, 207 nM, 200 nM, 186 nM, 172 nM, 136 nM, 113 nM, 104 nM, 101 nM, 100 nM, 90 nM, 83 nM, 79 nM, 74 nM, 54 nM, 50 nM, 45 nM, 42 nM, 40 nM, 35 nM, 32 nM, 30 nM, 25 nM, 24 nM, 22 nM, 20 nM, 19 nM, 18 nM, 17 nM, 16 nM, 15 nM, 12 nM, 10 nM, 9 nM, 8 nM, 7.5 nM, 7 nM, 6.5 nM, 6 nM, 5.5 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.5 nM, 0.3 nM, 0.1 nM, 0.01 nM, or 0.001 nM. In some 10 embodiments, the binding affinity is less than about any of 5000 nM, 4000 nM, 3000 nM, 2000 nM, 1000 nM, 900 nM, 800 nM, 250 nM, 200 nM, 100 nM, 50 nM, 30 nM, 20 nM, 10 nM, 7.5 nM, 7 nM, 6.5 nM, 6 nM, 5 nM, 4.5 nM, 4 nM, 3.5 nM, 3 nM, 2.5 nM, 2 nM, 1.5 nM, 1 nM, or 0.5 nM. Bispecific antibodies, monoclonal antibodies that have binding specificities for 15 at least two different antigens, can be prepared using the antibodies disclosed herein. Methods for making bispecific antibodies are known in the art (see, e.g., Suresh et al., Methods in Enzymology 121:210, 1986). Traditionally, the recombinant production of bispecific antibodies was based on the coexpression of two immunoglobulin heavy chain-light chain pairs, with the two heavy chains having 20 different specificities (Millstein and Cuello, Nature 305, 537-539, 1983). Accordingly, in one aspect, provided is a bispecific antibody wherein the bispecific antibody is a full-length human antibody, comprising a first antibody variable domain of the bispecific antibody specifically binding to a target antigen (e.g., EGFRvlll), and comprising a second antibody variable domain of the bispecific antibody capable of 25 recruiting the activity of a human immune effector cell by specifically binding to an effector antigen located on the human immune effector cell. The human immune effector cell can be any of a variety of immune effector cells known in the art. For example, the immune effector cell can be a member of the human lymphoid cell lineage, including, but not limited to, a T cell (e.g., a cytotoxic T 30 cell), a B cell, and a natural killer (NK) cell. The immune effector cell can also be, for  CA 02954802 2017-01-12 50054-294 - 59 - example without limitation, a member of the human myeloid lineage, including, but not limited to, a monocyte, a neutrophilic granulocyte, and a dendritic cell. Such immune effector cells may have either a cytotoxic or an apoptotic effect on a target cell or other desired effect upon activation by binding of an effector antigen. 5 The effector antigen is an antigen (e.g., a protein or a polypeptide) that is expressed on the human immune effector cell. Examples of effector antigens that can be bound by the heterodimeric protein (e.g., a heterodimeric antibody or a bispecific antibody) include, but are not limited to, human CD3 (or CD3 (Cluster of Differentiation) complex), CD16, NKG2D, NKp46, CD2, CD28, CD25, CD64, and 10 CD89. The target cell can be a cell that is native or foreign to humans. In a native target cell, the cell may have been transformed to be a malignant cell or pathologically modified (e.g., a native target cell infected with a virus, a plasmodium, or a bacterium). In a foreign target cell, the cell is an invading pathogen, such as a 15 bacterium, a plasmodium, or a virus. The target antigen is expressed on a target cell in a diseased condition (e.g., an inflammatory disease, a proliferative disease (e.g., cancer), an immunological disorder, a neurological disease, a neurodegenerative disease, an autoimmune disease, an infectious disease (e.g., a viral infection or a parasitic infection), an 20 allergic reaction, a graft-versus-host disease or a host-versus-graft disease). A target antigen is not effector antigen. In some embodiments, the target antigen is EGFRvlll. In some embodiments, provided is a bispecific antibody wherein the bispecific antibody is a full-length human antibody, comprising a first antibody variable domain of the bispecific antibody specifically binding to a target antigen, and comprising a 25 second antibody variable domain of the bispecific antibody capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen located on the human immune effector cell, wherein the first antibody variable domain comprises a heavy chain variable (VH) region comprising a VH CDR1, VH CDR2, and VH CDR3 of the VH sequence shown in SEQ ID NO: 1, 3, 5, 7, 9, 11 1, 3, 15, 17, 30 19, 21, 23, 25, 27, 30, 32, 34, 35, 37, 39, 41, 43, 44, 46, 48, 50, 52, 53, 54, 55, 56,  CA 02954802 2017-01-12 50054-294 - 60 - 57, 58, 59, 60, 61, 202, 203, 204, 205, 206, 207, 208, 209, 210, 214, 216, 217, or 218; and/or a light chain variable (VL) region comprising a VL CDR1, VL CDR2, and VL CDR3 of the VL sequence shown in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 29, 31, 33, 36, 38, 40, 42, 45, 47, 49, 51, 211, 212, 213, or 215. 5 In some embodiments, provided is a bispecific antibody wherein the bispecific antibody is a full-length human antibody, comprising a first antibody variable domain of the bispecific antibody specifically binding to a target antigen, and comprising a second antibody variable domain of the bispecific antibody capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen 10 located on the human immune effector cell, wherein the first antibody variable domain comprises (a) a heavy chain variable (VH) region comprising (i) a VH complementarity determining region one (CDR1) comprising the sequence shown in SEQ ID NO: 62, 63, 64, 74, 75, 76, 80, 81, 82, 88, 89, 90, 93, 94, 95, 99, 100, 101, 109, 110, 111, 115, 116, 117, 121, 122, 123, 132, 133, 134, 137, 138, 139, 143, 144, 15 or 145; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 65, 66, 68, 69, 70, 71, 77, 78, 83, 84, 86, 87, 91, 92, 96, 97, 98, 102, 103, 105, 106, 112, 113, 118, 119, 124, 125, 127, 128, 130, 131, 135, 136, 140, 141, 146, 147, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, or 237; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 67, 72, 73, 79, 85, 104, 107, 108, 114, 120, 126, 20 129, 142, 148, 219, 220, 221, 222, 223, or 236; and/or (b) a light chain variable (VL) region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 149, 154, 156, 159, 162, 165, 166, 168, 169, 170, 171, 173, 174, 176, 178, 181, 182, 185, 187, 190, 192, 195, 198, 238, or 239; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 150, 152, 155, 157, 160, 163, 172, 175, 179, 183, 25 186, 188, 191, 193, 196, or 199; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 151, 153, 158, 161, 164, 167, 177, 180, 184, 189, 194, 197, or 200. In some embodiments, the second antibody variable domain comprises a heavy chain variable (VH) region comprising a VH CDR1, VH CDR2, and VH CDR3 of the VH sequence shown in SEQ ID NO: 240; and/or a light chain variable (VL)  CA 02954802 2017-01-12 50054-294 - 61 - region comprising VL CDR1, VL CDR2, and VL CDR3 of the VL sequence shown in SEQ ID NO: 241. In some embodiments, the second antibody variable domain comprises (a) a heavy chain variable (VH) region comprising (i) a VH complementary determining 5 region one (CDR1) comprising the sequence shown in SEQ ID NO: 244, 110, or 245; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 246 or 247; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 248; and/or (b) a light chain variable (VL) region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 249; (ii) a VL CDR2 comprising the sequence shown in SEQ ID 10 NO: 250; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 251. Table 3 shows the specific amino acid and nucleic acid sequences of the second antibody variable domain, which is specific to CD3. In Table 3, the underlined sequences are CDR sequences according to Kabat and in bold according to Chothia. Table 3 mAb Light Chain Heavy Chain h2B4„ DIVMTQSPDSLAVSLGERATINC EVQLVESGGGLVQPGGSLRLSCA KSSQSLFNVRSRKNYLAWYQQK ASGFTFSDYYMTWVRQAPGKGLE HNPS PGQPPKLLISWASTRESGVPDRF WVAFIRNRARGYTSDHNPSVKGR _VH SGSGSGTDFTLTISSLQAEDVAV FTISRDNAKNSLYLQMNSLRAEDT YYCKQSYDLFTFGSGTKLEIK AVYYCARDRPSYYVLDYWGQGTT 1d_T2 (SEQ ID NO: 241) VTVSS (SEQ ID NO: 240) 4K_VL h2B4_ GACATTGTGATGACTCAATCCC GAAGTCCAACTTGTCGAATCGGG CCGACTCCCTGGCTGTGTCCCT AGGAGGCCTTGTGCAACCCGGT HNPS CGGCGAACGCGCAACTATCAAC GGATCCCTGAGGCTGTCATGCG _VH TGTAAAAGCAGCCAGTCCCTGT CGGCCTCGGGCTTCACC I I I ICC TCAACGTCCGGTCGAGGAAGAA GATTACTACATGACCTGGGTCAG 1d_T2 CTACCTGGCCTGGTATCAGCAG ACAGGCCCCTGGAAAGGGGTTG 4K_VL AAACCTGGGCAGCCGCCGAAG GAATGGGTGGCATTCATCCGGA CTTCTGATCTCATGGGCCTCAA ATAGAGCCCGCGGATACACTTCC CTCGGGAAAGCGGAGTGCCAG GACCACAACCCCAGCGTGAAGG ATAGATTCTCCGGATCTGGCTC GGCGGTTCACCATTAGCCGCGA CGGAACCGACTTCACCCTGACG CAACGCCAAGAACTCCCTCTACC ATTTCGAGCTTGCAAGCGGAGG TCCAAATGAACAGCCTGCGGGC 81802864 -62- mAb Light Chain Heavy Chain ATGTGGCCGTGTACTACTGCAA GGAGGATACCGCTGTGTACTACT GCAGTCCTACGACCTCTTCACC GCGCCCGCGACCGGCCGTCCTA TTTGGTTCGGGCACCAAGCTGG CTATGTGCTGGACTACTGGGGC AGATCAAA (SEQ ID NO: 243) CAGGGTACTACGGTCACCGTCT CCTCA (SEQ ID NO: 242) Table 4 shows the examples of CDR sequences of the second antibody variable domain, which is specific to CD3. Table 4 Heavy Chain mAb CDRH1 CDRH2 CDRH3 h2B4_H SDYYMT (SEQ ID FIRNRARGYTSDH (SEQ ID DRPSYYVLDY NO: 244) (Kabat); NPS NO: 246) (Kabat) (SEQ ID NO: 248) GFTFSD (SEQ ID NO: 110) (Chothia); FIRNRARGYTSDHNPSVKG (SEQ ID NO: 247) GFTFSDYYMT (SEQ (Extended) ID NO: 245) (Extended) Light Chain mAb CDRH1 CDRH2 CDRH3 h2B4- KSSQSLFNVRSRKN WASTRES KQSYDLFT YLA 1d_T24 (SEQ ID NO: 250) (SEQ ID NO: 251) (SEQ ID NO: 249) K In some embodiments, a bispecific antibody provided herein which contains a CD3-specific variable domain contains an anti-CD3 sequence as provided in U.S. Publication No. 20160297885. Date Re^ue/Date Received 2023-06-14  CA 02954802 2017-01-12 50054-294 - 63 - According to one approach to making bispecific antibodies, antibody variable domains with the desired binding specificities (antibody-antigen combining sites) are fused to immunoglobulin constant region sequences. The fusion preferably is with an immunoglobulin heavy chain constant region, comprising at least part of the hinge, 5 CH2 and CH3 regions. It is preferred to have the first heavy chain constant region (CH1), containing the site necessary for light chain binding, present in at least one of the fusions. DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are cotransfected into a suitable host organism. This provides for great flexibility in 10 adjusting the mutual proportions of the three polypeptide fragments in embodiments when unequal ratios of the three polypeptide chains used in the construction provide the optimum yields. It is, however, possible to insert the coding sequences for two or all three polypeptide chains in one expression vector when the expression of at least two polypeptide chains in equal ratios results in high yields or when the ratios are of 15 no particular significance. In another approach, the bispecific antibodies are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. This asymmetric structure, with an immunoglobulin light chain in 20 only one half of the bispecific molecule, facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations. This approach is described in PCT Publication No. WO 94/04690. In another approach, the bispecific antibodies are composed of amino acid modification in the first hinge region in one arm, and the substituted/replaced amino 25 acid in the first hinge region has an opposite charge to the corresponding amino acid in the second hinge region in another arm. This approach is described in International Patent Application No. PCT/US2011/036419 (WO2011/143545). In another approach, the formation of a desired heteromultimeric or heterodimeric protein (e.g., bispecific antibody) is enhanced by altering or 30 engineering an interface between a first and a second immunoglobulin-like Fc region  CA 02954802 2017-01-12 50054-294 - 64 - (e.g., a hinge region and/or a CH3 region). In this approach, the bispecific antibodies may be composed of a CH3 region, wherein the CH3 region comprises a first CH3 polypeptide and a second CH3 polypeptide which interact together to form a CH3 interface, wherein one or more amino acids within the CH3 interface destabilize 5 homodimer formation and are not electrostatically unfavorable to homodimer formation. This approach is described in International Patent Application No. PCT/US2011/036419 (WO2011/143545). In another approach, the bispecific antibodies can be generated using a glutamine-containing peptide tag engineered to the antibody directed to an epitope 10 (e.g., EGFRvlll) in one arm and another peptide tag (e.g., a Lys-containing peptide tag or a reactive endogenous Lys) engineered to a second antibody directed to a second epitope in another arm in the presence of transglutaminase. This approach is described in International Patent Application No. PCT/IB2011/054899 (WO2012/059882). 15 In some embodiments, the heterodimeric protein (e.g., bispecific antibody) as described herein comprises a full-length human antibody, wherein a first antibody variable domain of the bispecific antibody specifically binding to a target antigen (e.g., EGFRvlll), and comprising a second antibody variable domain of the bispecific antibody capable of recruiting the activity of a human immune effector cell by 20 specifically binding to an effector antigen (e.g., CD3) located on the human immune effector cell, wherein the first and second antibody variable domain of the heterodimeric protein comprise amino acid modifications at positions 223, 225, and 228 (e.g., (C223E or C223R), (E225R), and (P228E or P228R)) in the hinge region and at position 409 or 368 (e.g., K409R or L368E (EU numbering scheme)) in the 25 CH3 region of human lgG2 (SEQ ID NO: 290). In some embodiments, the first and second antibody variable domains of the heterodimeric protein comprise amino acid modifications at positions 221 and 228 (e.g., (D221R or D221E) and (P228R or P228E)) in the hinge region and at position 409 or 368 (e.g., K409R or L368E (EU numbering scheme)) in the CH3 region of 30 human lgG1 (SEQ ID NO: 291).  CA 02954802 2017-01-12 50054-294 - 65 - In some embodiments, the first and second antibody variable domains of the heterodimeric protein comprise amino acid modifications at positions 228 (e.g., (P228E or P228R)) in the hinge region and at position 409 or 368 (e.g., R409 or L368E (EU numbering scheme)) in the CH3 region of human lgG4 (SEQ ID 5 NO: 292). The amino acid sequence of the wild type Fc regions of human lgG1, lgG2, and lgG4 are listed below: lqG2 (SEQ ID NO: 290) ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV 10 LQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAP PVAGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVQFNWYVDGVEVHNAKT KPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPRE PQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSD GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 15 lqG1 (SEQ ID NO: 291) ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVH 20 NAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK lqG4 (SEQ ID NO: 292) 25 ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV LQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAP EFLGGPSVFLFPPKPKDTLMISRTPEVTCWVDVSQEDPEVQFNWYVDGVEVHNAK TKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR EPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 30 DGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK The antibodies useful in the present invention can encompass monoclonal antibodies, polyclonal antibodies, antibody fragments (e.g., Fab, Fab’, F(ab’)2, Fv, Fc, etc.), chimeric antibodies, bispecific antibodies, heteroconjugate antibodies, single 35 chain (ScFv), mutants thereof, fusion proteins comprising an antibody portion (e.g., a domain antibody), humanized antibodies, and any other modified configuration of the immunoglobulin molecule that comprises an antigen recognition site of the required  CA 02954802 2017-01-12 50054-294 - 66 - specificity, including glycosylation variants of antibodies, amino acid sequence variants of antibodies, and covalently modified antibodies. The antibodies may be murine, rat, human, or any other origin (including chimeric or humanized antibodies). In some embodiments, the EGFRvlll antibody as described herein is a 5 monoclonal antibody. For example, the EGFRvlll antibody is a humanized monoclonal antibody or a chimeric monoclonal antibody. In some embodiments, the antibody comprises a modified constant region, such as, for example without limitation, a constant region that has increased potential for provoking an immune response. For example, the constant region may be 10 modified to have increased affinity to an Fc gamma receptor such as, e.g., FcyRI, FcyRUA, or FcyIH. In some embodiments, the antibody comprises a modified constant region, such as a constant region that is immunologically inert, that is, having a reduced potential for provoking an immune response. In some embodiments, the constant 15 region is modified as described in Eur. J. Immunol., 29:2613-2624, 1999; PCT Application No. PCT/GB99/01441; and/or UK Patent Application No. 98099518. The Fc can be human lgG1, human lgG2, human lgG3, or human lgG4. The Fc can be human lgG2 containing the mutation A330P331 to S330S331 (lgG2Aa), in which the amino acid residues are numbered with reference to the wild type lgG2 20 sequence. Eur. J. Immunol., 29:2613-2624, 1999. In some embodiments, the antibody comprises a constant region of lgG4 comprising the following mutations (Armour et al., Molecular Immunology 40 585-593, 2003): E233F234L235 to P233V234A235 (lgG4Ac), in which the numbering is with reference to wild type lgG4. In yet another embodiment, the Fc is human lgG4 E233F234L235 to 25 P233V234A235 with deletion G236 (lgG4Ab). In another embodiment, the Fc is any human lgG4 Fc (lgG4, lgG4Ab or lgG4Ac) containing hinge stabilizing mutation S228 to P228 (Aalberse et al., Immunology 105, 9-19, 2002). In another embodiment, the Fc can be aglycosylated Fc. In some embodiments, the constant region is aglycosylated by mutating the 30 oligosaccharide attachment residue (such as Asn297) and/or flanking residues that  CA 02954802 2017-01-12 50054-294 - 67 - are part of the glycosylation recognition sequence in the constant region. In some embodiments, the constant region is aglycosylated for N-linked glycosylation enzymatically. The constant region may be aglycosylated for N-linked glycosylation enzymatically or by expression in a glycosylation deficient host cell. 5 In some embodiments, the constant region has a modified constant region that removes or reduces Fc gamma receptor binding. For example, the Fc can be human lgG2 containing the mutation D265, in which the amino acid residues are numbered with reference to the wild type lgG2 sequence (SEQ ID NO: 290). Accordingly, in some embodiments, the constant region has a modified constant region having the 10 sequence shown in SEQ ID NO: 252: ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV LQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCRVRCPRCPAP PVAGPSVFLFPPKPKDTLMISRTPEVTCVWAVSHEDPEVQFNWYVDGVEVHNAKT KPREEQFNSTFRVVSVLTWHQDWLNGKEYKCKVSNKGLPSSIEKTISKTKGQPRE 15 PQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSD GSFFLYSRLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK. The nucleic acid encoding the sequence shown in SEQ ID NO: 252 is shown in SEQ ID NO: 253: 20 GCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCAC CTCCGAGAGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAAC CGGTGACGGTGTCGTGGAACTCAGGCGCTCTGACCAGCGGCGTGCACACCTTC CCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTAGTGACCGT GCCCTCCAGCAACTTCGGCACCCAGACCTACACCTGCAACGTAGATCACAAGC 25 CCAGCAACACCAAGGTGGACAAGACAGTTGAGCGCAAATGTCGTGTCAGGTGC CCAAGGTGCCCAGCACCACCTGTGGCAGGACCGTCAGTCTTCCTCTTCCCCCC AAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGG TGGTGGCCGTGAGCCACGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGAC GGCGTGGAGGTGCATAATGCCAAGACAAAGCCACGGGAGGAGCAGTTCAACAG 30 CACGTTCCGTGTGGTCAGCGTCCTCACCGTCGTGCACCAGGACTGGCTGAACG  CA 02954802 2017-01-12 50054-294 - 68 - GCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCATCCTCCATCGAGA AAACCATCTCCAAAACCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTG CCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGT CAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGC 5 CGGAGAACAACTACAAGACCACACCTCCCATGCTGGACTCCGACGGCTCCTTCT TCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTC TTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGC CTCTCCCTGTCTCCGGGTAAA. 10 In some embodiments, the constant region has a modified constant region having the sequence shown in SEQ ID NO: 254: ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV LQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCEVECPECPAP PVAGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVQFNWYVDGVEVHNAKT 15 KPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPSSIEKTISKTKGQPRE PQVYTLPPSREEMTKNQVSLTCEVKGFYPSDIAVEWESNGQPENNYKTTPPMLDS DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK. The nucleic acid encoding the sequence shown in SEQ ID NO: 254 is shown in SEQ ID NO: 255: 20 GCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCAC CTCCGAGAGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAAC CGGTGACGGTGTCGTGGAACTCAGGCGCTCTGACCAGCGGCGTGCACACCTTC CCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTAGTGACCGT GCCCTCCAGCAACTTCGGCACCCAGACCTACACCTGCAACGTAGATCACAAGC 25 CCAGCAACACCAAGGTGGACAAGACAGTTGAGCGCAAATGTGAGGTCGAGTGC CCAGAGTGCCCAGCACCACCTGTGGCAGGACCGTCAGTCTTCCTCTTCCCCCC AAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGG TGGTGGCCGTGAGCCACGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGAC GGCGTGGAGGTGCATAATGCCAAGACAAAGCCACGGGAGGAGCAGTTCAACAG 30 CACGTTCCGTGTGGTCAGCGTCCTCACCGTCGTGCACCAGGACTGGCTGAACG  CA 02954802 2017-01-12 50054-294 - 69 - GCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCATCCTCCATCGAGA AAACCATCTCCAAAACCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTG CCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCGAGGT CAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGC 5 CGGAGAACAACTACAAGACCACACCTCCCATGCTGGACTCCGACGGCTCCTTCT TCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTC TTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGC CTCTCCCTGTCTCCGGGTAAA. The amino acid of the human Kappa constant region is shown in SEQ ID 10 NO: 256: GTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESV TEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC. And the nucleic acid encoding the sequence of SEQ ID NO: 256 is shown in SEQ ID NO: 257: 15 GGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTG AAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAG GCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGA GAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCC TGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCA 20 CCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT TAG. One way of determining binding affinity of antibodies to EGFRvlll is by measuring binding affinity of the bivalent antibody to monomeric EGFRvlll protein. The affinity of an EGFRvlll antibody can be determined by surface plasmon 25 resonance (BiacoreTM3000™ surface plasmon resonance (SPR) system, Biacore™, INC, Piscataway NJ) equipped with pre-immobilized anti-mouse Fc or anti-human Fc using HBS-EP running buffer (0.01M HEPES, pH 7.4, 0.15 NaCI, 3 mM EDTA, 0.005% v/v Surfactant P20). Monomeric 8-histidine tagged human EGFRvlll extracellular domain can be diluted into HBS-EP buffer to a concentration of less than 30 0.5 pg/mL and injected across the individual chip channels using variable contact  CA 02954802 2017-01-12 50054-294 - 70 - times, to achieve two ranges of antigen density, either 50-200 response units (RU) for detailed kinetic studies or 800-1,000 RU for screening assays. Regeneration studies have shown that 25 mM NaOH in 25% v/v ethanol effectively removes the bound EGFRvlll protein while keeping the activity of EGFRvlll antibodies on the chip for 5 over 200 injections. Typically, serial dilutions (spanning concentrations of 0.1-1Ox estimated KD) of purified 8-histidine tagged EGFRvlll samples are injected for 1 min at 100 pL/minute and dissociation times of up to 2 hours are allowed. The concentrations of the EGFRvlll proteins are determined by absorbance at 280nm based on sequence specific extinction coefficient of the 8-histidine tagged EGFRvlll 10 protein. Kinetic association rates (kon or ka) and dissociation rates (koff or kd) are obtained simultaneously by fitting the data globally to a 1:1 Langmuir binding model (Karlsson, R. Roos, H. Fagerstam, L. Petersson, B. (1994). Methods Enzymology 6. 99-110) using the BIAevaluation program. Equilibrium dissociation constant (Kd) values are calculated as kOff/kOn- This protocol is suitable for use in determining 15 binding affinity of an antibody to any monomeric EGFRvlll, including human EGFRvlll, EGFRvlll of another mammal (such as mouse EGFRvlll, rat EGFRvlll, or primate EGFRvlll), as well as different forms of EGFRvlll (e.g., glycosylated EGFRvlll). Binding affinity of an antibody is generally measured at 25°C, but can also be measured at 37°C. 20 The antibodies as described herein may be made by any method known in the art. For the production of hybridoma cell lines, the route and schedule of immunization of the host animal are generally in keeping with established and conventional techniques for antibody stimulation and production, as further described herein. General techniques for production of human and mouse antibodies are 25 known in the art and/or are described herein. It is contemplated that any mammalian subject including humans or antibody producing cells therefrom can be manipulated to serve as the basis for production of mammalian, including human and hybridoma cell lines. Typically, the host animal is inoculated intraperitoneally, intramuscularly, orally, subcutaneously, intraplantar, 30 and/or intradermally with an amount of immunogen, including as described herein.  CA 02954802 2017-01-12 50054-294 - 71 - Hybridomas can be prepared from the lymphocytes and immortalized myeloma cells using the general somatic cell hybridization technique of Kohler, B. and Milstein, C., Nature 256:495-497, 1975 or as modified by Buck, D. W., et al., In Vitro, 18:377-381, 1982. Available myeloma lines, including but not limited to X63- 5 Ag8.653 and those from the Salk Institute, Cell Distribution Center, San Diego, Calif., USA, may be used in the hybridization. Generally, the technique involves fusing myeloma cells and lymphoid cells using a fusogen such as polyethylene glycol, or by electrical means well known to those skilled in the art. After the fusion, the cells are separated from the fusion medium and grown in a selective growth medium, such as 10 hypoxanthine-aminopterin-thymidine (HAT) medium, to eliminate unhybridized parent cells. Any of the media described herein, supplemented with or without serum, can be used for culturing hybridomas that secrete monoclonal antibodies. As another alternative to the cell fusion technique, EBV immortalized B cells may be used to produce the monoclonal antibodies of the subject invention. The hybridomas are 15 expanded and subcloned, if desired, and supernatants are assayed for anti¬ immunogen activity by conventional immunoassay procedures (e.g., radioimmunoassay, enzyme immunoassay, or fluorescence immunoassay). Hybridomas that may be used as source of antibodies encompass all derivatives, progeny cells of the parent hybridomas that produce monoclonal 20 antibodies specific for EGFRvlll, or portions thereof. Hybridomas that produce such antibodies may be grown in vitro or in vivo using known procedures. The monoclonal antibodies may be isolated from the culture media or body fluids, by conventional immunoglobulin purification procedures such as ammonium sulfate precipitation, gel electrophoresis, dialysis, 25 chromatography, and ultrafiltration, if desired. Undesired activity, if present, can be removed, for example, by running the preparation over adsorbents made of the immunogen attached to a solid phase and eluting or releasing the desired antibodies off the immunogen. Immunization of a host animal with cells expressing human EGFRvlll, a human EGFRvlll protein, or a fragment containing the target amino acid 30 sequence conjugated to a protein that is immunogenic in the species to be  CA 02954802 2017-01-12 50054-294 - 72 - immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N- hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride, 5 SOCI2, or R1N=C=NR, where R and R1 are different alkyl groups, can yield a population of antibodies (e.g., monoclonal antibodies). If desired, the antibody (monoclonal or polyclonal) of interest may be sequenced and the polynucleotide sequence may then be cloned into a vector for expression or propagation. The sequence encoding the antibody of interest may be 10 maintained in vector in a host cell and the host cell can then be expanded and frozen for future use. Production of recombinant monoclonal antibodies in cell culture can be carried out through cloning of antibody genes from B cells by means known in the art. See, e.g. Tiller et al., J. Immunol. Methods 329, 112, 2008; U.S. Pat. No. 7,314,622. 15 In an alternative, the polynucleotide sequence may be used for genetic manipulation to “humanize” the antibody or to improve the affinity, or other characteristics of the antibody. For example, the constant region may be engineered to more nearly resemble human constant regions to avoid immune response if the antibody is used in clinical trials and treatments in humans. It may be desirable to 20 genetically manipulate the antibody sequence to obtain greater affinity to EGFRvlll and greater efficacy in inhibiting EGFRvlll. There are four general steps to humanize a monoclonal antibody. These are: (1) determining the nucleotide and predicted amino acid sequence of the starting antibody light and heavy variable domains (2) designing the humanized antibody, i.e., 25 deciding which antibody framework region to use during the humanizing process (3) the actual humanizing methodologies/techniques and (4) the transfection and expression of the humanized antibody. See, for example, U.S. Pat. Nos. 4,816,567; 5,807,715; 5,866,692; 6,331,415; 5,530,101; 5,693,761; 5,693,762; 5,585,089; and 6,180,370.  CA 02954802 2017-01-12 50054-294 - 73 - A number of “humanized” antibody molecules comprising an antigen binding site derived from a non-human immunoglobulin have been described, including chimeric antibodies having rodent or modified rodent V regions and their associated CDRs fused to human constant regions. See, for example, Winter et al. Nature 5 349:293-299, 1991, Lobuglio et al. Proc. Nat. Acad. Sci. USA 86:4220-4224, 1989, Shaw et al. J Immunol. 138:4534-4538, 1987, and Brown et al. Cancer Res. 47:3577- 3583, 1987. Other references describe rodent CDRs grafted into a human supporting framework region (FR) prior to fusion with an appropriate human antibody constant region. See, for example, Riechmann et al. Nature 332:323-327, 1988, Verhoeyen et 10 al. Science 239:1534-1536, 1988, and Jones et al. Nature 321:522-525, 1986. Another reference describes rodent CDRs supported by recombinantly engineered rodent framework regions. See, for example, European Patent Publication No. 0519596. These “humanized” molecules are designed to minimize unwanted immunological response toward rodent anti-human antibody molecules which limits 15 the duration and effectiveness of therapeutic applications of those moieties in human recipients. For example, the antibody constant region can be engineered such that it is immunologically inert (e.g., does not trigger complement lysis). See, e.g. PCT Publication No. PCT/GB99/01441; UK Patent Application No. 9809951.8. Other methods of humanizing antibodies that may also be utilized are disclosed by 20 Daugherty et al., Nucl. Acids Res. 19:2471-2476, 1991, and in U.S. Pat. Nos. 6,180,377; 6,054,297; 5,997,867; 5,866,692; 6,210,671; and 6,350,861; and in PCT Publication No. WO 01/27160. The general principles related to humanized antibodies discussed above are also applicable to customizing antibodies for use, for example, in dogs, cats, primate, 25 equines and bovines. Further, one or more aspects of humanizing an antibody described herein may be combined, e.g., CDR grafting, framework mutation and CDR mutation. In one variation, fully human antibodies may be obtained by using commercially available mice that have been engineered to express specific human 30 immunoglobulin proteins. Transgenic animals that are designed to produce a more  CA 02954802 2017-01-12 50054-294 - 74 - desirable (e.g., fully human antibodies) or more robust immune response may also be used for generation of humanized or human antibodies. Examples of such technology are Xenomouse™ from Abgenix, Inc. (Fremont, CA) and HuMAb-Mouse® and TC Mouse™ from Medarex, Inc. (Princeton, NJ). 5 In an alternative, antibodies may be made recombinantly and expressed using any method known in the art. In another alternative, antibodies may be made recombinantly by phage display technology. See, for example, U.S. Pat. Nos. 5,565,332; 5,580,717; 5,733,743; and 6,265,150; and Winter et al., Annu. Rev. Immunol. 12:433-455, 1994. Alternatively, the phage display technology (McCafferty 10 et al., Nature 348:552-553, 1990) can be used to produce human antibodies and antibody fragments in vitro, from immunoglobulin variable (V) domain gene repertoires from unimmunized donors. According to this technique, antibody V domain genes are cloned in-frame into either a major or minor coat protein gene of a filamentous bacteriophage, such as M13 or fd, and displayed as functional antibody 15 fragments on the surface of the phage particle. Because the filamentous particle contains a single-stranded DNA copy of the phage genome, selections based on the functional properties of the antibody also result in selection of the gene encoding the antibody exhibiting those properties. Thus, the phage mimics some of the properties of the B cell. Phage display can be performed in a variety of formats; for review see, 20 e.g., Johnson, Kevin S. and Chiswell, David J., Current Opinion in Structural Biology 3:564-571, 1993. Several sources of V-gene segments can be used for phage display. Clackson et al., Nature 352:624-628, 1991, isolated a diverse array of anti- oxazolone antibodies from a small random combinatorial library of V genes derived from the spleens of immunized mice. A repertoire of V genes from unimmunized 25 human donors can be constructed and antibodies to a diverse array of antigens (including self-antigens) can be isolated essentially following the techniques described by Mark et al., J. Mol. Biol. 222:581-597, 1991, or Griffith et al., EMBO J. 12:725-734, 1993. In a natural immune response, antibody genes accumulate mutations at a high rate (somatic hypermutation). Some of the changes introduced 30 will confer higher affinity, and B cells displaying high-affinity surface immunoglobulin  CA 02954802 2017-01-12 50054-294 - 75 - are preferentially replicated and differentiated during subsequent antigen challenge. This natural process can be mimicked by employing the technique known as “chain shuffling.” (Marks et al., Bio/Technol. 10:779-783, 1992). In this method, the affinity of “primary” human antibodies obtained by phage display can be improved by 5 sequentially replacing the heavy and light chain V region genes with repertoires of naturally occurring variants (repertoires) of V domain genes obtained from unimmunized donors. This technique allows the production of antibodies and antibody fragments with affinities in the pM-nM range. A strategy for making very large phage antibody repertoires (also known as “the mother-of-all libraries”) has 10 been described by Waterhouse et al., Nucl. Acids Res. 21:2265-2266, 1993. Gene shuffling can also be used to derive human antibodies from rodent antibodies, where the human antibody has similar affinities and specificities to the starting rodent antibody. According to this method, which is also referred to as “epitope imprinting”, the heavy or light chain V domain gene of rodent antibodies obtained by phage 15 display technique is replaced with a repertoire of human V domain genes, creating rodent-human chimeras. Selection on antigen results in isolation of human variable regions capable of restoring a functional antigen binding site, i.e., the epitope governs (imprints) the choice of partner. When the process is repeated in order to replace the remaining rodent V domain, a human antibody is obtained (see PCT Publication 20 No. WO 93/06213). Unlike traditional humanization of rodent antibodies by CDR grafting, this technique provides completely human antibodies, which have no framework or CDR residues of rodent origin. Antibodies may be made recombinantly by first isolating the antibodies and antibody producing cells from host animals, obtaining the gene sequence, and using 25 the gene sequence to express the antibody recombinantly in host cells (e.g., CHO cells). Another method which may be employed is to express the antibody sequence in plants (e.g., tobacco) or transgenic milk. Methods for expressing antibodies recombinantly in plants or milk have been disclosed. See, for example, Peeters, et al. Vaccine 19:2756, 2001; Lonberg, N. and D. Huszar Int. Rev. Immunol 13:65,  CA 02954802 2017-01-12 50054-294 - 76 - 1995; and Pollock, et al., J Immunol Methods 231:147, 1999. Methods for making derivatives of antibodies, e.g., humanized, single chain, etc. are known in the art. Immunoassays and flow cytometry sorting techniques such as fluorescence activated cell sorting (FACS) can also be employed to isolate antibodies that are 5 specific for EGFRvlll, or tumor antigens of interest. The antibodies as described herein can be bound to many different carriers. Carriers can be active and/or inert. Examples of well-known carriers include polypropylene, polystyrene, polyethylene, dextran, nylon, amylases, glass, natural and modified celluloses, polyacrylamides, agaroses, and magnetite. The nature of 10 the carrier can be either soluble or insoluble for purposes of the invention. Those skilled in the art will know of other suitable carriers for binding antibodies, or will be able to ascertain such, using routine experimentation. In some embodiments, the carrier comprises a moiety that targets the myocardium. DNA encoding the monoclonal antibodies is readily isolated and sequenced 15 using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies). The hybridoma cells serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors (such as expression vectors disclosed in PCT Publication No. WO 87/04462), which are then 20 transfected into host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. See, e.g., PCT Publication No. WO 87/04462. The DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain 25 constant regions in place of the homologous murine sequences, Morrison et al., Proc. Nat. Acad. Sci. 81:6851, 1984, or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. In that manner, “chimeric” or “hybrid” antibodies are prepared that have the binding specificity of a monoclonal antibody herein.  CA 02954802 2017-01-12 50054-294 - 77 - The EGFRvlll antibodies as described herein can be identified or characterized using methods known in the art, whereby reduction of EGFRvlll expression levels are detected and/or measured. In some embodiments, an EGFRvlll antibody is identified by incubating a candidate agent with EGFRvlll and 5 monitoring binding and/or attendant reduction of EGFRvlll expression levels. The binding assay may be performed with purified EGFRvlll polypeptide(s), or with cells naturally expressing, or transfected to express, EGFRvlll polypeptide(s). In one embodiment, the binding assay is a competitive binding assay, where the ability of a candidate antibody to compete with a known EGFRvlll antibody for EGFRvlll binding 10 is evaluated. The assay may be performed in various formats, including the ELISA format. Following initial identification, the activity of a candidate EGFRvlll antibody can be further confirmed and refined by bioassays, known to test the targeted biological activities. Alternatively, bioassays can be used to screen candidates directly. Some 15 of the methods for identifying and characterizing antibodies are described in detail in the Examples. EGFRvlll antibodies may be characterized using methods well known in the art. For example, one method is to identify the epitope to which it binds, or “epitope mapping.” There are many methods known in the art for mapping and characterizing 20 the location of epitopes on proteins, including solving the crystal structure of an antibody-antigen complex, competition assays, gene fragment expression assays, and synthetic peptide-based assays, as described, for example, in Chapter 11 of Harlow and Lane, Using Antibodies, a Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1999. In an additional example, 25 epitope mapping can be used to determine the sequence to which an antibody binds. Epitope mapping is commercially available from various sources, for example, Pepscan Systems (Edelhertweg 15, 8219 PH Lelystad, The Netherlands). The epitope can be a linear epitope, i.e., contained in a single stretch of amino acids, or a conformational epitope formed by a three-dimensional interaction of amino acids that 30 may not necessarily be contained in a single stretch. Peptides of varying lengths  CA 02954802 2017-01-12 50054-294 - 78 - (e.g., at least 4-6 amino acids long) can be isolated or synthesized (e.g., recombinantly) and used for binding assays with an EGFRvlll or other tumor antigen antibody. In another example, the epitope to which the EGFRvlll antibody binds can be determined in a systematic screening by using overlapping peptides derived from 5 the EGFRvlll sequence and determining binding by the EGFRvlll antibody. According to the gene fragment expression assays, the open reading frame encoding EGFRvlll is fragmented either randomly or by specific genetic constructions and the reactivity of the expressed fragments of EGFRvlll with the antibody to be tested is determined. The gene fragments may, for example, be produced by PCR and then 10 transcribed and translated into protein in vitro, in the presence of radioactive amino acids. The binding of the antibody to the radioactively labeled EGFRvlll is then determined by immunoprecipitation and gel electrophoresis. Certain epitopes can also be identified by using large libraries of random peptide sequences displayed on the surface of phage particles (phage libraries). Alternatively, a defined library of 15 overlapping peptide fragments can be tested for binding to the test antibody in simple binding assays. In an additional example, mutagenesis of an antigen binding domain, domain swapping experiments and alanine scanning mutagenesis can be performed to identify residues required, sufficient, and/or necessary for epitope binding. For example, domain swapping experiments can be performed using a 20 mutant EGFRvlll in which various fragments of the EGFRvlll protein have been replaced (swapped) with sequences from EGFRvlll from another species (e.g., mouse), or a closely related, but antigenically distinct protein (e.g., Trop-1). By assessing binding of the antibody to the mutant EGFRvlll, the importance of the particular EGFRvlll fragment to antibody binding can be assessed. In the case of 25 EGFRvlll specific antibody (i.e. antibody that does not bind EGFRwt (wild type) or any other proteins), epitope can be deduced from the sequence alignment of EGFRvlll to EGFRwt. Yet another method which can be used to characterize an EGFRvlll antibody is to use competition assays with other antibodies known to bind to the same antigen, 30 i.e., various fragments on EGFRvlll, to determine if the EGFRvlll antibody binds to  CA 02954802 2017-01-12 50054-294 - 79 - the same epitope as other antibodies. Competition assays are well known to those of skill in the art. An expression vector can be used to direct expression of an EGFRvlll antibody. One skilled in the art is familiar with administration of expression vectors 5 to obtain expression of an exogenous protein in vivo. See, e.g., U.S. Pat. Nos. 6,436,908; 6,413,942; and 6,376,471. In some embodiments, the invention encompasses compositions, including harmaceutical compositions, comprising antibodies described herein or made by the methods and having the characteristics described herein. As used herein, 10 compositions comprise one or more antibodies that bind to EGFRvlll, and/or one or more polynucleotides comprising sequences encoding one or more these antibodies. These compositions may further comprise suitable excipients, such as pharmaceutically acceptable excipients including buffers, which are well known in the art. 15 The invention also provides methods of making any of these antibodies. The antibodies of this invention can be made by procedures known in the art. The polypeptides can be produced by proteolytic or other degradation of the antibodies, by recombinant methods (i.e., single or fusion polypeptides) as described above or by chemical synthesis. Polypeptides of the antibodies, especially shorter polypeptides 20 up to about 50 amino acids, are conveniently made by chemical synthesis. Methods of chemical synthesis are known in the art and are commercially available. For example, an antibody could be produced by an automated polypeptide synthesizer employing the solid phase method. See also, U.S. Pat. Nos. 5,807,715; 4,816,567; and 6,331,415. 25 In another alternative, the antibodies can be made recombinantly using procedures that are well known in the art. In one embodiment, a polynucleotide comprises a sequence encoding the heavy chain and/or the light chain variable regions of antibody m62G7, h62G7, h62G7-H14/L1-DV, h62G7-EQ/L6, 42G9, 32A10, 20B9, 14C11, 21E11, 49B11, 46E10, 12H6, 19A9, 21E7, 11B11, 12B2, 11F10, 30 17G11, 29D5, 30D8, 20E12, 26B9, 32G8, 34E7, 20G5, C6, B5, 42G9-1, 32A10-1,  CA 02954802 2017-01-12 50054-294 - 80 - 20B9-1, 14C11-1, 21E11-1, 49B11-1, 46E10-1, 12H6-1, 19A9-1, 21E7-1, 11B11-1, 12B2-1, 11F10-1, 17G11-1, 29D5-1, 30D8-1, 20E12-1, 26B9-1, 32G8-1, 34E7-1, 20G5-1, 06-1, or B5-1. The sequence encoding the antibody of interest may be maintained in a vector in a host cell and the host cell can then be expanded and 5 frozen for future use. Vectors (including expression vectors) and host cells are further described herein. Heteroconjugate antibodies, comprising two covalently joined antibodies, are also within the scope of the invention. Such antibodies have been used to target immune system cells to unwanted cells (U.S. Pat. No. 4,676,980), and for treatment 10 of HIV infection (PCT Publication Nos. WO 91/00360 and WO 92/200373; EP 03089). Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents and techniques are well known in the art, and are described in U.S. Pat. No. 4,676,980. Chimeric or hybrid antibodies also may be prepared in vitro using known 15 methods of synthetic protein chemistry, including those involving cross-linking agents. For example, immunotoxins may be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate. In the recombinant humanized antibodies, the Fey portion can be modified to 20 avoid interaction with Fey receptor and the complement and immune systems. The techniques for preparation of such antibodies are described in WO 99/58572. For example, the constant region may be engineered to more resemble human constant regions to avoid immune response if the antibody is used in clinical trials and treatments in humans. See, for example, U.S. Pat. Nos. 5,997,867 and 5,866,692. 25 The invention encompasses modifications to the antibodies and polypeptides of the invention including variants shown in Table 5, including functionally equivalent antibodies which do not significantly affect their properties and variants which have enhanced or decreased activity and/or affinity. For example, the amino acid sequence may be mutated to obtain an antibody with the desired binding affinity to 30 EGFRvlll. Modification of polypeptides is routine practice in the art and need not be  CA 02954802 2017-01-12 50054-294 - 81 - described in detail herein. Examples of modified polypeptides include polypeptides with conservative substitutions of amino acid residues, one or more deletions or additions of amino acids which do not significantly deleteriously change the functional activity, or which mature (enhance) the affinity of the polypeptide for its ligand, or use 5 of chemical analogs. Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an antibody with an N-terminal 10 methionyl residue or the antibody fused to an epitope tag. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody of an enzyme or a polypeptide which increases the half-life of the antibody in the blood circulation. Substitution variants have at least one amino acid residue in the antibody 15 molecule removed and a different residue inserted in its place. The sites of greatest interest for substitutional mutagenesis include the hypervariable regions, but FR alterations are also contemplated. Conservative substitutions are shown in Table 5 under the heading of "conservative substitutions." If such substitutions result in a change in biological activity, then more substantial changes, denominated 20 "exemplary substitutions" in Table 5, or as further described below in reference to amino acid classes, may be introduced and the products screened. In some embodiments, substitution variants of antibodies provided herein have no more than 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 conservative substitution in the VH or VL region as compared to the reference parent antibody. In some embodiments, the 25 substitutions are not within a CDR of the VH or VL region.  CA 02954802 2017-01-12 50054-294 - 82 - Table 5: Amino Acid Substitutions Original Residue (naturally occurring amino Conservative acid) Substitutions Exemplary Substitutions Ala (A) Vai Vai; Leu; lie Arg (R) Lys Lys; Gin; Asn Asn (N) Gin Gin; His; Asp, Lys; Arg Asp (D) Glu Glu; Asn Cys (C) Ser Ser; Ala Gin (Q) Asn Asn; Glu Glu (E) Asp Asp; Gin Gly (G) Ala Ala His (H) Arg Asn; Gin; Lys; Arg Leu; Vai; Met; Ala; Phe; He (1) Leu Norleucine Norleucine; He; Vai; Met; Leu (L) He Ala; Phe Lys (K) Arg Arg; Gin; Asn Met (M) Leu Leu; Phe; lie Phe (F) Tyr Leu; Vai; lie; Ala; Tyr Pro (P) Ala Ala Ser (S) Thr Thr Thr (T) Ser Ser Trp (W) Tyr Tyr; Phe Tyr(Y) Phe Trp; Phe; Thr; Ser He; Leu; Met; Phe; Ala; Vai (V) Leu Norleucine Substantial modifications in the biological properties of the antibody are accomplished by selecting substitutions that differ significantly in their effect on 5 maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.  CA 02954802 2017-01-12 50054-294 - 83 - Naturally occurring amino acid residues are divided into groups based on common side-chain properties: (1) Non-polar: Norleucine, Met, Ala, Vai, Leu, lie; (2) Polar without charge: Cys, Ser, Thr, Asn, Gin; 5 (3) Acidic (negatively charged): Asp, Glu; (4) Basic (positively charged): Lys, Arg; (5) Residues that influence chain orientation: Gly, Pro; and (6) Aromatic: Trp, Tyr, Phe, His. Non-conservative substitutions are made by exchanging a member of one of 10 these classes for another class. Any cysteine residue not involved in maintaining the proper conformation of the antibody also may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant cross-linking. Conversely, cysteine bond(s) may be added to the antibody to improve its stability, particularly where the 15 antibody is an antibody fragment such as an Fv fragment. Amino acid modifications can range from changing or modifying one or more amino acids to complete redesign of a region, such as the variable region. Changes in the variable region can alter binding affinity and/or specificity. In some embodiments, no more than one to five conservative amino acid substitutions are 20 made within a CDR domain. In other embodiments, no more than one to three conservative amino acid substitutions are made within a CDR domain. In still other embodiments, the CDR domain is CDR H3 and/or CDR L3. Modifications also include glycosylated and nonglycosylated polypeptides, as well as polypeptides with other post-translational modifications, such as, for example, 25 glycosylation with different sugars, acetylation, and phosphorylation. Antibodies are glycosylated at conserved positions in their constant regions (Jefferis and Lund, Chern. Immunol. 65:111-128, 1997; Wright and Morrison, TibTECH 15:26-32, 1997). The oligosaccharide side chains of the immunoglobulins affect the protein’s function (Boyd et al., Mol. Immunol. 32:1311-1318, 1996; Wittwe and Howard, Biochem. 30 29:4175-4180, 1990) and the intramolecular interaction between portions of the  CA 02954802 2017-01-12 50054-294 - 84 - glycoprotein, which can affect the conformation and presented three-dimensional surface of the glycoprotein (Jefferis and Lund, supra; Wyss and Wagner, Current Opin. Biotech. 7:409-416, 1996). Oligosaccharides may also serve to target a given glycoprotein to certain molecules based upon specific recognition structures. 5 Glycosylation of antibodies has also been reported to affect antibody-dependent cellular cytotoxicity (ADCC). In particular, CHO cells with tetracycline-regulated expression of P(1,4)-N-acetylglucosaminyltransferase III (GnTIII), a glycosyltransferase catalyzing formation of bisecting GIcNAc, was reported to have improved ADCC activity (Umana et al., Mature Biotech. 17:176-180, 1999). 10 Glycosylation of antibodies is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine, asparagine-X- threonine, and asparagine-X-cysteine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to 15 the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used. 20 Addition of glycosylation sites to the antibody is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above¬ described tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original antibody (for O-linked glycosylation sites). 25 The glycosylation pattern of antibodies may also be altered without altering the underlying nucleotide sequence. Glycosylation largely depends on the host cell used to express the antibody. Since the cell type used for expression of recombinant glycoproteins, e.g. antibodies, as potential therapeutics is rarely the native cell, variations in the glycosylation pattern of the antibodies can be expected (see, e.g. 30 Hse et al., J. Biol. Chern. 272:9062-9070, 1997).  CA 02954802 2017-01-12 50054-294 - 85 - In addition to the choice of host cells, factors that affect glycosylation during recombinant production of antibodies include growth mode, media formulation, culture density, oxygenation, pH, purification schemes and the like. Various methods have been proposed to alter the glycosylation pattern achieved in a particular host 5 organism including introducing or overexpressing certain enzymes involved in oligosaccharide production (U.S. Pat. Nos. 5,047,335; 5,510,261 and 5,278,299). Glycosylation, or certain types of glycosylation, can be enzymatically removed from the glycoprotein, for example, using endoglycosidase H (Endo H), N-glycosidase F, endoglycosidase F1, endoglycosidase F2, endoglycosidase F3. In addition, the 10 recombinant host cell can be genetically engineered to be defective in processing certain types of polysaccharides. These and similar techniques are well known in the art. Other methods of modification include using coupling techniques known in the art, including, but not limited to, enzymatic means, oxidative substitution and 15 chelation. Modifications can be used, for example, for attachment of labels for immunoassay. Modified polypeptides are made using established procedures in the art and can be screened using standard assays known in the art, some of which are described below and in the Examples. Other antibody modifications include antibodies that have been modified as 20 described in PCT Publication No. WO 99/58572. These antibodies comprise, in addition to a binding domain directed at the target molecule, an effector domain having an amino acid sequence substantially homologous to all or part of a constant region of a human immunoglobulin heavy chain. These antibodies are capable of binding the target molecule without triggering significant complement dependent lysis, 25 or cell-mediated destruction of the target. In some embodiments, the effector domain is capable of specifically binding FcRn and/or FcyRllb. These are typically based on chimeric domains derived from two or more human immunoglobulin heavy chain CH2 domains. The invention includes affinity matured embodiments. For example, affinity 30 matured antibodies can be produced by procedures known in the art (Marks et al.,  CA 02954802 2017-01-12 50054-294 - 86 - Bio/Technology, 10:779-783, 1992; Barbas et aL, Proc Nat. Acad. Sci, USA 91:3809- 3813, 1994; Schier et al., Gene, 169:147-155, 1995; Yelton et al., J. Immunol., 155:1994-2004, 1995; Jackson et aL, J. Immunol., 154(7):3310-9, 1995, Hawkins et aL, J. Mol. BioL, 226:889-896, 1992; and PCT Publication No. WO2004/058184). 5 The following methods may be used for adjusting the affinity of an antibody and for characterizing a CDR. One way of characterizing a CDR of an antibody and/or altering (such as improving) the binding affinity of a polypeptide, such as an antibody, termed "library scanning mutagenesis". Generally, library scanning mutagenesis works as follows. One or more amino acid positions in the CDR are 10 replaced with two or more (such as 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) amino acids using art recognized methods. This generates small libraries of clones (in some embodiments, one for every amino acid position that is analyzed), each with a complexity of two or more members (if two or more amino acids are substituted at every position). Generally, the library also includes a clone 15 comprising the native (unsubstituted) amino acid. A small number of clones, e.g., about 20-80 clones (depending on the complexity of the library), from each library are screened for binding affinity to the target polypeptide (or other binding target), and candidates with increased, the same, decreased, or no binding are identified. Methods for determining binding affinity are well-known in the art. Binding affinity 20 may be determined using Biacore™ surface plasmon resonance analysis, which detects differences in binding affinity of about 2-fold or greater. Biacore™ is particularly useful when the starting antibody already binds with a relatively high affinity, for example a KD of about 10 nM or lower. Screening using Biacore™ surface plasmon resonance is described in the Examples, herein. 25 Binding affinity may be determined using Kinexa Biocensor, scintillation proximity assays, ELISA, ORIGEN immunoassay (IGEN), fluorescence quenching, fluorescence transfer, and/or yeast display. Binding affinity may also be screened using a suitable bioassay. In some embodiments, every amino acid position in a CDR is replaced (in 30 some embodiments, one at a time) with all 20 natural amino acids using art  CA 02954802 2017-01-12 50054-294 - 87 - recognized mutagenesis methods (some of which are described herein). This generates small libraries of clones (in some embodiments, one for every amino acid position that is analyzed), each with a complexity of 20 members (if all 20 amino acids are substituted at every position). 5 In some embodiments, the library to be screened comprises substitutions in two or more positions, which may be in the same CDR or in two or more CDRs. Thus, the library may comprise substitutions in two or more positions in one CDR. The library may comprise substitution in two or more positions in two or more CDRs. The library may comprise substitution in 3, 4, 5, or more positions, said positions 10 found in two, three, four, five or six CDRs. The substitution may be prepared using low redundancy codons. See, e.g., Table 2 of Balint et al., Gene 137(1):109-18, 1993. The CDR may be CDRH3 and/or CDRL3. The CDR may be one or more of CDRL1, CDRL2, CDRL3, CDRH1, CDRH2, and/or CDRH3. The CDR may be a 15 Kabat CDR, a Chothia CDR, or an extended CDR. Candidates with improved binding may be sequenced, thereby identifying a CDR substitution mutant which results in improved affinity (also termed an "improved" substitution). Candidates that bind may also be sequenced, thereby identifying a CDR substitution which retains binding. 20 Multiple rounds of screening may be conducted. For example, candidates (each comprising an amino acid substitution at one or more position of one or more CDR) with improved binding are also useful for the design of a second library containing at least the original and substituted amino acid at each improved CDR position (i.e., amino acid position in the CDR at which a substitution mutant showed 25 improved binding). Preparation, and screening or selection of this library is discussed further below. Library scanning mutagenesis also provides a means for characterizing a CDR, in so far as the frequency of clones with improved binding, the same binding, decreased binding or no binding also provide information relating to the importance of 30 each amino acid position for the stability of the antibody-antigen complex. For  CA 02954802 2017-01-12 50054-294 - 88 - example, if a position of the CDR retains binding when changed to all 20 amino acids, that position is identified as a position that is unlikely to be required for antigen binding. Conversely, if a position of CDR retains binding in only a small percentage of substitutions, that position is identified as a position that is important to CDR 5 function. Thus, the library scanning mutagenesis methods generate information regarding positions in the CDRs that can be changed to many different amino acids (including all 20 amino acids), and positions in the CDRs which cannot be changed or which can only be changed to a few amino acids. Candidates with improved affinity may be combined in a second library, which 10 includes the improved amino acid, the original amino acid at that position, and may further include additional substitutions at that position, depending on the complexity of the library that is desired, or permitted using the desired screening or selection method. In addition, if desired, adjacent amino acid position can be randomized to at least two or more amino acids. Randomization of adjacent amino acids may permit 15 additional conformational flexibility in the mutant CDR, which may in turn, permit or facilitate the introduction of a larger number of improving mutations. The library may also comprise substitution at positions that did not show improved affinity in the first round of screening. The second library is screened or selected for library members with improved 20 and/or altered binding affinity using any method known in the art, including screening using Biacore™ surface plasmon resonance analysis, and selection using any method known in the art for selection, including phage display, yeast display, and ribosome display. The invention also encompasses fusion proteins comprising one or more 25 fragments or regions from the antibodies of this invention. In one embodiment, a fusion polypeptide is provided that comprises at least 10 contiguous amino acids of the variable light chain region shown in SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 29, 31, 33, 36, 38, 40, 42, 45, 47, 49, 51, 211, 212, 213, or 215, and/or at least 10 amino acids of the variable heavy chain region shown in SEQ ID 30 NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 30, 32, 34, 35, 37, 39, 41, 43, 44,  CA 02954802 2017-01-12 50054-294 - 89 - 46, 48, 50, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 202, 203, 204, 205, 206, 207, 208, 209, 210, 214, 216, 217, or 218. In other embodiments, a fusion polypeptide is provided that comprises at least about 10, at least about 15, at least about 20, at least about 25, or at least about 30 contiguous amino acids of the variable light chain 5 region and/or at least about 10, at least about 15, at least about 20, at least about 25, or at least about 30 contiguous amino acids of the variable heavy chain region. In another embodiment, the fusion polypeptide comprises one or more CDR(s). In still other embodiments, the fusion polypeptide comprises CDR H3 (VH CDR3) and/or CDR L3 (VL CDR3). For purposes of this invention, a fusion protein contains one or 10 more antibodies and another amino acid sequence to which it is not attached in the native molecule, for example, a heterologous sequence or a homologous sequence from another region. Exemplary heterologous sequences include, but are not limited to a "tag" such as a FLAG tag or a 6His tag. Tags are well known in the art. A fusion polypeptide can be created by methods known in the art, for example, 15 synthetically or recombinantly. Typically, the fusion proteins of this invention are made by preparing an expressing a polynucleotide encoding them using recombinant methods described herein, although they may also be prepared by other means known in the art, including, for example, chemical synthesis. This invention also provides compositions comprising antibodies conjugated 20 (for example, linked) to an agent that facilitate coupling to a solid support (such as biotin or avidin). For simplicity, reference will be made generally to antibodies with the understanding that these methods apply to any of the EGFRvlll antibody embodiments described herein. Conjugation generally refers to linking these components as described herein. The linking (which is generally fixing these 25 components in proximate association at least for administration) can be achieved in any number of ways. For example, a direct reaction between an agent and an antibody is possible when each possesses a substituent capable of reacting with the other. For example, a nucleophilic group, such as an amino or sulfhydryl group, on one may be capable of reacting with a carbonyl-containing group, such as an  CA 02954802 2017-01-12 50054-294 - 90 - anhydride or an acid halide, or with an alkyl group containing a good leaving group (e.g., a halide) on the other. The invention also provides isolated polynucleotides encoding the antibodies of the invention, and vectors and host cells comprising the polynucleotide. 5 Accordingly, the invention provides polynucleotides (or compositions, including pharmaceutical compositions), comprising polynucleotides encoding any of the following: m62G7, h62G7, h62G7-H14/L1-DV, h62G7-EQ/L6, 42G9, 32A10, 20B9, 14C11, 21E11, 49B11, 46E10, 12H6, 19A9, 21E7, 11B11, 12B2, 11F10, 17G11, 29D5, 30D8, 20E12, 26B9, 32G8, 34E7, 20G5, C6, B5, 42G9-1 , 32A10-1, 20B9-1, 10 14C11-1, 21E11-1, 49B11-1, 46E10-1, 12H6-1, 19A9-1, 21E7-1, 11B11-1, 12B2-1, , 11F10-1, 17G11-1, 29D5-1, 30D8-1, 20E12-1, 26B9-1, 32G8-1, 34E7-1, 20G5-1 C6- 1, and B5-1, or any fragment or part thereof having the ability to bind EGFRvlll. In another aspect, the invention provides polynucleotides encoding any of the antibodies (including antibody fragments) and polypeptides described herein, such as 15 antibodies and polypeptides having impaired effector function. Polynucleotides can be made and expressed by procedures known in the art. In another aspect, the invention provides compositions (such as a pharmaceutical compositions) comprising any of the polynucleotides of the invention. In some embodiments, the composition comprises an expression vector comprising a 20 polynucleotide encoding any of the antibodies described herein. Expression vectors, and administration of polynucleotide compositions are further described herein. In another aspect, the invention provides a method of making any of the polynucleotides described herein. 25 Polynucleotides complementary to any such sequences are also encompassed by the present invention. Polynucleotides may be single-stranded (coding or antisense) or double-stranded, and may be DNA (genomic, cDNA or synthetic) or RNA molecules. RNA molecules include HnRNA molecules, which contain introns and correspond to a DNA molecule in a one-to-one manner, and 30 mRNA molecules, which do not contain introns. Additional coding or non-coding  CA 02954802 2017-01-12 50054-294 - 91 - sequences may, but need not, be present within a polynucleotide of the present invention, and a polynucleotide may, but need not, be linked to other molecules and/or support materials. Polynucleotides may comprise a native sequence (i.e., an endogenous 5 sequence that encodes an antibody or a portion thereof) or may comprise a variant of such a sequence. Polynucleotide variants contain one or more substitutions, additions, deletions and/or insertions such that the immunoreactivity of the encoded polypeptide is not diminished, relative to a native immunoreactive molecule. The effect on the immunoreactivity of the encoded polypeptide may generally be 10 assessed as described herein. Variants preferably exhibit at least about 70% identity, more preferably, at least about 80% identity, yet more preferably, at least about 90% identity, and most preferably, at least about 95% identity to a polynucleotide sequence that encodes a native antibody or a portion thereof. Two polynucleotide or polypeptide sequences are said to be "identical" if the 15 sequence of nucleotides or amino acids in the two sequences is the same when aligned for maximum correspondence as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. A "comparison window" as used herein, refers to a segment of at least about 20 20 contiguous positions, usually 30 to about 75, or 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Optimal alignment of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., 25 Madison, Wl), using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, M.O., 1978, A model of evolutionary change in proteins - Matrices for detecting distant relationships. In Dayhoff, M.O. (ed.) Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington DC Vol. 5, Suppl. 3, pp. 345-358; Hein J., 1990, 30 Unified Approach to Alignment and Phylogenes pp. 626-645 Methods in Enzymology  CA 02954802 2017-01-12 50054-294 - 92 - vol. 183, Academic Press, Inc., San Diego, CA; Higgins, D.G. and Sharp, P.M., 1989, CABIOS 5:151-153; Myers, E.W. and Muller W., 1988, CABIOS 4:11-17; Robinson, E.D., 1971, Comb. Theor. 11:105; Santou, N., Nes, M., 1987, Mol. Biol. Evol. 4:406- 425; Sneath, P.H.A. and Sokal, R.R., 1973, Numerical Taxonomy the Principles and 5 Practice of Numerical Taxonomy, Freeman Press, San Francisco, CA; Wilbur, W.J. and Lipman, D.J., 1983, Proc. Natl. Acad. Sci. USA 80:726-730. Preferably, the "percentage of sequence identity" is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polynucleotide or polypeptide sequence in the 10 comparison window may comprise additions or deletions (i.e., gaps) of 20 percent or less, usually 5 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid bases or amino acid residue occurs in 15 both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (i.e. the window size) and multiplying the results by 100 to yield the percentage of sequence identity. Variants may also, or alternatively, be substantially homologous to a native 20 gene, or a portion or complement thereof. Such polynucleotide variants are capable of hybridizing under moderately stringent conditions to a naturally occurring DNA sequence encoding a native antibody (or a complementary sequence). Suitable “moderately stringent conditions” include prewashing in a solution of 5 X SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50°C-65°C, 5 X SSC, 25 overnight; followed by washing twice at 65°C for 20 minutes with each of 2X, 0.5X and 0.2X SSC containing 0.1 % SDS. As used herein, "highly stringent conditions" or "high stringency conditions" are those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl 30 sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as  CA 02954802 2017-01-12 50054-294 - 93 - formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCI, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 5 0.1% sodium pyrophosphate, 5 x Denhardt’s solution, sonicated salmon sperm DNA (50 pg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary 10 to accommodate factors such as probe length and the like. It will be appreciated by those of ordinary skill in the art that, as a result of the degeneracy of the genetic code, there are many nucleotide sequences that encode a polypeptide as described herein. Some of these polynucleotides bear minimal homology to the nucleotide sequence of any native gene. Nonetheless, 15 polynucleotides that vary due to differences in codon usage are specifically contemplated by the present invention. Further, alleles of the genes comprising the polynucleotide sequences provided herein are within the scope of the present invention. Alleles are endogenous genes that are altered as a result of one or more mutations, such as deletions, additions and/or substitutions of nucleotides. The 20 resulting mRNA and protein may, but need not, have an altered structure or function. Alleles may be identified using standard techniques (such as hybridization, amplification and/or database sequence comparison). The polynucleotides of this invention can be obtained using chemical synthesis, recombinant methods, or PCR. Methods of chemical polynucleotide 25 synthesis are well known in the art and need not be described in detail herein. One of skill in the art can use the sequences provided herein and a commercial DNA synthesizer to produce a desired DNA sequence. For preparing polynucleotides using recombinant methods, a polynucleotide comprising a desired sequence can be inserted into a suitable vector, and the vector 30 in turn can be introduced into a suitable host cell for replication and amplification, as  CA 02954802 2017-01-12 50054-294 - 94 - further discussed herein. Polynucleotides may be inserted into host cells by any means known in the art. Cells are transformed by introducing an exogenous polynucleotide by direct uptake, endocytosis, transfection, F-mating or electroporation. Once introduced, the exogenous polynucleotide can be maintained 5 within the cell as a non-integrated vector (such as a plasmid) or integrated into the host cell genome. The polynucleotide so amplified can be isolated from the host cell by methods well known within the art. See, e.g., Sambrook et al., 1989. Alternatively, PCR allows reproduction of DNA sequences. PCR technology is well known in the art and is described in U.S. Patent Nos. 4,683,195, 4,800,159, 10 4,754,065 and 4,683,202, as well as PCR: The Polymerase Chain Reaction, Mullis et al. eds., Birkauswer Press, Boston, 1994. RNA can be obtained by using the isolated DNA in an appropriate vector and inserting it into a suitable host cell. When the cell replicates and the DNA is transcribed into RNA, the RNA can then be isolated using methods well known to 15 those of skill in the art, as set forth in Sambrook et al., 1989, supra, for example. Suitable cloning vectors may be constructed according to standard techniques, or may be selected from a large number of cloning vectors available in the art. While the cloning vector selected may vary according to the host cell intended to be used, useful cloning vectors will generally have the ability to self-replicate, may possess a 20 single target for a particular restriction endonuclease, and/or may carry genes for a marker that can be used in selecting clones containing the vector. Suitable examples include plasmids and bacterial viruses, e.g., pUC18, pUC19, Bluescript (e.g., pBS SK+) and its derivatives, mp18, mp19, pBR322, pMB9, ColE1, pCR1, RP4, phage DNAs, and shuttle vectors such as pSA3 and pAT28. These and many other cloning 25 vectors are available from commercial vendors such as BioRad, Strategene, and Invitrogen. Expression vectors generally are replicable polynucleotide constructs that contain a polynucleotide according to the invention. It is implied that an expression vector must be replicable in the host cells either as episomes or as an integral part of 30 the chromosomal DNA. Suitable expression vectors include but are not limited to  CA 02954802 2017-01-12 50054-294 - 95 - plasmids, viral vectors, including adenoviruses, adeno-associated viruses, retroviruses, cosmids, and expression vectors) disclosed in PCT Publication No. WO 87/04462. Vector components may generally include, but are not limited to, one or more of the following: a signal sequence; an origin of replication; one or more 5 marker genes; suitable transcriptional controlling elements (such as promoters, enhancers and terminator). For expression (i.e., translation), one or more translational controlling elements are also usually required, such as ribosome binding sites, translation initiation sites, and stop codons. The vectors containing the polynucleotides of interest can be introduced into 10 the host cell by any of a number of appropriate means, including electroporation, transfection employing calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, or other substances; microprojectile bombardment; lipofection; and infection (e.g., where the vector is an infectious agent such as vaccinia virus). The choice of introducing vectors or polynucleotides will often depend on features of the 15 host cell. The invention also provides host cells comprising any of the polynucleotides described herein. Any host cells capable of over-expressing heterologous DNAs can be used for the purpose of isolating the genes encoding the antibody, polypeptide or protein of interest. Non-limiting examples of mammalian host cells include but not 20 limited to COS, HeLa, and CHO cells. See also PCT Publication No. WO 87/04462. Suitable non-mammalian host cells include prokaryotes (such as E. coli or B. subtillis) and yeast (such as S. cerevisae, S. pombe; or K. lactis). Preferably, the host cells express the cDNAs at a level of about 5 fold higher, more preferably, 10 fold higher, even more preferably, 20 fold higher than that of the corresponding endogenous 25 antibody or protein of interest, if present, in the host cells. Screening the host cells for a specific binding to EGFRvlll is effected by an immunoassay or FACS. A cell overexpressing the antibody or protein of interest can be identified.  CA 02954802 2017-01-12 50054-294 - 96 - EGFRvlll Antibody Conjugates The present invention also provides a conjugate (or immunoconjugate) of the EGFRvlll antibody as described herein, wherein the antibody is conjugated to an agent (e.g., a cytotoxic agent) for targeted immunotherapy (e.g., antibody-drug 5 conjugates) either directly or indirectly via a linker. For example, a cytotoxic agent can be linked or conjugated to the EGFRvlll antibody as described herein for targeted local delivery of the cytotoxic agent moiety to tumors (e.g., EGFRvlll expressing tumor). Methods for conjugating cytotoxic agent or other therapeutic agents to 10 antibodies have been described in various publications. For example, chemical modification can be made in the antibodies either through lysine side chain amines or through cysteine sulfhydryl groups activated by reducing interchain disulfide bonds for the conjugation reaction to occur. See, e.g., Tanaka et al., FEBS Letters 579:2092-2096, 2005, and Gentle et al., Bioconjugate Chern. 15:658-663, 2004. 15 Reactive cysteine residues engineered at specific sites of antibodies for specific drug conjugation with defined stoichiometry have also been described. See, e.g., Junutula et al., Nature Biotechnology, 26:925-932, 2008. Conjugation using an acyl donor glutamine-containing tag or an endogenous glutamine made reactive (i.e., the ability to form a covalent bond as an acyl donor) by polypeptide engineering in the presence 20 of transglutaminase and an amine (e.g., a cytotoxic agent comprising or attached to a reactive amine) is also described in international applications WO2012/059882 and WO2015015448. In some embodiments, the EGFRvlll antibody or the conjugate as described herein comprises an acyl donor glutamine-containing tag engineered at a specific site 25 of the antibody (e.g., a carboxyl terminus, an amino terminus, or at another site in the EGFRvlll antibody). In some embodiments, the tag comprises an amino acid glutamine (Q) or an amino acid sequence LQG, LLQGG (SEQ ID NO: 258), LLQG (SEQ ID NO: 259), LSLSQG (SEQ ID NO: 260), GGGLLQGG (SEQ ID NO: 261), GLLQG (SEQ ID NO: 262), LLQ, GSPLAQSHGG (SEQ ID NO: 263), GLLQGGG 30 (SEQ ID NO: 264), GLLQGG (SEQ ID NO: 265), GLLQ (SEQ ID NO: 266),  CA 02954802 2017-01-12 50054-294 - 97 - LLQLLQGA (SEQ ID NO: 267), LLQGA (SEQ ID NO: 268), LLQYQGA (SEQ ID NO: 269), LLQGSG (SEQ ID NO: 270), LLQYQG (SEQ ID NO: 271), LLQLLQG (SEQ ID NO: 272), SLLQG (SEQ ID NO: 273), LLQLQ (SEQ ID NO: 274), LLQLLQ (SEQ ID NO: 275), LLQGR (SEQ ID NO: 276), LLQGPP (SEQ ID NO: 277), LLQGPA 5 (SEQ ID NO: 278), GGLLQGPP (SEQ ID NO: 279), GGLLQGA (SEQ ID NO: 280), LLQGPGK (SEQ ID NO: 281), LLQGPG (SEQ ID NO: 282), LLQGP (SEQ ID NO: 283), LLQP (SEQ ID NO: 284), LLQPGK (SEQ ID NO: 285), LLQAPGK (SEQ ID NO: 286), LLQGAPG (SEQ ID NO: 287), LLQGAP (SEQ ID NO: 288), and LLQLQG (SEQ ID NO: 289). 10 Also provided is an isolated antibody comprising an acyl donor glutamine- containing tag and an amino acid modification at position 222, 340, or 370 of the antibody (EU numbering scheme) wherein the modification is an amino acid deletion, insertion, substitution, mutation, or any combination thereof. In some embodiments, the amino acid modification is a substitution from lysine to arginine (e.g., K222R, 15 K340R, or K370R). The agents that can be conjugated to the EGFRvlll antibodies of the present invention include, but are not limited to, cytotoxic agents, immunomodulating agents, imaging agents, therapeutic proteins, biopolymers, or oligonucleotides. Examples of a cytotoxic agent include, but are not limited to, anthracycline, an 20 auristatin, a dolastatin, a combretastatin, a duocarmycin, a pyrrolobenzodiazepine dimer, an indolino-benzodiazepine dimer, an enediyne, a geldanamycin, a maytansine, a puromycin, a taxane, a vinca alkaloid, a camptothecin, a tubulysin, a hemiasterlin, a spliceostatin, a pladienolide, and stereoisomers, isosteres, analogs, or derivatives thereof. 25 The anthracyclines are derived from bacteria Strepomyces and have been used to treat a wide range of cancers, such as leukemias, lymphomas, breast, uterine, ovarian, and lung cancers. Exemplary anthracyclines include, but are not limited to, daunorubicin, doxorubicin (i.e., adriamycin), epirubicin, idarubicin, valrubicin, and mitoxantrone.  CA 02954802 2017-01-12 50054-294 - 98 - Dolastatins and their peptidic analogs and derivatives, auristatins, are highly potent antimitotic agents that have been shown to have anticancer and antifungal activity. See, e.g., U.S. Pat. No. 5,663,149 and Pettit et al., Antimicrob. Agents Chemother. 42:2961-2965, 1998. Exemplary dolastatins and auristatins include, but 5 are not limited to, dolastatin 10, auristatin E, auristatin EB (AEB), auristatin EFP (AEFP), MMAD (Monomethyl Auristatin D or monomethyl dolastatin 10), MMAF (Monomethyl Auristatin F or N-methylvaline-valine-dolaisoleuine-dolaproine- phenylalanine), MMAE (Monomethyl Auristatin E or N-methylvaline-valine- dolaisoleuine-dolaproine-norephedrine), 5-benzoylvaleric acid-AE ester (AEVB), and 10 other novel auristatins (such as the ones described in U.S. Publication No. 2013/0129753). In some embodiments, the auristatin is 0101 (2-methylalanyl-/V- [(3R,4S,5S)-3-methoxy-1-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-{[(1S)-2- phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4- yl]-/V-methyl-L-valinamide) having the following structure: In some embodiments, the auristatin is 3377 (N,2-dimethylalanyl-N-{(1S,2R)-4- {(2S)-2-[(1R,2R)-3-{[(1S)-1-carboxyl-2-phenylethyl]amino}-1-methoxy-2-methyl-3- oxopropyl]pyrrolidin-1-yl}-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl)-N-methyl-L- valinamide) having the following structure: In some embodiments, the auristatin is 0131-OMe (N,2-dimethylalanyl-N- [(3R,4S,5S)-3-methoxy-1-{(2S)-2-[(1R,2R)-1-methoxy-3-{[(2S)-1-methoxy-1-oxo-3-  CA 02954802 2017-01-12 50054-294 - 99 - phenylpropan-2-yl]amino}-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-5-methyl-1- oxoheptan-4-yl]-N-methylL-valinamide) having the following structure: In other embodiments, the auristatin is 0131 (2-methyl-L-proly-N-[(3R,4S,5S)- 5 1-{(2S)-2-[(1R,2R)-3-{[(1S)-1-carboxy-2-phenylethyl]amino}-1-methoxy-2-methyl-3- oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L- valinamide) having the following structure: In other embodiments, the auristatin is 0121 (2-methyl-L-proly-N-[(3R,4S,5S)- 10 1-{(2S)-2-[(1R,2R)-3-{[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino}-1-methoxy- 2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N- methyl-L-valinamide) having the following structure: 15 Camptothecin is a cytotoxic quinoline alkaloid which inhibits the enzyme topoisomerase I. Examples of camptothecin and its derivatives include, but are not limited to, topotecan and irinotecan, and their metabolites, such as SN-38. Combretastatins are natural phenols with vascular disruption properties in tumors. Exemplary combretastatins and their derivatives include, but are not limited 20 to, combretastatin A-4 (CA-4) and ombrabulin.  CA 02954802 2017-01-12 50054-294 - 100 - Duocarmycin and CC-1065 are DNA alkylating agents with cytotoxic potency. See Boger and Johnson, PNAS 92:3642-3649 (1995). Exemplary duocarmycin and CC-1065 include, but are not limited to, (+)-duocarmycin A and (+)-duocarmycin SA, (+)-CC-1065, and the compounds as disclosed in the international application 5 PCT/IB2015/050280 including, but not limited to, N~2~-acetyl-L-lysyl-L-valyl-N~5~- carbamoyl-N-[4-({[(2-{[({(1S)-1-(chloromethyl)-3-[(5-{[(1S)-1-(chloromethyl)-5- (phosphonooxy)-l ,2-dihydro-3H-benzo[e]indol-3-yl]carbonyl}thiophen-2-yl)carbonyl]- 2,3-di hydro-1H-benzo[e]indol-5- yl}oxy)carbonyl](methyl)amino}ethyl)(methyl)carbamoyl]oxy}methyl)phenyl]-L- 10 ornithinamide having the structure: N~2~-acetyl-L-lysyl-L-valyl-N~5~-carbamoyl-N-[4-({[(2-{[({(8S)-8-(chloromethyl)-6-[(3- {[(1S)-1-(chloromethyl)-8-methyl-5-(phosphonooxy)-1,6-dihydropyrrolo[3,2-e]indol- 3(2H)-yl]carbonyl}bicyclo[1.1.1]p ent-1-yl)carbonyl]-1-methyl-3,6,7,8- 15 tetrahydropyrrolo[3,2-e]indol-4- yl}oxy)carbonyl](methyl)amino}ethyl)(methyl)carbamoyl]oxy}methyl)phenyl]-L- ornithinamide having the structure:  CA 02954802 2017-01-12 50054-294 - 101 - N~2— acetyl-L-lysyl-L-valyl-N~5— carbamoyl-N-[4-({[(2-{[({(8S)-8-(chloromethyl)-6-[(4- {[(1S)-1-(chloromethyl)-8-methyl-5-(phosphonooxy)-1,6-dihydropyrrolo[3,2-e]indol- 3(2H)-yl]carbonyl}pentacyclo[4.2.0.0~2,5~.0~3,8~.0~4,7~]oct-1-yl)carbonyl]-1-methyl- 5 3,6,7,8-tetrahydropyrrolo[3,2-e]indol-4- yl}oxy)carbonyl](methyl)amino}ethyl)(methyl)carbamoyl]oxy}methyl)phenyl]-L- ornithinamide having the structure: ci  CA 02954802 2017-01-12 50054-294 - 102 - Enediynes are a class of anti-tumor bacterial products characterized by either nine- and ten-membered rings or the presence of a cyclic system of conjugated triple¬ double-triple bonds. Exemplary enediynes include, but are not limited to, calicheamicin, esperamicin, uncialamicin, dynemicin, and their derivatives. 5 Geldanamycins are benzoquinone ansamycin antibiotic that bind to Hsp90 (Heat Shock Protein 90) and have been used antitumor drugs. Exemplary geldanamycins include, but are not limited to, 17-AAG (17-N-Allylamino-17- Demethoxygeldanamycin) and 17-DMAG (17-Dimethylaminoethylamino-17- demethoxygeldanamycin). 10 Hemiasterlin and its analogues (e.g., HTI-286) bind to the tubulin, disrupt normal microtubule dynamics, and, at stoichiometric amounts, depolymerize microtubules. Maytansines or their derivatives maytansinoids inhibit cell proliferation by inhibiting the microtubules formation during mitosis through inhibition of 15 polymerization of tubulin. See Remillard et al., Science 189:1002-1005, 1975. Exemplary maytansines and maytansinoids include, but are not limited to, mertansine (DM1) and its derivatives as well as ansamitocin. Pyrrolobenzodiazepine dimers (PBDs) and indolino-benzodiazepine dimers (IGNs) are anti-tumor agents that contain one or more immine functional groups, or 20 their equivalents, that bind to duplex DNA. PBD and IGN molecules are based on the natural product athramycin, and interact with DNA in a sequence-selective manner, with a preference for purine-guanine-purine sequences. Exemplary PBDs and their analogs include, but are not limited to, SJG-136. Spliceostatins and pladienolides are anti-tumor compounds which inhibit 25 splicing and interacts with spliceosome, SF3b. Examples of spliceostatins include, but are not limited to, spliceostatin A, FR901464, and (2S,3Z)-5-{[(2R,3R,5S,6S)-6- {(2E,4E)-5-[(3R,4R,5R,7S)-7-(2-hydrazinyl-2-oxoethyl)-4-hydroxy-1,6- dioxaspiro[2.5]oct-5-yl]-3-methylpenta-2,4-dien-1-yl}-2,5-dimethyltetrahydro-2H- pyran-3-yl]amino}-5-oxopent-3-en-2-yl acetate having the structure of  CA 02954802 2017-01-12 50054-294 Examples of pladienolides include, but are not limited to, Pladienolide B, Pladienolide D, or E7107. Taxanes are diterpenes that act as anti-tubulin agents or mitotic inhibitors. Exemplary taxanes include, but are not limited to, paclitaxel (e.g., TAXOL®) and 5 docetaxel (TAXOTERE®). Tubulysins are natural products isolated from a strain of myxobacteria that has been shown to depolymerize microtubules and induce mitotic arrest. Exemplary tubulysins include, but are not limited to, tubulysin A, tubulysin B, and tubulysin D. Vinca alkyloids are also anti-tubulin agents. Exemplary vinca alkyloids 10 include, but are not limited to, vincristine, vinblastine, vindesine, and vinorelbine. Accordingly, in some embodiments, the cytotoxic agent is selected from the group consisting of MMAD (Monomethyl Auristatin D), 0101 (2-methylalanyl-A/- [(3R,4S,5S)-3-methoxy-1-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-{[(1S)-2- phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4- 15 yl]-/V-methyl-L-valinamide), 3377 (N,2-dimethylalanyl-N-{(1S,2R)-4-{(2S)-2-[(1R,2R)- 3-{[(1S)-1-carboxyl-2-phenylethyl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin- 1-yl}-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl}-N-methyl-L-valinamide), 0131 (2- methyl-L-proly-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S)-1-carboxy-2- phenylethyl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5- 20 methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide), 0131-OMe (N,2-dimethylalanyl-N- [(3R,4S,5S)-3-methoxy-1-{(2S)-2-[(1R,2R)-1-methoxy-3-{[(2S)-1-methoxy-1-oxo-3- phenylpropan-2-yl]amino}-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-5-methyl-1- oxoheptan-4-yl]-N-methylL-valinamide), 0121(2-methyl-L-proly-N-[(3R,4S,5S)-1- {(2S)-2-[(1R,2R)-3-{[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino}-1-methoxy-2- 25 methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl- L-valinamide), and (2S,3Z)-5-{[(2R,3R,5S,6S)-6-{(2E,4E)-5-[(3R,4R,5R,7S)-7-(2-  CA 02954802 2017-01-12 50054-294 - 104 - hydrazinyl-2-oxoethyl)-4-hydroxy-1,6-dioxaspiro[2.5]oct-5-yl]-3-methylpenta-2,4-dien- 1-yl}-2,5-dimethyltetrahydro-2H-pyran-3-yl]amino}-5-oxopent-3-en-2-yl acetate. In some embodiments, the agent is an immunomodulating agent. Examples of an immunomodulating agent include, but are not limited to, gancyclovier, etanercept, 5 tacrolimus, sirolimus, voclosporin, cyclosporine, rapamycin, cyclophosphamide, azathioprine, mycophenolgate mofetil, methotrextrate, glucocorticoid and its analogs, cytokines, stem cell growth factors, lymphotoxins, tumor necrosis factor (TNF), hematopoietic factors, interleukins (e.g., interleukin-1 (IL-1), IL-2, IL-3, IL-6, IL-10, IL- 12, IL-18, and IL-21), colony stimulating factors (e.g., granulocyte-colony stimulating 10 factor (G-CSF) and granulocyte macrophage-colony stimulating factor (GM-CSF)), interferons (e.g., interferons-a, -£ and -y), the stem cell growth factor designated “S 1 factor,” erythropoietin and thrombopoietin, or a combination thereof. In some embodiments, the agent moiety is an imaging agent (e.g., a fluorophore or a chelator), such as fluorescein, rhodamine, lanthanide phosphors, 15 and their derivatives thereof, or a radioisotope bound to a chelator. Examples of fluorophores include, but are not limited to, fluorescein isothiocyanate (FITC) (e.g., 5- FITC), fluorescein amidite (FAM) (e.g., 5-FAM), eosin, carboxyfluorescein, erythrosine, Alexa Fluor® (e.g., Alexa 350, 405, 430, 488, 500, 514, 532, 546, 555, 568, 594, 610, 633, 647, 660, 680, 700, or 750), carboxytetramethylrhodamine 20 (TAMRA) (e.g., 5,-TAMRA), tetramethylrhodamine (TMR), and sulforhodamine (SR) (e.g., SR101). Examples of chelators include, but are not limited to, 1,4,7,10- tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA), 1,4,7-triazacyclononane- 1,4,7-triacetic acid (NOTA), 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (deferoxamine), diethylenetriaminepentaacetic acid (DTPA), and 1,2-bis(o- 25 aminophenoxy)ethane-N,N,N',N'-tetraacetic acid) (BAPTA). In some embodiments, therapeutic or diagnostic radioisotopes or other labels (e.g., PET or SPECT labels) can be incorporated in the agent for conjugation to the EGFRvlll antibodies as described herein. Examples of a radioisotope or other labels include, but are not limited to, 3H, 11C, 13N, 14C, 15N, 15O, 35S, 18F, 32P, 33P, 47Sc, 51Cr, 30 57Co, 58Co, 59Fe, 62Cu, 64Cu, 67Cu, 67Ga, 68Ga, 75Se, 76Br, 77Br, 86Y, 89Zr, 90Y, 94Tc,  CA 02954802 2017-01-12 50054-294 - 105 - 95Ru, 97Ru, "Tc, 103Ru, 105Rh, 105Ru, 107Hg, 109Pd, 111Ag, 111ln, 113ln, 121Te, 122Te, 123l, 124| 125| 125-|-e 126| 131| 131 1 n 133 1 142pr 143pr ISSp^ 153gm 161^^ 165Tm 166Qy 166H 167Tm, 168Tm, 169Yb, 177Lu, 186Re, 188Re, 189Re, 197Pt, 198Au, 199Au, 201TI, 203Hg, 211At, 212Bi, 212Pb, 213Bi, 223Ra, 224Ac, or 225Ac. 5 In some embodiments, the agent is a therapeutic protein including, but is not limited to, a toxin, a hormone, an enzyme, and a growth factor. Examples of a toxin protein (or polypeptide) include, but are not limited to, dipththeria (e.g., diphtheria A chain), Pseudomonas exotoxin and endotoxin, ricin (e.g., ricin A chain), abrin (e.g., abrin A chain), modeccin (e.g., modeccin A chain), 10 alpha-sarcin, Aleurites fordii proteins, dianthin proteins, ribonuclease (RNase), DNase I, Staphylococcal enterotoxin-A, pokeweed antiviral protein, gelonin, diphtherin toxin, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, mitogellin, restrictocin, phenomycin, enomycin, tricothecenes, inhibitor cystine knot (ICK) 15 peptides (e.g., ceratotoxins), and conotoxin (e.g., KIIIA or Smilla). In some embodiments, the agent is a biocompatible polymer. The EGFRvlll antibodies as described herein can be conjugated to the biocompatible polymer to increase serum half-life and bioactivity, and/or to extend in vivo half-lives. Examples of biocompatible polymers include water-soluble polymer, such as polyethylene glycol 20 (PEG) or its derivatives thereof and zwitterion-containing biocompatible polymers (e.g., a phosphorylcholine containing polymer). In some embodiments, the agent is an oligonucleotide, such as anti-sense oligonucleotides. In another aspect, the invention provides a conjugate of the antibody as 25 described herein, wherein the conjugate comprises the formula: antibody-(acyl donor glutamine-containing tag)-(linker)-(cytotoxic agent). Examples of a linker containing one or more reactive amines include, but are not limited to, Ac-Lys-Gly (acetyl-lysine-glycine), aminocaproic acid, Ac-Lys-P-Ala (acetyl-lysine-p-alanine), amino-PEG2 (polyethylene glycol)-C2, amino-PEG3-C2, 30 amino-PEG6-C2 (or amino PEG6-propionyl), Ac-Lys-Val-Cit-PABC (acetyl-lysine-  CA 02954802 2017-01-12 50054-294 - 106 - valine-citrulline-p-aminobenzyloxycarbonyl), amino-PEG6-C2-Val-Cit-PABC, aminocaproyl-Val-Cit-PABC, [(3R,5R)-1-{3-[2-(2- aminoethoxy)ethoxy]propanoyl}piperidine-3,5-diyl]bis-Val-Cit-PABC, [(3S,5S)-1-{3-[2- (2-aminoethoxy)ethoxy]propanoyl}piperidine-3,5-diyl]bis-Val-Cit-PABC, putrescine, or 5 Ac-Lys-putrescine. Compositions In one aspect, the present invention provides a pharmaceutical composition comprising an antibody (e.g., monospecific or bispecific) or an antibody conjugate, of 10 the invention or portion thereof as described above in a pharmaceutically acceptable carrier. In certain embodiments, the polypeptides of the invention may be present in a neutral form (including zwitter ionic forms) or as a positively or negatively-charged species. In some embodiments, the polypeptides may be complexed with a counterion to form a "pharmaceutically acceptable salt," which refers to a complex 15 comprising one or more polypeptides and one or more counterions, where the counterions are derived from pharmaceutically acceptable inorganic and organic acids and bases. Generally, the antibody (e.g., monospecific or bispecific) or the antibody 20 conjugate disclosed herein or portions thereof may be formulated in association with one or more pharmaceutically acceptable excipient(s). The term 'excipient' is used herein to describe any ingredient other than the compound(s) of the invention. As used herein, “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and 25 absorption delaying agents, and the like that are physiologically compatible. Some examples of pharmaceutically acceptable excipients are water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the 30 composition. Additional examples of pharmaceutically acceptable substances are  CA 02954802 2017-01-12 50054-294 - 107 - wetting agents or minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the antibody. Pharmaceutical compositions of the present invention and methods for their 5 preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in Remington’s Pharmaceutical Sciences, 19th Edition (Mack Publishing Company, 1995). Pharmaceutical compositions are preferably manufactured under GMP conditions. The following examples are offered for illustrative purposes only, and are not 10 intended to limit the scope of the present invention in any way. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. 15 Examples Example 1: Affinity Determination for Recombinant Anti-EGFRvlll Murine-Human Chimeric Antibody and Humanized Antibodies This example determines the affinity of chimeric and humanized anti-EGFRvlll 20 antibodies at 25°C and 37°C. Anti-EGFRvlll mouse (m) antibody, m62G7, generated from hybridomas was sequenced and subcloned into suitable vectors for expression as murine-human chimeric antibodies. The CDRs of mouse antibody m62G7 were grafted onto human framework and expressed as human lgG1 recombinant antibody, h62G7. Affinity 25 variants of h62G7 were made by introducing mutations in the CDRs of the heavy and light chains. The affinities of recombinant anti-EGFRvlll chimeric antibody m62G7 and humanized h62G7 antibodies were measured on a surface plasmon resonance Biacore™ T200 biosensor equipped with a research-grade anti-human Fc coupled CM4 sensor chip (GE Healthcare Inc., Piscataway, NJ). Anti-EGFRvlll antibodies 30 were then captured by anti-human Fc. Monomeric 8-histidine tagged human  CA 02954802 2017-01-12 50054-294 - 108 - EGFRvlll extracellular domain was then injected as the analyte at 10-fold dilution series with top concentration at 1000 nM. Affinity of anti-EGFRvlll antibodies towards human EGFRvlll was measured at both 25°C and 37°C (Table 6). None of these antibodies showed detectable binding to 1000 nM 8-histidine tagged recombinant 5 wild-type protein EGFRwt under the same assay condition. In Table 6, variants of h62G7 are described with reference to the heavy chain variation then the light chain variation. For example, antibody clone “h62G7-EQ/L6” refers to the h62G7 clone containing the “EQ” variation in the heavy chain (also referred to herein as “h62G7-EQ”) and the “L6” variation in the light chain (also 10 referred to herein as “h62G7-L6”). These heavy chain and light chain amino acid sequences are provided in Table 2. Also, in the present application, a h62G7 variant may be referred to with either the heavy chain or the light chain variant written first - so, for example, “h62G7-EQ/L6” and “h62G7-L6/EQ” both refer to an antibody which contains a h62G7-EQ heavy chain and a h62G7-L6 light chain. 15 Table 6 25°C 37°C Antibody ka(1/Ms) kd(1/s) KD(nM) ka(1/Ms) kd(1/s) KD(nM) m62G7 7.30E+05 6.40E-02 88.7 8.00E+05 1.70E-01 207.0 h62G7-EQ/L6 2.40E+05 1.00E-02 43.8 6.60E+05 7.40E-02 112.8 h62G7-EQ/L1-DV 2.00E+05 1.20E-05 59.9 3.70E+05 6.90E-02 185.8 h62G7-H14/L1-DV 1.80E+04 2.00E-02 1087.9 6.60E+04 1.00E-01 1539.6 h62G7-H14/L6 1.30E+04 1.30E-02 992.2 4.30E+04 6.80E-02 1583.3 Example 2: Affinity Determination for Human Anti-EGFRvlll Antibodies This example determines the affinity of various human anti-EGFRvlll antibodies at 37°C. 20 To generate human antibodies against EGFRvlll, transgenic AlivaMab mice (Ablexis LLC, San Francisco, CA) were immunized with alternating schedule of rat glioblastoma cell line expressing EGFRvlll, F98-npEGFRvlll (American Type Culture Collection, Manassas, VA) and peptides (SEQ ID NO: 227: CGSGSGLEEKKGNYVVTDH) directed to the junction region in EGFRvlll. 25 Hybridomas were generated using standard techniques. To determine the binding  CA 02954802 2017-01-12 50054-294 - 109 - affinity and specificity of these hybridomas to EGFRvlll, antibodies in culture supernatants were captured by anti-mouse Fc using Biacore™ T200 biosensor equipped with anti-mouse Fc coupled CM4 sensor chips (Biacore™ AB, Uppsala, Sweden - now GE Healthcare). Monomeric 8-histidine tagged human EGFRvlll 5 extracellular domain was then injected as the analyte at 10-fold dilution series starting with top concentration 1000 nM. Affinity of anti-EGFRvlll antibodies towards human EGFRvlll was measured at 37°C (Table 7). None of these hybridoma antibodies showed detectable binding to 1000 nM 8-histidine tagged recombinant wild-type protein EGFRwt under the same assay condition. Table 7 EGFRvlll binding at 37°C Antibody ka(1/Ms) kd(1/s) KD(nM) 42G9 6.88E+04 5.63E-04 8.2 32A10 6.54E+04 6.26E-04 9.6 21E11 6.66E+04 6.32E-04 9.5 49B11 7.64E+04 6.95E-04 9.1 46E10 5.97E+04 7.16E-04 12.0 12H6 5.93E+04 7.33E-04 12.4 19A9 5.58E+04 1.04E-03 18.6 11B11 5.21E+04 1.13E-03 21.7 21E7 6.52E+04 1.30E-03 19.9 20B9 4.67E+04 1.50E-03 32.1 12B2 7.38E+04 1.79E-03 24.3 11F10 6.63E+04 2.81E-03 42.4 17G11 5.61E+04 3.00E-03 53.5 29D5 1.02E+05 4.24E-03 41.6 14C11 7.55E+04 5.93E-03 78.5 20E12 3.99E+04 1.41E-02 353.4 20G5 1.25E+05 2.89E-02 231.2 26B9 1.31E+05 3.20E-02 244.3 30D8 1.61E+05 2 77E-02 172.0 32G8 6.82E+03 1.22E-02 1788.9 34E7 3.77E+04 1.28E-02 339.5  CA 02954802 2017-01-12 50054-294 - 110 - Example 3: Binding Specificity of Anti-EGFRvlll Antibodies to EGFRvlll expressing Cell Lines by Flow Cytometry This example demonstrates the cell binding specificity of anti-EGFRvlll antibodies to EGFRvlll expressing cells. 5 To assess the cell binding specificity of anti-EGFRvlll antibodies generated from the AlivaMab mice, three isogenic rat glioblastoma cell lines and a human cancer cell line were used: F98 (does not express any form of human EGFR), F98- EGFRwt (expresses wild-type EGFR), F98-npEGFRvlll (expresses EGFRvlll) and A431 (an epidermoid carcinoma cell line with wild-type EGFR over-expression), all 10 obtained from American Type Culture Collection (Manassas, VA). For cell staining, 500,000 cells were incubated with 50 pl hybridoma supernatants for 45 min at 4°C, washed with binding buffer (PBS (Phosphate Buffered Saline) + 0.5% BSA (Bovine Serum Albumin)), followed by incubation with FITC-conjugated goat anti-mouse Fc specific secondary antibody from Jackson ImmunoResearch Laboratories (West 15 Grove, PA). Tables 8A and 8B show mean fluorescent intensities (MFI) of EGFRvlll antibodies (except clone 20G5) on EGFRvlll expressing cell line were at least 10-fold higher than on non-expressing cell lines. FIG. 1A, FIG. 1B, and FIG. 1C show examples of the FACS binding histograms of three EGFRvlll specific clones which had been cloned and expressed as recombinant human lgG1 antibodies, 42G9 (FIG. 20 1A), 32A10 (FIG. 1B) and 32G8 (FIG. 1C), to the three F98 cell lines. Table 8A F98 F98-EGFRwt F98-EGFRvlll A431 % % % % Antibody MFI positive MFI positive MFI positive MFI positive 2nd Ab only 170 0.6 202 1.7 258 2.3 592 0.4 anti-EGFR(wt 163 0.5 9608 98.3 5329 99.4 55240 100.0 and vlll) 42G9 159 0.4 185 1.6 3247 98.5 538 0.3 32A10 159 0.5 185 1.4 3349 98.3 531 0.2 21E11 159 0.3 184 1.3 3105 98.5 555 0.5 49B11 156 0.6 185 1.3 2980 98.5 599 0.8 46E10 158 0.4 187 1.6 2986 98.7 560 0.5 12H6 157 0.5 188 1.9 3445 98.3 569 0.8  CA 02954802 2017-01-12 50054-294 - 111 - F98 F98-EGFRwt F98-EGFRvlll A431 % % % % Antibody MFI positive MFI positive MFI positive MFI positive 19A9 158 0.5 168 1.6 3100 98.1 578 1.0 11B11 161 0.6 187 1.7 3391 98.2 589 1.2 21E7 159 0.3 184 1.3 3105 98.5 603 1.1 20B9 157 0.3 189 1.8 3418 98.3 558 0.7 12B2 156 0.4 185 1.5 2749 97.9 571 0.8 11F10 155 0.5 187 1.6 3283 98.0 582 1.1 17G11 157 0.6 184 1.5 3357 98.1 556 0.7 29D5 155 0.3 185 1.3 2829 97.9 531 0.4 14C11 157 0.4 185 1.3 3213 98.2 580 0.8 Table 8B F98 F98-EGFRwt F98-EGFRvlll A431 % % % % Antibody MFI positive MFI positive MFI positive MFI positive 2nd Ab only 235 0.2 252 0.2 322 1.3 185 0.7 anti-EGFR(wt 245 0.3 6857 97.2 5827 99.4 44493 100.0 and vlll) 20E12 381 6.0 348 3.4 3976 97.9 302 2.6 20G5 1248 16.8 1070 12.6 4639 98.5 391 2.0 26B9 310 4.1 298 2.3 5405 98.6 276 1.7 30D8 296 4.0 280 1.7 5165 98.6 269 1.3 32G8 329 4.9 301 1.6 3734 98.6 271 1.2 34E7 485 6.9 371 4.0 4128 98.5 294 1.1 Example 4: Affinity Determination for Fully Human Anti-EGFRvlll Antibodies from 5 phage library This example determines the affinity of various human anti-EGFRvlll antibodies at 25°C. Human anti-EGFRvlll antibodies obtained from phage library screen were sequenced and subcloned into suitable vectors for expression as recombinant human 10 lgG1 antibodies. The affinities of antibodies were measured at 25°C (Table 9) on a surface plasmon resonance Biacore™ T200 biosensor equipped with an anti-human Fc coupled CM4 sensor chip (GE Healthcare Inc., Piscataway, NJ). Anti-EGFRvlll  CA 02954802 2017-01-12 50054-294 - 112 - antibodies were captured by anti-human Fc. Monomeric 8-histidine tagged human EGFRvlll extracellular domain was then injected as the analyte at 10-fold dilution series starting at 1000 nM. Among the two antibodies, only C6 showed very weak but detectable binding to 1000 nM 8-histidine tagged recombinant wild-type protein 5 EGFRwt at 25°C. Table 9 EGFRvlll binding at 25°C Antibody ka(1/Ms) kd(1/s) KD(nM) B5 2.08E+04 1.41E-02 677.9 C6 1.68E+04 8.94E-03 532.1 Example 5: Generation and Characterization of GBM Cell Lines Expression EGFRvlll 10 This example demonstrates the expression of wild-type EGFR and EGFRvlll in GBM cell lines. Five GFP (green fluorescent protein) and luciferase transduced human glioblastoma cell lines, DKMG, LN18, LN18-EGFRvlll, LN229 and LN229-EGFRvlll were used for functional characterization. DKMG, which expresses both endogenous 15 wild-type EGFR and EGFRvlll, was obtained from DSMZ (Braunschweig, Germany). LN18 and LN229, which express only wild-type EGFR, were obtained from American Type Culture Collection (Manassas, VA). To generate GFP-luciferase labeled cell lines, DKMG, LN18 and LN229 were transduced with lentivirus particles (Amsbio, Cambridge, MA) encoding both GFP (green fluorescent protein) and luciferase in a 20 bicistronic system. LN18-EGFRvlll and LN229-EGFRvlll were then generated by transduction of the parental cell lines, with a lentivirus vector encoding the full length EGFRvlll gene (SEQ ID NO: 201). Wild-type EGFR and EGFRvlll expression in each cell line was then analysed using flow cytometer. For cell staining, 300,000 cells were incubated with 3 pg EGFR wild-type specific or EGFRvlll specific antibody 25 in 100 pl binding buffer (PBS (Phosphate Buffered Saline) + 2% FBS) for 45 min at 4°C, washed with binding buffer, followed by incubation with Alexa Fluor 647- conjugated goat anti-human Fc specific secondary antibody from Jackson  CA 02954802 2017-01-12 50054-294 - 113 - ImmunoResearch Laboratories (West Grove, PA). FIGs. 2A-C show the expression profiles of wild-type EGFR and EGFRvlll in LN229-EGFRvlll, LN18-EGFRvlll and DKMG, respectively. 5 Example 6: In vitro cytotoxicity assays with EGFRvlll-CD3 bispecific antibodies This example demonstrates the cytotoxicity of EGFRvlll-CD3 bispecific antibodies towards EGFRvlll expressing GBM cell lines. To generate EGFRvlll-CD3 bispecific antibodies, the heavy-chain variable domains of anti-EGFRvlll and anti-CD3 antibodies were subcloned into the 10 appropriate human lgG2 based bispecific vectors and expressed with their corresponding light-chain in HEK293 cells. Purification of the EGFRvlll-CD3 bispecific antibodies was done according to published methods (J Mol Biol, 2012, 3, pp204-219; US patent publication 2013/0115208). In these assays, the EGFRvlll- CD3 bispecific antibodies contain the anti-EGFRvlll sequence of anti-EGFRvlll 15 clones h62G7-EQ/L6, 30D8, or 42G9. Target cells in this Example were: EGFRvlll transduced LN18-EGFRvlll cells (FIG. 3A) and parental LN18 (FIG. 3B) cells; EGFRvlll transduced LN229-EGFRvlll (FIG. 4A) and parental LN229 (FIG. 4B) cells; and DKMG cells (which express endogenous EGFRvlll and EGFR wild-type proteins) (FIG. 5). 20 For the cytotoxicity assays, luciferase transduced target cells were plated in white 96-well plates at 10,000 cells/well in PBMC media (RPMI, 10% FBS, 2 mM L- glutamine, 1% Pen/Strep, 20 uM p-mercaptoethanol, 10 mM HEPES, 1% non- essential amino acids, 1 mM sodium pyruvate) and incubated at 37 °C. Twenty-four hours later, activated T cells at the desired T:E (targeteffector) ratio (10,000 T cells 25 for 1:1, for LN18 and LN229 cells; 50,000 T cells for 1:5, for DKMG cells) were added to target cells along with the EGFRvlll-CD3 bispecific antibodies, negative control human IgG, negative control CD3 monovalent antibody in bispecific Fc backbone, or negative control bivalent anti-EGFRvlll mAb 42G9 in wild-type human IgG. Cells were incubated for another 24 h at 37 °C. To detect the amount of viable target cells 30 at the end of assay, the media was discarded and 100 pl of 150 pg/ml luciferin was  CA 02954802 2017-01-12 50054-294 - 114 - added to each well. Luminescence signal was acquired on SpectraMax M5 Plate Reader (Molecular Devices, Sunnyvale, CA). Percentage of live target cells was determined by normalizing the luminescence reading for each sample to that of control well containing only target cells. 5 The results are summarized in FIGs. 3A, 3B, 4A, 4B, and 5. In the graphs, the EGFRvlll-CD3 bispecific antibody data are represented by open symbols, and the negative control antibody data are represented by solid symbols. Target cells that expressed EGFRvlll showed a dose-dependent response to treatment with EGFRvlll-CD3 bispecific antibodies h62G7-EQ/L6/CD3 biFc, 10 30D8/CD3 biFc, and 42G9/CD3 biFc. In contrast, target cells that expressed EGFR wild-type protein only were not killed, thus indicating the specificity of the EGFRvlll- CD3 bispecific antibodies for cells expressing EGFRvlll. In addition, target cells that expressed EGFRvlll did not show a response to treatment with negative control antibodies human IgG, CD3 monovalent biFc, or42G1 hlgG1 (anti-EGFRvlll 15 antibody). For example, LN18-EGFRvlll target cells treated with 0.01 nM h62G7- EQ/L6/CD3 biFc were only about 20% viable at the end of the assay. In contrast, LN18-EGFRvlll target cells treated with 0.1 nM control IgG, CD3 mono biFc, or 42G9 hlgG1 were about 100% viable at the end of the assay (FIG. 3A). In addition, 20 parental cell line LN18 target cells treated with 0.01 nM h62G7-EQ/L6/CD3 biFc were about 100% viable at the end of the assay (FIG 3B). In another example, LN229-EGFRvlll target cells treated with 0.01 nM 42G9/CD3 biFc were only about 35% viable at the end of the assay. In contrast, LN229-EGFRvlll target cells treated with 0.1 nM control IgG, CD3 mono biFc, or 25 42G9 hlgG1 were about 90-100% viable at the end of the assay (FIG. 4A). In addition, parental cell line LN229 target cells treated with 0.01 nM 42G9/CD3 biFc were about 100% viable at the end of the assay (FIG 4B). In another example, DKMG target cells treated with 1 nM h62G7-EQ/L6/CD3 biFc were only about 35% viable at the end of the assay (FIG. 5). In contrast, DKMG  CA 02954802 2017-01-12 50054-294 - 115 - target cells treated with 1 nM control IgG, CD3 mono biFc, or 42G9 hlgG1 were about 100% viable at the end of the assay (FIG. 5). These data demonstrate that EGFRvlll-CD3 bispecific antibodies effectively mediate killing by T cells of EGFRvlll expressing cells. 5 Example 7: In Vivo Study of Anti-EGFRvlll-CD3 Bispecific Antibodies in a GBM model LN229-EGFRvlll This example determines the in vivo anti-tumor activity of anti-EGFRvlll bispecific antibodies in a subcutaneous LN229-EGFRvlll GBM cell line model. 10 Three million LN229-EGFRvlll cells were implanted subcutaneously into 5-6 weeks old NSG mice (Jackson Laboratory, Sacramento, CA). Tumor volume was measured once a week by a caliper device and calculated with the following formula: Tumor volume = (length x width2) /2. On day 18 post tumor implantation, animals were randomized by tumor sizes into five animals per group. A single dose of 20 15 million fresh pan T cells was administered intraperitoneally, followed by bolus tail vein injection of 0.5 mg/kg of EGFRvlll-CD3 bispecific antibodies (the antibodies contained the anti-EGFRvlll sequence of anti-EGFRvlll clones h62G7-EQ/L6, 30D8, or 42G9), or CD3 monovalent control in bispecifc Fc backbone. The results are summarized in FIG. 6. In the graph, the EGFRvlll-CD3 20 bispecific antibody data are represented by open symbols, and the negative control antibody data are represented by solid symbols. The EGFRvlll-CD3 bispecific antibodies h62G7-EQ/L6/CD3 biFc, 30D8/CD3 biFc, and 42G9/CD3 biFc inhibited the in vivo growth of the EGFRvlll-expressing LN229-EGFRvlll GBM cells. In contrast, the negative control antibody CD3 25 monovalent biFc and a no treatment control (i.e. the mouse was not dosed with T cells or antibody) did not inhibit the in vivo growth of the LN229-EGFRvlll GBM cells. For example, at day 37 post tumor implantation, the mean tumor volume for mice treated with the EGFRvlll-CD3 bispecific antibodies 30D8/CD3 biFc and 42G9/CD3 biFc was less than 100 mm3, whereas the mean tumor volume for mice without 30 treatment or treated with the CD3 monovalent biFc was greater than 1200 mm3.  81802864 - 116- These data demonstrate the in vivo anti-tumor activities of EGFRvlll-CD3 bispecific antibodies against EGFRvlll expressing tumor cells. Although the disclosed teachings have been described with reference to 5 various applications, methods, kits, and compositions, it will be appreciated that various changes and modifications can be made without departing from the teachings herein and the claimed invention below. The foregoing examples are provided to better illustrate the disclosed teachings and are not intended to limit the scope of the teachings presented herein. While the present teachings have been described in 10 terms of these exemplary embodiments, the skilled artisan will readily understand that numerous variations and modifications of these exemplary embodiments are possible without undue experimentation. All such variations and modifications are within the scope of the current teachings. In the event that one or more cited literature and similar materials differs from or 15 contradicts this application, including but not limited to defined terms, term usage, described techniques, or the like, this application controls. The foregoing description and Examples detail certain specific embodiments of the invention and describes the best mode contemplated by the inventors. It will be appreciated, however, that no matter how detailed the foregoing may appear in text, 20 the invention may be practiced in many ways and the invention should be construed in accordance with the appended claims and any equivalents thereof. Date Regue/Date Received 2023-06-14

Claims (27)

  1.  81802864 - 117 - CLAIMS: 1. An isolated antibody, which specifically binds to Epidermal Growth Factor Receptor Variant III (EGFRvlll), wherein the antibody comprises: (a) a heavy chain variable (VH) region comprising (i) a VH complementarity 5 determining region one (CDR1) comprising the sequence shown in SEQ ID NO: 74, 75, or 76; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 77 or 78; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 79; and a light chain variable (VL) region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 156; (ii) a VL CDR2 comprising the sequence shown in 10 SEQ ID NO: 157; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 158; or (b) a VH region comprising (i) a CDR1 comprising the sequence shown in SEQ ID NO: 80, 81, or 82; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 83 or 84; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 85; and 15 a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 159; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 160; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 161 or; (c) a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 80, 81, or 82; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 20 86 or 87; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 79; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 162; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 163; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 164; or (d) a VH region comprising (i) a VH CDR1 comprising the sequence shown in 25 SEQ ID NO: 88, 89, or 90; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 91 or 92; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 85; and Date ReQue/Date Received 2023-06-14  81802864 - 118 - a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 165; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 163; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 161 or; (e) a VH region comprising (i) a VH CDR1 comprising the sequence shown in 5 SEQ ID NO: 93, 94, or 95; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 96 or 97; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 79; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 166; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 163; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 167; or 10 (f) a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 93, 94, or 95; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 96 or 97; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 85 and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 168; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 163; and (iii) a 15 VL CDR3 comprising the sequence shown in SEQ ID NO: 167; or (g) a VH region comprising (i) a CDR1 comprising the sequence shown in SEQ ID NO: 80, 81, or 82; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 83 or 84; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 85; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ 20 ID NO: 169; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 163; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 161 or; (h) a VH region comprising (i) a CDR1 comprising the sequence shown in SEQ ID NO: 80, 81, or 82; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 83 or 84; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 85; and Date ReQue/Date Received 2023-06-14  81802864 - 119 - a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 170; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 163; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 161 or; (i) a VH region comprising (i) a VH CDR1 comprising the sequence shown in 5 SEQ ID NO: 80, 81, or 82; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 98 or 78; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 85; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 171; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 172; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 167; or 10 (j) a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 80, 81, or 82; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 98 or 78; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 85; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 174; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 175; and (iii) a 15 VL CDR3 comprising the sequence shown in SEQ ID NO: 167; or (k) a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 99, 100, or 101; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 83 or 84; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 85; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ 20 ID NO: 173; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 163; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 161 or; (I) a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 74, 75, or 76; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 102 or 103; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 104; and Date ReQue/Date Received 2023-06-14  81802864 - 120 - a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 176; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 172; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 177; or (m) a VH region comprising (i) a CDR1 comprising the sequence shown in SEQ 5 ID NO: 74, 75, or 76; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 105 or 103; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 107; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 178; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 179; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 180; or 10 (n) a VH region comprising (i) a CDR1 comprising the sequence shown in SEQ ID NO: 74, 75, or 76; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 102 or 103; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 108; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 176; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 172; and (iii) a 15 VL CDR3 comprising the sequence shown in SEQ ID NO: 177; or (o) a VH region comprising (i) a CDR1 comprising the sequence shown in SEQ ID NO: 74, 75, or 76; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 106 or 87; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 85; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ 20 ID NO: 181; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 172; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 167; or (p) a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 109, 110, or 111; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 112 or 113; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 114; 25 and Date ReQue/Date Received 2023-06-14  81802864 -121 - a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 182; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 183; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 184; or (q) a VH region comprising (i) a VH CDR1 comprising the sequence shown in 5 SEQ ID NO: 115, 116, or 177; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 118 or 119; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 120; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 185; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 186; and (iii) a 10 VL CDR3 comprising the sequence shown in SEQ ID NO: 184; or (r) a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 121, 122, or 123; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 124 or 125; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 126; and 15 a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 187; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 188; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 189; or (s) a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 115, 116, or 117; (ii) a VH CDR2 comprising the sequence shown in SEQ ID 20 NO: 127 or 128; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 129; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 185; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 186; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 184; or 25 (t) a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 115, 116, or 117; (ii) a VH CDR2 comprising the sequence shown in SEQ ID Date ReQue/Date Received 2023-06-14  81802864 -122- NO: 130 or 131; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 120; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 190; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 191; and (iii) a 5 VL CDR3 comprising the sequence shown in SEQ ID NO: 184; or (u) a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 132, 133, or 134; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 135 or 136; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 126; and 10 a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 192; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 193; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 194.
  2. 2. The isolated antibody according to claim 1,wherein the antibody comprises: a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ 15 ID NO: 88, 89, or 90; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 91 or 92; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 85; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 165; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 163; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 161. 20
  3. 3. The isolated antibody according to claim 1, wherein the antibody comprises: a VH region comprising (i) a CDR1 comprising the sequence shown in SEQ ID NO: 80, 81 or, 82; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 83 or 84; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 85; and Date ReQue/Date Received 2023-06-14  81802864 -123- a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 159; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 160; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 161.
  4. 4. The isolated antibody according to claim 1,wherein the antibody comprises: 5 a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 121, 122, or 123; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 124 or 125; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 126; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 187; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 188; and (iii) a 10 VL CDR3 comprising the sequence shown in SEQ ID NO: 189.
  5. 5. The isolated antibody according to claim 1,wherein the antibody comprises: a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 109, 110, or 111; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 112 or 113; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 114; and 15 a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 182; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 183; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 184.
  6. 6. The isolated antibody according to claim 1,wherein the antibody comprises: a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ 20 ID NO: 74, 75, or 76; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 102 or 103; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 104; and a VL region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 176; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 172; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 177. 25
  7. 7. The isolated antibody according to claim 1,wherein the antibody comprises: Date ReQue/Date Received 2023-06-14  81802864 -124- (a) a VH region comprising the sequence shown in SEQ ID NO: 9; and a VL region comprising the sequence shown in SEQ ID NO: 10; or (b) a VH region comprising the sequence shown in SEQ ID NO: 11; and a VL region comprising the sequence shown in SEQ ID NO: 12; or 5 (c) a VH region comprising the sequence shown in SEQ ID NO: 13; and a VL region comprising the sequence shown in SEQ ID NO: 14; or (d) a VH region comprising the sequence shown in SEQ ID NO: 15; and a VL region comprising the sequence shown in SEQ ID NO: 16; or (e) a VH region comprising the sequence shown in SEQ ID NO: 17; and 10 a VL region comprising the sequence shown in SEQ ID NO: 18; or (f) a VH region comprising the sequence shown in SEQ ID NO: 19; and a VL region comprising the sequence shown in SEQ ID NO: 20; or (g) a VH region comprising the sequence shown in SEQ ID NO: 21; and a VL region comprising the sequence shown in SEQ ID NO: 22; or 15 (h) a VH region comprising the sequence shown in SEQ ID NO: 23; and a VL region comprising the sequence shown in SEQ ID NO: 24; or (i) a VH region comprising the sequence shown in SEQ ID NO: 25; and a VL region comprising the sequence shown in SEQ ID NO: 26; or (j) a VH region comprising the sequence shown in SEQ ID NO: 25; and 20 a VL region comprising the sequence shown in SEQ ID NO: 29; or (k) a VH region comprising the sequence shown in SEQ ID NO: 27; and a VL region comprising the sequence shown in SEQ ID NO: 28; or (I) a VH region comprising the sequence shown in SEQ ID NO: 30; and a VL region comprising the sequence shown in SEQ ID NO: 31; or Date ReQue/Date Received 2023-06-14  81802864 -125- (m) a VH region comprising the sequence shown in SEQ ID NO: 32; and a VL region comprising the sequence shown in SEQ ID NO: 33; or (n) a VH region comprising the sequence shown in SEQ ID NO: 34; and a VL region comprising the sequence shown in SEQ ID NO: 31; or 5 (o) a VH region comprising the sequence shown in SEQ ID NO: 35; and a VL region comprising the sequence shown in SEQ ID NO: 36; or (p) a VH region comprising the sequence shown in SEQ ID NO: 37; and a VL region comprising the sequence shown in SEQ ID NO: 38; or (q) a VH region comprising the sequence shown in SEQ ID NO: 39; and 10 a VL region comprising the sequence shown in SEQ ID NO: 40; or (r) a VH region comprising the sequence shown in SEQ ID NO: 41; and a VL region comprising the sequence shown in SEQ ID NO: 42; or (s) a VH region comprising the sequence shown in SEQ ID NO: 43; and a VL region comprising the sequence shown in SEQ ID NO: 40; or 15 (t) a VH region comprising the sequence shown in SEQ ID NO: 44; and a VL region comprising the sequence shown in SEQ ID NO: 45; or (u) a VH region comprising the sequence shown in SEQ ID NO: 46; and a VL region comprising the sequence shown in SEQ ID NO: 47.
  8. 8. The isolated antibody according to claim 1,wherein the antibody comprises a 20 VH region comprising the sequence shown in SEQ ID NO: 15; and a VL region comprising the sequence shown in SEQ ID NO: 16.
  9. 9. The isolated antibody according to claim 1,wherein the antibody comprises a VH region comprising the sequence shown in SEQ ID NO: 11; and Date ReQue/Date Received 2023-06-14  81802864 -126- a VL region comprising the sequence shown in SEQ ID NO: 12.
  10. 10. The isolated antibody according to claim 1,wherein the antibody comprises a VH region comprising the sequence shown in SEQ ID NO: 41; and a VL region comprising the sequence shown in SEQ ID NO: 42. 5
  11. 11. The isolated antibody according to claim 1,wherein the antibody comprises a VH region comprising the sequence shown in SEQ ID NO: 37; and a VL region comprising the sequence shown in SEQ ID NO: 38.
  12. 12. The isolated antibody according to claim 1,wherein the antibody comprises a VH region comprising the sequence shown in SEQ ID NO: 30; and 10 a VL region comprising the sequence shown in SEQ ID NO: 31.
  13. 13. The isolated antibody according to any one of claims 1-12, wherein the antibody is a bispecific antibody, wherein the bispecific antibody is a full-length antibody further comprising a second antibody specifically binding to an effector antigen located on a human immune effector cell. 15
  14. 14. The isolated antibody according to claim 13, wherein the effector antigen is CD3 and the second antibody comprises a VH region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 244, 110 or 245; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 246 or 247; (iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 248; and a VL region comprising (i) a VL CDR1 comprising the sequence 20 shown in SEQ ID NO: 249; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 250; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO; 251.
  15. 15. The isolated antibody according to claim 14, wherein the second antibody comprises a VH region comprising the sequence shown in SEQ ID NO: 240 and a VL region comprising the sequence shown in SEQ ID NO: 241. Date ReQue/Date Received 2023-06-14  81802864 -127-
  16. 16. The isolated antibody of any one of claims 13-15, wherein the bispecific antibody comprises amino acid modifications at positions 223, 225, and 228 in the hinge region and at position 409 or 368 (Ell numbering scheme) in the CH3 region of a human lgG2 (SEQ ID NO: 290). 5
  17. 17. The isolated antibody of claim 16, further comprising an amino acid modification at one or more of positions 265, 330 and 331 (EU numbering scheme) of the human lgG2.
  18. 18. The antibody of any one of claims 1-17, wherein the antibody comprises an acyl donor glutamine-containing tag engineered at a specific site. 10
  19. 19. The antibody of any one of claims 1-17, wherein the antibody comprises a linker.
  20. 20. A nucleic acid encoding the antibody of any one of claims 1-19.
  21. 21. A vector comprising the nucleic acid of claim 20.
  22. 22. A host cell comprising the nucleic acid of claim 20 or the vector of claim 20. 15
  23. 23. A conjugate of the antibody of any one of claims 1-19, wherein the antibody is conjugated to an agent, wherein the agent is selected from the group consisting of a cytotoxic agent, an immunomodulating agent, an imaging agent, a therapeutic protein, a biopolymer, and an oligonucleotide.
  24. 24. A pharmaceutical composition comprising the antibody of any one of claims 1- 20 19, or the conjugate of claim 23.
  25. 25. The antibody of any one of claims 1-19, the conjugate of claim 23, or the pharmaceutical composition of claim 24, for use as a medicament.
  26. 26. The antibody of any one of claims 1-19, the conjugate of claim 23, or the pharmaceutical composition of claim 24, for use in treatment of: cancer; a condition 25 associated with malignant cells expressing EGFRvlll; tumor growth, progression, or Date ReQue/Date Received 2023-06-14  81802864 -128- metastasis in a subject who has malignant cells expressing EGFRvlll; or an EGFRvlll related cancer selecting from the group consisting of glioblastoma multiforme, anaplastic astrocytoma, giant cell glioblastoma, gliosarcoma, anaplastic oligodendroglioma, anaplastic ependymoma, anaplastic oligoastrocytoma, choroid plexus carcinoma, anaplastic 5 ganglioglioma, pineoblastoma, pineocytoma, meningioma, medulloepithelioma, ependymoblastoma, medulloblastoma, supraentorial primitive neuroectodermal tumor, atypical teratoid/rhabdoid tumor, mixed glioma, head and neck cancer, non-small cell lung cancer, breast cancer, ovarian cancer, prostate cancer, medullobastoma, colorectal cancer, anal cancer, cervical cancer, renal cancer, skin cancer, pancreatic cancer, liver cancer, 10 bladder cancer, gastric cancer, thyroid cancer, mesothelioma, uterine cancer, lymphoma, and leukemia.
  27. 27. A method of producing an antibody according to any one of claims 1-19, comprising culturing the host cell of claim 22 under conditions that result in production of the antibody or bispecific antibody, and isolating the antibody or bispecific antibody from the host 15 cell or culture. Date ReQue/Date Received 2023-06-14
CA2954802A 2016-01-21 2017-01-12 Antibodies specific for epidermal growth factor receptor variant iii Active CA2954802C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662281543P 2016-01-21 2016-01-21
US62/281,543 2016-01-21
US201662431766P 2016-12-08 2016-12-08
US62/431,766 2016-12-08

Publications (2)

Publication Number Publication Date
CA2954802A1 CA2954802A1 (en) 2017-07-21
CA2954802C true CA2954802C (en) 2025-09-16

Family

ID=57838442

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2954802A Active CA2954802C (en) 2016-01-21 2017-01-12 Antibodies specific for epidermal growth factor receptor variant iii

Country Status (9)

Country Link
US (2) US10221242B2 (en)
EP (1) EP3405490B1 (en)
JP (2) JP2019506398A (en)
CN (1) CN109219618B (en)
CA (1) CA2954802C (en)
DK (1) DK3405490T3 (en)
ES (1) ES2904593T3 (en)
TW (2) TW201936640A (en)
WO (1) WO2017125831A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117466C2 (en) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. STABLE COMPOSITION IN THE VIEW OF AN ANTIBODY ANTIBODY TO IL-23p19
ES2904593T3 (en) 2016-01-21 2022-04-05 Pfizer Monospecific and bispecific antibodies to epidermal growth factor receptor variant III and CD3 and their uses
BR112018014585A2 (en) * 2016-01-21 2018-12-11 Pfizer chimeric antigen receptors that direct variant epidermal growth factor receptor iii
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN110913906A (en) 2017-05-02 2020-03-24 默沙东公司 Preparation of anti-LAG3 antibody and co-formulation of anti-LAG3 antibody and anti-PD-1 antibody
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
US20210032351A1 (en) * 2017-12-13 2021-02-04 Xdcexplorer (Shanghai) Co., Ltd. Egfrviii antibody and conjugate, and preparation method and use thereof
MX2020008183A (en) 2018-02-01 2020-09-22 Pfizer Antibodies specific for cd70 and their uses.
MX2020008184A (en) 2018-02-01 2020-09-22 Pfizer CHIMERIC ANTIGEN RECEPTORS DIRECTED TO CD70.
CN111936516B (en) * 2018-03-19 2023-03-03 上海药明生物技术有限公司 Novel anti-EGFR antibody polypeptides
US11525010B2 (en) * 2018-05-23 2022-12-13 Pfizer Inc. Antibodies specific for GUCY2c and uses thereof
CN119405833A (en) 2018-06-01 2025-02-11 卫材R&D管理有限公司 Splicing modulating antibody-drug conjugates and methods of use thereof
CN109265561B (en) * 2018-09-25 2021-05-25 山东兴瑞生物科技有限公司 Anti-EGFRvIII safe chimeric antigen receptor, its preparation method, NK cells modified by the same and its application
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
MX2021004356A (en) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulations of anti-rsv antibodies and methods of use thereof.
MA54089A (en) 2018-10-31 2022-02-09 Merck Sharp & Dohme HUMAN ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF
JP7503056B6 (en) 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー Co-formulation of anti-LAG3 and anti-PD-1 antibodies
CN113603783B (en) * 2018-12-21 2022-07-12 浙江时迈药业有限公司 Protease cleavable bispecific antibodies and uses thereof
CA3131036A1 (en) * 2019-02-22 2020-08-27 Wuhan Yzy Biopharma Co., Ltd. Cd3 antigen-binding fragment and application thereof
TWI915311B (en) 2019-03-29 2026-02-21 荷蘭商美勒斯公司 Cd3 binding molecules
AU2020385991A1 (en) 2019-11-21 2022-06-23 Unity Biotechnology Antibodies directed to Tie-2 and methods of use
CN111072772B (en) * 2019-12-31 2023-08-04 上海良润生物医药科技有限公司 A peptide tag and its application in detecting or purifying fusion protein
CN115379848A (en) * 2020-04-01 2022-11-22 加利福尼亚大学董事会 Immunotherapeutic diagnostic agent targeting mesenchymal stem cell-derived cancer cells and mesenchymal stem cell-related diseases
EP4225792A1 (en) 2020-10-08 2023-08-16 Affimed GmbH Trispecific binders
CN112661844B (en) * 2020-11-18 2022-05-03 贵州医科大学 Single-chain antibody targeting EGFRvIII and application thereof
CN114539418A (en) * 2020-11-26 2022-05-27 上海华奥泰生物药业股份有限公司 Bispecific antibodies and uses thereof
WO2022166739A1 (en) * 2021-02-04 2022-08-11 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing thymic stromal lymphopoietin and uses thereof
JPWO2023286840A1 (en) * 2021-07-16 2023-01-19
JP2024529381A (en) 2021-07-30 2024-08-06 アフィメド ゲーエムベーハー Duplex Body
AU2021467228A1 (en) * 2021-09-29 2024-04-04 National Research Council Of Canada Humanized anti-egfrviii antibodies and antigen-binding fragments thereof
TW202334221A (en) 2021-11-03 2023-09-01 德商安富美德有限公司 Bispecific cd16a binders
CN116333117B (en) * 2021-12-16 2024-04-26 徕特康(苏州)生物制药有限公司 Anti-EGF receptor antibody, preparation method and application thereof
CN116047081B (en) * 2023-01-10 2024-02-13 北京新源长青生物科技有限公司 Kits and methods for detecting Aβ40 and Aβ42
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025257588A1 (en) 2024-06-10 2025-12-18 Affimed Gmbh Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0737750T3 (en) 1989-03-21 2003-09-01 Vical Inc Expression of exogenous polynucleotide sequences in vertebrates
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU8295491A (en) 1990-06-29 1992-01-23 Biosource Technologies Incorporated Melanin production by transformed microorganisms
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
ATE237694T1 (en) 1991-08-20 2003-05-15 Us Gov Health & Human Serv ADENOVIRUS-MEDIATED GENE TRANSFER INTO THE GASTROINTESTINAL TRACT
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
JP3540315B2 (en) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル Production of Chimeric Antibodies-Combination Approach
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
FR2688514A1 (en) 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS FOR TARGETING SPECIFIC TISSUES.
EP0644946A4 (en) 1992-06-10 1997-03-12 Us Health VECTOR PARTICLES RESISTANT TO HUMAN SERUM INACTIVATION.
WO1994002610A1 (en) 1992-07-17 1994-02-03 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
DE69308573T2 (en) 1992-08-17 1997-08-07 Genentech Inc SPECIFIC IMMUNOADHESINE
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
AU6818094A (en) 1993-04-22 1994-11-08 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
WO1995007994A2 (en) 1993-09-15 1995-03-23 Viagene, Inc. Recombinant alphavirus vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DE69435223D1 (en) 1993-10-25 2009-09-03 Canji Inc Recombinant adenovirus vector and method of use
HUT75162A (en) 1993-11-16 1997-04-28 Depotech Corp Vesicles with controlled release of actives
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
DE69535669T2 (en) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. RETROVIRAL VECTORS WITH REDUCED RECOMBINATION RATE
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DE69739286D1 (en) 1996-05-06 2009-04-16 Oxford Biomedica Ltd RECOMBINATION-INCOMPATIBLE RETROVIRAL VECTORS
WO1999018792A1 (en) 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
DK1575517T3 (en) 2002-12-24 2012-05-14 Rinat Neuroscience Corp ANTI-NGF ANTIBODIES AND PROCEDURES FOR USING THE SAME
MXPA05014155A (en) 2003-06-27 2006-05-25 Abgenix Inc Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof.
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
EP2010911A4 (en) 2006-03-31 2009-05-13 Massachusetts Inst Technology TREATMENT OF TUMORS EXPRESSING EGF MUTANT RECEPTORS
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
US9249217B2 (en) * 2010-12-03 2016-02-02 Secretary, DHHS Bispecific EGFRvIII x CD3 antibody engaging molecules
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP3459560B1 (en) 2011-04-08 2021-02-24 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
AU2012340174A1 (en) * 2011-11-16 2014-05-29 Amgen Inc. Methods of treating epidermal growth factor deletion mutant VIII related disorders
EP2780039B9 (en) 2011-11-17 2018-04-18 Pfizer Inc Cytotoxic peptides and antibody drug conjugates thereof
JP6154895B2 (en) * 2012-06-07 2017-06-28 デューク ユニバーシティー Human bispecific EGFRvIII antibody binding molecule
KR20150029714A (en) 2012-07-13 2015-03-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Enhancing activity of car t cells by co-introducing a bispecific antibody
AU2013312838B2 (en) 2012-09-04 2018-11-29 Cellectis Multi-chain chimeric antigen receptor and uses thereof
SG11201505896YA (en) 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
US20160017058A1 (en) * 2013-03-14 2016-01-21 The California Institute For Biomedical Research Bispecific antibodies and uses thereof
CA2917919C (en) * 2013-07-09 2019-07-02 Duke University Certain improved human bispecific egfrviii antibody engaging molecules
US10195289B2 (en) 2013-07-31 2019-02-05 Rinat Neuroscience Corp. Engineered polypeptide conjugates using transglutaminase
CN105555804B (en) 2013-08-07 2020-12-25 阿菲姆德股份有限公司 Antibody binding site specific for EGFRvIII
WO2015092024A2 (en) 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
RU2017102769A (en) 2014-07-29 2018-08-28 Пфайзер Инк. EGFRvIII SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY
HUE057285T2 (en) 2015-04-13 2022-04-28 Pfizer Therapeutic antibodies and their uses
TWI744242B (en) * 2015-07-31 2021-11-01 德商安美基研究(慕尼黑)公司 Antibody constructs for egfrviii and cd3
ES2904593T3 (en) 2016-01-21 2022-04-05 Pfizer Monospecific and bispecific antibodies to epidermal growth factor receptor variant III and CD3 and their uses
BR112018014585A2 (en) 2016-01-21 2018-12-11 Pfizer chimeric antigen receptors that direct variant epidermal growth factor receptor iii

Also Published As

Publication number Publication date
CN109219618A (en) 2019-01-15
DK3405490T3 (en) 2022-01-10
CN109219618B (en) 2022-08-09
US20170210812A1 (en) 2017-07-27
US20190194335A1 (en) 2019-06-27
ES2904593T3 (en) 2022-04-05
JP2019506398A (en) 2019-03-07
US10221242B2 (en) 2019-03-05
US11279764B2 (en) 2022-03-22
TW201936640A (en) 2019-09-16
CA2954802A1 (en) 2017-07-21
WO2017125831A1 (en) 2017-07-27
EP3405490B1 (en) 2021-10-20
TW201738271A (en) 2017-11-01
TWI657096B (en) 2019-04-21
JP7222024B2 (en) 2023-02-14
EP3405490A1 (en) 2018-11-28
JP2021129602A (en) 2021-09-09

Similar Documents

Publication Publication Date Title
US11279764B2 (en) Antibodies specific for epidermal growth factor receptor variant III and their uses
US11155630B2 (en) Therapeutic antibodies and their uses
US11091544B2 (en) Antibodies specific for Trop-2 and their uses
HK40000515B (en) Mono and bispecific antibodies for epidermal growth factor receptor variant iii and cd3 and their uses

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220112

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241218

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241218

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241218

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20250612

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250612

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20250915

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20250916